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Abstract 
Epidermolysis Bullosa encompasses a group of inherited heterogeneous diseases involving 
trauma induced blistering of the skin. Recessive Dystrophic Epidermolysis Bullosa (RDEB) is 
one of the most debilitating variants of the disease and patients are predisposed to 
developing aggressive cutaneous Squamous Cell Carcinoma (SCC).  Unlike SCC in the 
general population, the primary cause of RDEB associated SCC is not UV-radiation.  SCC in 
RDEB patients has poor prognosis due to a high frequency of recurrence and metastasis. 
70% of all severe generalized RDEB patients die from SCC by the age of 45, compared to 
only 1.25% of all patients with UV-induced SCC in the general population (Fine et al. 2008), 
making SCC the leading cause of death in these RDEB patients. 
 
The aim of this investigation was to identify therapeutic targets for RDEB associated SCC.  
Global gene expression studies identified 36 candidate genes which were differentially 
regulated in RDEB SCC (n=4) compared with non-RDEB SCC (n=5) primary keratinocyte 
cultures.  The validation of these genes by qRT-PCR in replicate cultures of RDEB SCC (n=3), 
non-RDEB SCC (n=3) keratinocytes and normal human keratinocytes as a control, deduced 5 
genes to be significantly differentially regulated.  Of particular interest, is the over-
expression of SLCO1B3 by 6.25 fold in RDEB SCC keratinocytes (p = 0.035).  SLCO1B3 
encodes the organic anion transporter OATP1B3, which is normally exclusively expressed 
on the basolateral membrane of hepatocytes.  qRT-PCR revealed the mRNA expression 
level of SLCO1B3 is reduced in RDEB SCC keratinocyte cultures when COL7A1, the causal 
gene mutated in RDEB, is re-expressed, suggesting that COL7A1 which encodes the Type VII 
Collagen protein and is secreted into the extracellular matrix, may suppress the 
transcription of SLCO1B3.  Immunofluorescent staining of RDEB SCC keratinocytes and 
23 
 
tissue identified OATP1B3 expression, whilst qRT-PCR using mRNA isolated from freshly 
frozen skin and SCC tissue samples from both RDEB and non-RDEB individuals identified 
increased SLCO1B3 mRNA expression in RDEB SCC in vivo.  
 
Over expression of SLCO1B3 and increased activity of OATP1B3 is associated with breast, 
colon and pancreatic cancer and is a known transporter of chemotherapeutic agents, such 
as Methotrexate and Paclitaxel.  These observations have led to speculation that, as a 
transporter over expressed in cancer and capable of introducing drugs into cells, OATP1B3 
represents a potential therapeutic target.  Preliminary results from a cell viability assay 
suggest that exposing RDEB SCC cells to Microcystin-LR specifically reduces cell viability in a 
SLCO1B3 dependent manner.  This supports the conclusion that SLCO1B3 represents a 
viable RDEB SCC specific therapeutic target and provides a pathway which can be exploited 
to deliver anti-cancer drugs directly to tumour cells whilst reducing the systemic toxicity of 
these agents. 
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Chapter 1 
 
Introduction 
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1.1 Skin, structure and function 
The skin is the largest organ of the body and its crucial function is to protect the body from 
damage.  It does this by creating a self-renewing physical barrier against the environment 
and thus provides protection against pathogens, guards the underlying muscles, bones, 
ligaments and internal organs and prevents dehydration and nutrient loss (Poumay and 
Coquette 2007). 
 
The uppermost layer of the skin, known as the epidermis, is mainly composed of 
keratinocytes that can undergo proliferation and differentiation.  This is a progressive 
maturing of the cells to create the 4 layers of the epidermis; the stratum corneum being the 
outermost layer followed by the granular, spinous and finally the basal layer (Figure 1.0). 
Keratinisation occurs when cells are formed by mitosis in the basal layer and daughter cells 
migrate up through the strata.  During terminal differentiation of these cells, they undergo 
morphological changes from undifferentiated proliferative cuboid cells to a squamous 
morphology of the cornified layer (Poumay and Coquette 2007).  The epidermis also 
consists of other minor cell types including; merkel cells that when in the presence of 
neurons create synapses (Shimohira-Yamasaki et al. 2006), antigen-presenting langerhans 
cells and pigment producing cells known as melanocytes (Pittelkow and Shipley 1989).    
 
Beneath the epidermis is the dermis; however separating these two layers is the basement 
membrane zone (BMZ), which securely connects the two layers.  The BMZ is composed of a 
number of proteins, including keratins, plakins, laminin 332 and collagens, to name a few, 
that are responsible for the structural integrity and association of the epidermis to the 
underlying dermis (Uitto and Richard 2005).   
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Figure 1.0 Basic Skin Structure 
The skin is composed of 2 layers, the dermis followed by the overlying epidermis, comprising of 4 
layers; basal layer, spinous layer, granular layer and stratum corneum which are primarily composed 
of keratinocytes at different stages of differentiation.  The two skin layers are separated by the 
basement membrane zone.  Figure adapted from (Fuchs and Raghavan 2002). 
 
The dermis is composed of cells dispersed among an extracellular matrix containing 
connective tissue, hair follicles, sebaceous glands, apocrine glands and blood vessels 
(Aumailley et al. 2006).  Structurally it can be divided into 2 sections; first an area of loose 
areolar connective tissue known as the papillary dermis followed by a thick layer of dense 
irregular connective tissue known as the reticular region which has strength, extensibility 
and elasticity.   
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Finally, although not considered to be a separate layer of the skin; the subcutaneous layer 
composed of loose connective tissue and elastin attaches the skin to the underlying bone 
and muscle.  This layer supplies the skin with blood vessels and nerves, and is mainly 
comprised of fibroblasts, macrophages and adipocytes.  
 
The skin is a dynamic and resilient organ that is able to constantly renew and heal itself.  
However, the skin’s function becomes compromised and challenged when mutations in the 
molecular makeup of this tissue occur.  The altered DNA sequences of genes involved in the 
skin can cause a wide array of cutaneous diseases most of which are caused by germline 
mutations, an example of which is the rare genetically inherited disease Epidermolysis 
Bullosa, which this thesis focuses on. 
 
1.2 Epidermolysis Bullosa 
Approximately 5000 people in the UK suffer from a rare genetic condition known as 
Epidermolysis Bullosa (EB) (Pillay 2008).  EB encompasses a complex group of genetic skin 
diseases affecting approximately 1 in 17,000 live births, with an estimated 500,000 cases 
worldwide (Featherstone 2007).  EB was first described by Kobner in 1886, however it 
wasn’t until the 1960’s that a distinct classification of the disease was established (Pearson 
1962).  The manifestations of the disease are heterogeneous and many subtypes of the 
condition exist.  Briefly, EB consists of a group of mechanobullous diseases involving trauma 
induced blistering and chronic erosions of the skin.  There is also extracutaneous 
involvement where blistering affects a number of specialised mucosal membranes such as 
those of the oral cavity, pharynx, oesophagus and gastrointestinal tract (Briggaman and 
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Wheeler 1975; Uitto et al. 1992).  All variants of EB are produced as a result of 
dysfunctional cell adhesion molecules. 
 
The EB classification system has been under recurrent revision since the first categorisation 
of the disease, with the most recent review occurring in 2009.  Current classification states 
four major types of the disease exist, which can be distinguished by identifying the plane of 
cleavage through the dermal-epidermal BMZ (Fine et al. 2009).  The subtypes of EB can be 
diagnosed and distinguished by electron microscopy (EM) of the skin, but it has been 
suggested that for an accurate diagnosis to be made by EM, this can only be provided by a 
person experienced in using this technique, and therefore it is likely to play a lesser role in 
diagnosis of EB in the future (Fine et al. 2009).  However, the definitive diagnosis is 
ultimately dependent on DNA mutational analysis (Sawamura et al. 2010).  
 
EB diagnosis generally begins with immunoflourescence and electron microscopy of skin 
tissues followed by analysis of the proteins and antigen mapping by immunofluorescence 
microscopy.  Diagnosis of the specific subtypes is essential, as in neonates the disease 
subtypes may present with similar clinical features but the actual prognosis of the disease is 
very different depending on the variant of EB.  Furthermore, many genetic therapies 
require accurate knowledge of the specific mutations of a particular patient and therefore 
it is important that a definitive molecular diagnosis is made.  This is also beneficial for 
developing an understanding of the disease mechanisms, allowing progress to be made in 
employing accurate mouse and cell models of EB for research investigations.  Skin biopsies 
allow identification of the level of separation occurring and protein deficiencies can be seen 
using monoclonal antibodies, an important step in the pursuit of a correct diagnosis of EB 
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subtype.  Prenatal diagnosis is offered when one or both parents are patients and have 
already had one affected pregnancy.  The test comprises of taking a sample of free-fetal 
DNA in the plasma faction of maternal blood, which represents 3-6% of the total DNA in 
maternal plasma. 
 
1.2.1 Subtypes of EB 
The four entities include EB Simplex (EBS), Junctional EB (JEB), Dystrophic EB (DEB) and 
Kindler Syndrome (KS).  The main types of EB can be further sub-classified based on the 
mode of inheritance and clinical features of the disease, as outlined in Table 1.0.  The 
majority of pathogenic mutations in EBS are within the KRT5, KRT14 and PLEC1 genes, 
where cleavage of the BMZ occurs in the basal keratinocyte (Figure 1.1).  JEB has separation 
at the level of the lamina lucida with the main mutations occurring in LAMA3, LAMB3, 
LAMC2, COL17A1 and α6β4 integrin (Pfendner and Lucky 1993).  DEB is exclusively caused 
by mutations of the COL7A1 gene and is identified by blister formation below the lamina 
densa, as shown in Figure 1.1.  Finally, KS has mutations of the KIND1 gene (Fine et al. 
2008), with cleavage occurring in multiple regions of the BMZ.  Although EB encompasses a 
wide spectrum of skin fragility diseases, the main focus of this introduction will be 
Recessive Dystrophic Epidermolysis Bullosa (RDEB). 
 
1.2.2 Epidermolysis Bullosa Simplex 
EB Simplex is the mildest and most common form of EB and with an occurrence of 1 in 
every 25,000 live births (Coulombe et al. 2009).  There are several phenotypes of EBS, and 
these can be confined to two broad subtypes; suprabasal (EBS-S) and basal (EBS-B).   EBS 
was the first disorder shown to be caused by mutations in a gene encoding an intermediate 
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filament protein and also the first epithelial skin fragility condition to have its etiology 
revealed (Coulombe et al. 2009).  EBS is chiefly inherited in an autosomal dominant pattern 
although recessive inheritance has been reported (Pfendner and Bruckner 1993).   
Major EB Type Major EB Subtype Minor Sub-classifications 
EB Simplex Suprabasal Lethal ancatholytic EB 
  Plakophilin deficiency 
  EBS superficialis  
 Basal EBS EBS, localised 
  EBS, Dowling-Meara 
  EBS, generalised other 
  EBS with mottled skin pigmentation 
  EBS with muscular dystrophy 
  EBS with pyloric atresia 
  EBS, autosomal recessive 
  EBS, Ogna 
  EBS, migratory circinate 
Junctional EB JEB-Herlitz N/A 
 JEB, other JEB, non-Herlitz generalised 
  JEB, non-Herlitz localised 
  JEB with pyloric atresia 
  JEB, inversa 
  JEB, late onset 
  LOC syndrome 
Dystrophic EB Dominant DEB DDEB, generalised 
  DDEB, acral 
  DDEB, pretibial 
  DDEB, pruriginosa 
  DDEB, nails only 
  DDEB, bullous dermolysis of the new born 
 Recessive DEB RDEB, severe generalised 
  RDEB, generalised other 
  RDEB, inversa 
  RDEB, pretibial 
  RDEB, pruriginosa 
  RDEB, centri petalis 
  RDEB, bullous dermolysis of the new born  
Kindler Syndrome N/A  
Table 1.0 Epidermolysis Bullosa subtype lineage  
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The main EBS subtypes are EBS-generalised other, which is characterised by blisters that 
occur all over the body.  EBS-localised is normally used to describe the condition when 
blisters are confined to the hands and feet.  Finally, EBS Dowling-Meara is the most severe 
form of this EB subtype.  Patients suffer from generalised skin involvement, which can 
appear as hemorrhagic clusters of blisters (Coulombe et al. 2009). The causal gene 
mutations give rise to cluster formation in the helix initiation motif or termination motif of 
KRT5 and KRT14 whereas the less severe EBS-localised generally result from mutations in 
the same genes but within H1 and H2 domains (Titeux et al. 2006).  KRT5 and KRT14 genes 
produce Keratin 14 or 5 proteins, which produce type I and II intermediate filament 
proteins that assemble into cytoskeletal intermediate filaments.  The group termed 
Suprabasal EBS, contains other classifications of EB caused by PKP1 and DSP gene 
mutations.  These genes encode the desmosomal proteins; Plakophilin-1 and Desmoplakin 
proteins (O'Shaughnessy and Christiano 2004).  
 
A rare recessive form of EBS is associated with Muscular Dystrophy, a severe 
neuromuscular disease, with known mutations of the PLEC1 gene encoding the protein 
plectin (Smith et al. 1996).  Plectin is a cytolinker protein that integrates various 
cytoskeletal and cell-adhesive elements into a functionally unified network (McLean et al. 
1996).  
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Figure 1.1 Schematic diagram of structural components of the skin important in EB  
The interactions between basal keratinocytes, basement membrane protein and the papillary dermis 
are important factors in EB.  The diagram represents the basic structural interactions and the genes 
which are involved in each layer and the corresponding EB subtype. 
 
1.2.3 Junctional Epidermolysis Bullosa 
Junctional EB is inherited recessively and is quite rare, affecting approximately only 500 
patients worldwide (Pfendner et al. 2007).  Herlitz-JEB (JEB-H) often carries the hallmark of 
prolific granulation tissue (Fine et al. 2008), however lesions generally heal with very mild 
or no scarring.  The other-JEB (JEB-O) group contains sub-classifications of JEB commonly 
associated with mutations of COL17A1, ITGB4 and ITGA6 (Pfendner et al. 2007).  
 
1.2.4 Kindler Syndrome 
Kindler Syndrome (KS) is an autosomal recessive condition that has recently been added to 
the EB classification due to the clinical appearance of the disease which mimics that of H-
JEB and DEB in the neonate period (Fine et al. 2008).  Onset of the disease starts at birth, 
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with generalized skin involvement, blisters, nail dystrophy (Siegel et al. 2003), progressive 
poikiloderma which is where hyperpigmentation of the skin which leads to a mottled  
appearance, skin atrophy (Jobard et al. 2003) and varying degrees of photosensitivity 
(Jobard et al. 2003; Ashton 2004).  These latter specific clinical features distinguish KS from 
the other types of EB (Burch et al. 2006).  The condition arises due to mutations in the 
KIND1 gene, encoding the protein Kindlin-1, a molecule involved in actin cytoskeleton 
attachment through focal contacts (Ashton et al. 2004; Burch et al. 2006).  Approximately 
17 different mutations have been identified in KIND1 in over 40 families (Ashton et al. 2004; 
Burch et al. 2006).  Unlike other subtypes types of EB, KS has multiple planes of cleavage 
within the basal keratinocytes, lamina lucida and aberrations of the lamina densa (Shimizu 
et al. 1997).   
 
1.2.5 Dystrophic Epidermolysis Bullosa 
Dystrophic EB (DEB) can be clinically characterised by trauma induced blistering, resulting in 
chronic ulcerations and scarring of the skin (Hovnanian et al. 1997).  There are 3 main 
subtypes that come under the category of DEB; firstly the autosomal Dominant DEB (DDEB) 
and the two autosomal recessive subtypes; severe-generalised RDEB (sev-gen RDEB), 
previously referred to as Hallopeau-Siemens RDEB, and the final subtype is classed as 
generalised-other RDEB (RDEB-O) (Fine et al. 2008).  In general, the clinical severity is 
widely variable ranging from minor dystrophy of the nails to major skin fragility.  The RDEB 
phenotype is more severe than that of DDEB, and in the most severe cases patients present 
with recurrent wounds, infections, scarring, failure to thrive and development of Squamous 
Cell Carcinoma (SCC) which can result in death (Mallipeddi 2002). 
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Defective COL7A1 which encodes the extracellular matrix protein Type VII Collagen is the 
exclusive causal defect that results in the development of all dystrophic EB variants 
(Sawamura et al. 2010).  COL7A1 is a complex gene that consists of 118 exons and a 
transcribed mRNA sequence of 9.2 kb in length (Christiano et al. 1994).  It is an excreted 
protein produced primarily by keratinocytes (Yuspa and Epstein 2005).  Type VII Collagen is 
the main component of anchoring fibrils (Sakai et al. 1986), the proteins assemble into 
these functional structures by associating into a homotrimeric ultra structural protein that 
consists of a central triple helical collagenous domain, with non-collagenous (NC) domains 
at both the amino and carboxyl ends, known as the NC1 and NC2 domains, respectively 
(Hovnanian et al. 1997) (Figure 1.2).  Type VII Collagen molecules assemble to form anti-
parallel dimers that overlap at the NC2 domain which then produce anchoring fibrils 
(Bruckner-Tuderman et al. 1995) (Figure 1.3).  These fibrils are key structures in the 
integrity of the BMZ of the skin and are responsible for providing structural stability by 
forming bands that trap dermal extracellular matrix proteins and bind them to the 
basement membrane and thus securing the epidermis to the underlying dermis (Burgeson 
1993).  
 
Molecular research into DEB has revealed a wide spectrum of COL7A1 mutations that cause 
separation of the basement membrane below the lamina densa, with over 300 mutations 
having been reported (Dang and Murrell 2008; Almaani et al 2011.).  Separation in the skin 
occurs as a result of absent or a reduced number of functional anchoring fibrils which are 
truncated as a result of the various mutations causing reduced adherence and weak 
attachment of the epidermis to the dermis (Rodeck and Uitto 2007).  Glycine substitutions 
on one allele of the COL7A1 gene are strongly associated with DDEB (Christiano et al. 1994).  
Although pathogenic heterozygous mutations cause DDEB, non-sense mutations, 
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Figure 1.2 Structure of Type VII Collagen polypeptides 
Type VII Collagen is a complex protein consisting of 118 exons.  The domain organisation of Type VII 
Collagen polypeptides has been deduced from the 9.2kb cDNA sequence.  It indicates that each 
polypeptide consists of a triple-helical domain which contains a 39 amino acid non-collagenous 
“hinge” region.  This domain is flanked by an amino terminal non-collagenous (NC1) domain and 
carboxy terminal non-collagenous (NC2) domain.   
 
frameshift, or splice site mutations on both alleles are required for the development of 
RDEB.  However, it has emerged that genotype-phenotype correlations in DEB exist in 
which glycine substitutions in the triple helix may lead to diagnostic difficulties as certain 
mutations can result in either dominant or recessive DEB.  In particular four newly 
identified glycine missense mutations; p.Gly1483Asp, p.Gly1770Ser, p.Gly2213Arg and 
p.Gly2369Ser which can lead to both DDEB and RDEB (Almaani et al. 2011).  Sev-gen RDEB 
shows a complete absence of Type VII Collagen expression at the basement membrane 
(Bruckner-Tuderman et al. 1989), with a previous study postulating that loss of COL7A1 
identified by lack of antibody binding suggests inadequate synthesis of Type VII Collagen or 
excessive breakdown (Leigh et al. 1988) this is a likely explanation given that in the most 
severe form of RDEB, premature termination codons (PTC) occur on both alleles of COL7A1.  
PTC can occur in milder forms on one allele but are usually accompanied by a further 
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missense mutation or in-frame mutation on the other allele, in which case some Type VII 
Collagen expression is observed (Christiano et al. 1993). 
 
1.2.5.1 Dominant Dystrophic Epidermolysis Bullosa 
DDEB patients suffer from trauma-induced blistering which is confined to the hands, feet, 
knees and elbows and is accompanied by nail dystrophy and milia.  This is one of the 
mildest forms of DEB therefore blisters are generally innocuous but nevertheless heal with 
scars.  Typically, glycine substitutions in the collagenous triple helical domain of Type VII 
collagen occur, which subsequently causes poor folding of the triple helices and disruption 
of anchoring fibril assembly (Varki et al. 2007).  Furthermore, shortened Type VII Collagen 
polypeptides are sometimes seen in DDEB and are produced by genomic deletions within 
COL7A1 exons (Mellerio 1999). 
 
1.2.5.2 Recessive Dystrophic Epidermolysis Bullosa 
The 3 main types of RDEB are; severe-generalized RDEB (sev-gen RDEB), which is the most 
debilitating classification of DEB with the milder forms are known as generalized-other 
RDEB (RDEB-O) and pruriginosa RDEB (Fine et al. 2008).  Many patients suffer from chronic 
blistering induced by mild trauma and is often accompanied by complications including; 
anaemia, scarring and fusion of digits (pseudosyndactyly) (Bodemer et al. 2003).   
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Figure 1.3 Schematic presentation of anchoring fibril formation under normal physiological 
conditions.  Firstly, pro-α1(VII) polypeptides are synthesized and then three polypeptides associate 
through their carboxy-terminal end and collagenous domains to form triple helices. These 
polypeptides are then secreted into the extracellular space, whereby the triple helical type VII 
collagen molecules form anti-parallel dimers, after which the carboxy terminal is proteolytically 
cleaved and dimer assembly is stabilised by disulfide bonds.  Several dimers then laterally assemble 
to form cross-striated anchoring fibrils with the NC1 amino-terminal domain attached to the lamina 
densa thus stabilising the association with the underlying dermis.   
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RDEB-O can result from glycine substitutions on one allele and a premature termination 
codon (PTC) on the other allele, which results in a small quantity of partially functional Type 
VII Collagen protein (Pfendner et al. 2007).  Milder phenotypes of RDEB can also be 
produced by amino acid substitutions, but it is almost impossible to generalise which 
mutations cause a certain characteristic of RDEB-O as widely variable phenotypes have 
been observed and over 500 mutations have been reported (Mellerio 1999). 
 
Severe-generalised RDEB can be clinically characterised by severe and haemorrhagic 
blistering induced by mild trauma with chronic unhealing wounds and extensive scarring 
(Tomlinson 1983).  It is accompanied by complications including; malnutrition, anaemia, 
oesophageal strictures, corneal erosions, recurrent infections such as pneumonia and 
pseudosyndactyly in which the digits fuse together during wound healing and scar 
formation (Bodemer et al., 2003; Csikos et al., 2003).  Incidence of sev-gen RDEB is reported 
to be 0.4-0.6 cases per million live births in the United States (Vendrell et al. 2011). 
 
The molecular hallmark of sev-gen RDEB is PTCs on both alleles of the COL7A1 gene 
(Christiano et al. 1993).  PTCs are the result of insertion, deletion or substitution mutations 
which lead to a frame shift of the DNA sequence up or downstream of the alteration.  These 
mutations tend to be span across the entire length of the COL7A1 coding sequence (Rodeck 
and Uitto 2007).  However, as mentioned already, glycine substitutions have been reported 
to cause both DDEB and RDEB (Almaani et al. 2011). 
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Although, sev-gen RDEB is one of the most mutilating forms of EB, clinical management of 
the disease and its complications has greatly improved, with fewer patients dying from the 
primary disease.  However, it has become evident over the last 20 years at least that this 
subset of patients have a grossly increased susceptibility to developing aggressive 
cutaneous Squamous Cell Carcinoma (SCC).  They have a 90% lifetime risk of developing 
metastatic SCC which is closely mirrored by an 80% risk of mortality by SCC thus 
representing the prevalent cause of death in RDEB patients (Fine et al. 2009).  With no 
curative treatment and tumour excision as the main treatment modality there is a universal 
need for the development of new more effective treatment strategies, this patient group 
and complication is the primary focus of this thesis.  This will be discussed in section 1.3 and 
1.5. 
 
1.1.6 Epidermolysis Bullosa Treatment 
The heterogeneity of these diseases and the various genes involved in their pathogenesis 
mean that no single treatment is likely to treat or cure EB.  However, extensive research is 
ongoing in this area with varying degrees of success.  
 
Recent attention has been drawn to cell based therapies ranging from cutaneous injections 
of fibroblasts to autologous gene corrected bone marrow transplants (Woodley et al. 2003; 
Woodley et al. 2007; Fritsch et al. 2008; Wong et al. 2008; Kern et al. 2009; Tolar et al. 
2009).  One new report looked at the use of induced pluripotent stem cells (iPSCs) as a 
useful substitute for embryonic stem cells (ESCs) which have the potential of unlimited 
proliferative capacity and extensive differentiation capability (Itoh et al. 2011).  Itoh and 
colleagues used autologous iPSCs generated from an individual’s somatic cells and 
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exogenously expressed defined transcription factors to generate cells with similar biological 
characterisations to ESCs (Itoh et al. 2011).  They created these cells from both normal and 
RDEB fibroblasts and were able to generate 3D skin equivalents using iPSC derived 
keratinocytes.  This study demonstrated a new potential source for cells for regenerative 
therapies for use in RDEB patients which would circumvent ethical issues raised from the 
use of ESCs and immunological rejection possibilities.  
 
Gene-corrected RDEB keratinocytes have also been used for cell therapy in which they are 
harvested and injected intradermally into immunocompetent mice.  This study revealed 
retention of Type VII Collagen for up to 2 months, supported by positive staining in the 
basement membrane zone (Woodley et al. 2004).  This study was followed by another 
which tested the clinical efficacy of this application by treating 5 RDEB patients with a single 
intradermal injection of allogenic fibroblasts (Wong et al. 2008).  Results showed an 
increase in anchoring fibrils after 3 months that were lacking normal morphology but still 
increased adherence at the dermal-epidermal junction (Wong et al. 2008).   
 
Gene therapy is an attractive treatment option for EB, by theoretically restoring the 
function of an absent or abnormal gene with a normal healthy gene.  Du Luca’s (Phase I/II 
clinical trial) reported the first ever successful gene therapy for treatment of EB (De Luca et 
al. 2009). Several genetically modified epidermal sheets were grown in culture and 
transplanted onto both legs to cover a total area of 500cm2, curing areas of skin on the legs 
of a non-Herlitz JEB patient.  The epidermal sheets were grown from the patient’s own 
laminin 332-β3-chain-deficient epidermal stem cells taken from palm biopsies and 
transfected ex vivo with a retroviral vector expressing the normal laminin 332.  The 
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epidermal sheets were prepared using the same method used for preparing skin grafts for 
burn patients.  The JEB patient had a low level of basal laminin expression which helped 
prevent graft rejection; this clinical trial showed success in complete epidermal 
regeneration after 8 days and retained a normal epidermis for 1 year (De Luca et al. 2009).  
There has been continual research in this area, looking at both in vivo and ex vivo 
approaches.  Ex vivo models using retroviral vectors in animal models of JEB has had some 
success, however using retroviral vectors limits the size of the target gene and with 
cumbersome genes such as COL7A1, retroviral expression although is not impossible is 
often unsustainable (Pfendner et al. 2007).  A significant challenge of gene therapy is 
delivery not only to the skin, but cell linings of the mouth, oesophagus, gastrointestinal 
tract and other affected internal sites (Featherstone 2007).   
 
Paradoxically, dermal fibroblasts have been suggested to be a more suitable target for gene 
therapy rather than keratinocytes, which in vivo are the predominant source of Type VII 
Collagen.  The reason being that when gene corrected DEB skin cells are made into a skin 
equivalent and transplanted onto rodents, Type VII Collagen from fibroblasts contributes 
substantially more to the basement membrane (Goto et al. 2006).  A recent investigation by 
Woodley and colleagues (2007) has shown intravenous injection of RDEB fibroblasts re-
expressing COL7A1 in athymic mice led to improved wound healing compare to non-
corrected RDEB fibroblasts (Woodley et al. 2007). 
 
Other potential treatments include using gene corrected skin grafts which have 
demonstrated stable delivery of Type VII Collagen in mouse models (Chen et al. 2002; Ortiz-
Urda et al. 2002).  This method has been shown to have clinical success for the treatment of 
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JEB through the sustained delivery and expression of LAMB3 (Mavilio et al. 2006).   It has 
been reported that matrix metalloproteinases (MMP) 1, 2, 3 and 9 are highly expressed in 
RDEB, suggesting that pharmacological MMP inhibitors could be beneficial to RDEB patients 
with greater MMP activity (Bodemer et al. 2003).  MMPs are a family of zinc dependent 
endopeptidases.  Implicated in the degradation of extracellular matrix molecules, they are 
also known to play a pivotal part in tissue remodelling, cell migration, wound healing, 
inflammation and cancer invasiveness (Titeux et al. 2008).  A SNP in the promoter of MMP1 
causes an up-regulation of MMP1 and has been found to have a strong genetic association 
with RDEB disease severity (Titeux et al. 2008).  Col7a1 null mice were used to study the 
effects of repetitive intradermal injections of recombinant full length Type VII Collagen 
(Remington et al. 2009).  They reported that Type VII Collagen was incorporated into the 
epidermal-dermal junction and was found at distant sites but was still present in the skin 
for 2 months.  Over the 2 months there was significant improvement of the phenotype 
shown by decreased blistering and prolonged survival of the mice (Remington et al. 2009). 
 
1.3 Squamous Cell Carcinoma 
RDEB patients have a high propensity to develop aggressive cutaneous squamous cell 
carcinomas that readily metastasize.  This type of cancer forms part of a group of tumours 
known as non melanoma skin cancer (NMSC).  Non-melanoma skin cancer in the general 
population is the most common cancer in the USA, with 80% being accounted for by Basal 
Cell Carcinoma (BCC) and the other 20% being Squamous Cell Carcinoma (SCC) (Kwa et al. 
1992).  Cutaneous SCC is the second most common human cancer among Caucasians (Alam 
and Ratner 2001) and there is the general perception that these tumours develop from a 
multi-step process (Boukamp 2005), with the primary causative agent being ultraviolet (UV) 
radiation (Armstrong and Kricker 2001).  SCC can develop in several tissues and organs, 
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such as; the skin, lips, mouth, oesophagus, bladder and lungs.  The tumours develop in the 
squamous epithelium and in the skin they are derived from keratinocyte transformation 
(Dazard et al. 2003).  
 
In the multistep process of carcinogenesis, initiation is brought about by cumulative UV 
radiation primarily from sun exposure causing the development of UV specific mutations in 
target genes, followed tumour promotion by clonal expansion of the damaged cells and 
finally progression through uncontrolled proliferation and invasion (Dazard et al. 2003).  UV 
specific mutations occur in TP53 and p16ink4a, two of the body’s main tumour suppressor 
genes.  These specific mutations are known as UV-signature mutations; which will be 
explained in further detail in Chapter 3.  The body has its own surveillance system to 
protect itself in the event of harmful DNA damage; under normal circumstances UV induced 
DNA damage to normal skin cells is detected and a process is initiated whereby the p53 
signalling cascade is activated to commence cell cycle regulation to prevent replication and 
initiate apoptosis thus destroying the aberrant cells to thwart further damage from 
occurring.  However when mutations go unnoticed and another mutation occurs in the p53 
gene resulting in a faulty protein function, the surveillance and protection mechanism 
becomes defective and the cell is unable to initiate DNA repair mechanisms or apoptosis.  
Therefore, promoting tumour formation in the tissue as the cell is able to undergo cell 
division and proliferate uncontrollably causing premalignant lesions such as Actinic 
Keratoses (AK) that can develop further into malignancy.   
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1.3.1 Incidence 
Of all skin cancers; 80% are accounted for by basal cell carcinoma (BCC), 16% are SCC and 
4% are melanoma (Alam and Ratner 2001).  The lifetime risk of developing SCC is 9-14% for 
men and 4-9% amongst women (Miller and Weinstock 1994).  
 
1.3.2 Molecular Mechanisms 
The tumour suppressor gene TP53, encodes the p53 tumour suppressor protein and is most 
studied aberration in skin cancer and is mutated in 90% of SCCs (Brash 2006).  This tumour 
suppressor protein has many functions primarily aimed at protecting cells against damage 
(Vousden and Lane 2007).  Two such mechanisms are DNA repair and the induction of 
apoptosis (Hofseth et al. 2004).  The TP53 gene carries UV-signature mutations in sporadic 
SCC; traditionally this involves the transition of cytosine to thymine nucleotides, where two 
pyramidines are adjacent in the DNA sequence.  When the TP53 gene becomes mutated its 
normal function which is activated by cellular stress, is altered in a dominant negative 
fashion and causes genomic instability and thus contributes to cancer initiation and 
progression.  p53 function will be discussed at greater length in Chapter 3.   Also implicated 
in the pathogenesis of SCC is the cyclin-dependent kinase inhibitor known as p16INK4a also a 
tumour suppressor protein, is located within in the 9p22 chromosomal region that is 
frequently altered in cancer (Suzuki et al. 2007).  This protein inhibits progression of the G1 
phase of the cell cycle by blocking cyclin-dependent kinase 4 from phosphorylating the 
retinoblastoma protein (Brown et al. 2004).  
 
Studies have shown a paradox in the role of NF-κB in tumourigenesis.  A report has shown 
inhibition of NF-κB in skin can lead to increased cell proliferation and even cancer (Dajee et 
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al. 2003).  Conversely, in other cell lineages NF-κB is known to play a role in promoting cell 
proliferation and protecting against apoptosis (Bolotin and Fuchs 2003).  Mutations of CYLC 
gene encoding a regulator of protein degradation in the NF-κB pathway predispose people 
to head and neck tumours known as cylindroma (Yuspa and Epstein 2005).       
 
 The human papillomavirus (HPV) is a small DNA virus that infects epithelial cells and can 
induce a variety of proliferative lesions, such as warts, laryngeal papillomas, and cervical 
carcinoma (Masini et al. 2003).  Additionally, they are known to be associated with skin 
cancer in individuals with epidermodysplasia verruciformis (EV), a rare inherited condition 
characterized by widespread HPV infection and eventual development of multiple SCCs, 
predominantly on sun-exposed sites (Masini et al. 2003).  One study suggested that 
individuals from the general population with positive serologic findings for HPV-8 had a 3 
fold risk of cSCC (Masini et al. 2003).  
 
1.3.3 Premalignant Lesions 
Actinic Keratoses (AK) are premalignant neoplasms that sometimes precede SCC.  They 
contain UV induced p53 mutations.  The site at which AKs occur generally show field 
change, whereby an area of skin between 2-6cm becomes scaly, involuted, and is more 
easily felt than seen.  Usually patients have many lesions and although p53 is known to be 
mutated the molecular mechanisms that cause these lesions to evolve into malignant 
neoplasms is unknown. Other premalignant lesions include kerato-acanthoma and Bowen's 
disease (Lanssens and Ongenae 2011). 
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1.3.4 Treatment 
Total body examination of the skin is the only screening test available for cutaneous SCC.  
Early detection of the disease provides a good prognosis for patients.  The main treatment 
of SCC is wide local surgical excision which can be followed by dissection of regional lymph 
nodes and adjuvant radiation therapy (Clayman et al. 2005).  Other standard dermatologic 
management treatments can also be used for lower risk SCCs such as cryoablation therapy 
and topical cytotoxic therapy (Martinez and Otley 2001).  Electrodessication, curettage, 
excision or cryosurgery can eliminate up to 90% of local tumours with a low risk of 
metastasis (Martinez and Otley 2001).   Whilst cryosurgery, electrodessication and 
curettage are relatively inexpensive to perform, surgical excision and Moh’s surgery provide 
lower rates of recurrence and metastasis for patients with higher risk tumours but both are 
more costly to perform.   
 
1.3.5 Metastasis/Recurrence 
Invasive SCC has the potential to re-occur and metastasize.  The 5 year recurrence rate for 
primary cutaneous lesions is 8%, and the 5 year metastasis rate is 5% (Rowe et al. 1992).  
The 5 year survival rates for metastatic SCC is 25-50% (Veness 2006).  There is a correlation 
between tumour size and location and the risk of metastasis. Tumours at high risk of 
metastasis include those >2cm, poorly differentiated tumours and invasive tumours 
infiltrating into or beyond the dermis (Kwa et al. 1992; Rowe et al. 1992).  
 
1.4 RDEB associated SCC 
RDEB associated SCC is very aggressive and has a high rate of metastasis, consequently 
prognosis is often poor with many patients dying within 5 years of the first SCC diagnosis 
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(Fine 2004).  It is known that even well differentiated tumours can be aggressive and have 
high metastatic potential (Fine et al. 2009).  Although most SCCs arise in the skin other 
areas can be affected by SCC development including the tongue, lips and hard palate (Fine 
et al. 2008).   
 
1.4.1 Incidence 
RDEB associated SCC has a short latency and tumours can develop in early adolescence 
(Fine et al. 2009).  There has even been a report of tumour development as early as 6 years 
of age (Shivaswamy et al. 2009).  Recent reports conveyed a 75% risk of developing SCC by 
the age of 45 for sev-gen RDEB (Fine et al. 2009).    
1.4.2 Pathogenesis and molecular mechanisms of RDEB associated SCC 
Some reports have suggested that chronic wound healing represents the driving force for 
the development of highly malignant SCCs in both the general population and RDEB 
patients (Rodeck and Uitto 2007).  Malignant lesions that present in RDEB patients are 
often difficult to diagnose as they are found within the margins of non-healing ulcerations 
(Arbiser et al. 2004), with some individuals presenting with multiple primary tumours.  
 
Gene expression studies aimed at identifying genes present in chronic EB wounds has 
identified a 5-fold increase in L-arginine (ARG1) (Wessagowit et al. 2004).  This involves 
changes in arginine metabolism and arginine-nitric oxide synthase pathway which is 
thought to impair wound healing.  Not only would this contribute to the chronic non-
healing ulcerations often seen in RDEB patients but also contribute to their susceptibility to 
malignant transformation.  
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No definitive molecular mechanisms have been identified as causal in the pathogenesis of 
RDEB associated SCC.  Research shows that TP53 is mutated in 30% of RDEB SCC samples in 
one cohort and was not associated with UV radiation (Arbiser et al. 2004), whilst, 
hypermethylation of p16 has been seen in some RDEB SCC samples (Arbiser et al. 2004).   
 
One gene that has been implicated in RDEB associated SCC is insulin growth factor binding 
protein (IGFBP-3), an average reduction of 5.8 fold in RDEB SCC was seen compared to non-
RDEB SCC (Mallipeddi et al. 2004).  In a normal state, IGFBP-3 plays an important role in 
cancer cell apoptosis which is mediated through retinoid X receptor alpha (RXRα).  It has 
long been hypothesised that the absence of Type VII Collagen in RDEB is a major 
contributor to the aggressive nature of SCC (McGrath et al. 1992), furthermore knock-down 
of COL7A1 in non-RDEB SCC keratinocytes in vitro resulted in increased migration and 
invasion, decreased terminal  epithelia differentiation and enhanced mesenchymal 
transition all characteristics of tumorigenesis (Martins et al. 2009).   However one study 
specifically implies that the NC1 fragment of Type VII Collagen is essential for 
transformation of RDEB keratinocytes to malignancy (Ortiz-Urda et al. 2005).  However, 
following this, a separate study investigated COL7A1 expression in RDEB SCC (Pourreyron et 
al., 2007). Contrary, to those results presented by Ortiz Urda (2007), this study showed 
RDEB patients developed SCC regardless of COL7A1 expression, this was proven by 
examination of Type VII Collagen expression in 17 SCC tumours excised from 11 patients, 2 
of which harboured heterozygous mutations within the region of COL7A1 encoding the NC1 
domain (Pourreyron et al. 2007).  This evidence suggests COL7A1 expression is not a 
reliable predictor of SCC development and would not be useful biomarker of 
tumourigenesis.   
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The cellular pathways that predispose these patients to develop aggressive cSCC remain 
undefined, but the following have been implicated; p53 gene, suppression of p16 activity, 
increased collagenase activity and increased Basic Fibroblast Growth Factor (bFGF) in some 
patients (Arbiser et al. 1998; Arbiser et al. 2004).  Increased BFGF was seen in 51% of RDEB 
patients, and it has been postulated that this may promote tumour initiation though 
mitogenic and angiogenic effects, although increased levels of BFGF was also be detected in 
unaffected family members (7 of 33 RDEB unaffected family members) (Arbiser et al. 1998).   
 
It can be speculated that the molecular mechanisms of RDEB associated SCC may arise from 
the interplay of many signals and proteins that control the wound healing process.  RDEB 
skin is chronically blistered and therefore there is a constant turnover of cells due to 
activated wound healing processes in the skin.  Normal wound healing involves a complex 
process of activating signals and proteins being expressed to specifically enhance the repair 
of the skin.  Initially, open wounds are plugged by platelet activation and aggregation 
providing a bolus of secreted proteins.  Signals are initiated to increase the migration of 
cells to close up the wound.  It is interesting that SCC in RDEB develop within non-healing 
wounds, therefore suggesting that wound healing is directly linked to the initiation of 
tumourigenesis in these patients.  It could be postulated that because RDEB skin is in a 
constant state of repair the signalling that aids the healing process also enhances the 
growth and survival of rogue cells, which remain undetected by the immune system.   
 
Not only is migration enhanced in wound healing but angiogenesis is activated in which 
new blood vessels develop.  Again, this could further contribute to the survival of tumour 
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cells, as angiogenesis has been reported to be required for tumour development and 
metastasis (Nishida et al. 2006).  Wounds are also associated with inflammation, some 
genes and proteins that are specifically seen in inflammatory environments include; TGFβ, 
selectins, chemokines and their appropriate receptors.  They have also been reported to be 
expressed in tumour cells and furthermore have be shown to promote invasion and 
metastasis (Coussens and Werb 2002).  Another example of this association between 
inflammation and cancer is the tumour microenvironment which is orchestrated by 
inflammatory cells that are essential for neoplastic conversion and is known to increase 
migration, proliferation and survival.   Sustained proliferation of cells in an inflammatory 
environment which contains growth factors and activated stroma can potentiate the risk of 
cancer.  Normally wound healing is a self-limiting process, dysregulation of any of these 
factors can lead to abnormalities which could eventually enhance the pathogenesis of 
tumour development (Arwert et al. 2011).  The process of wound healing, angiogenesis and 
inflammation may be exploited by rogue pre-malignant cells in RDEB patients and greatly 
increase the risk of neoplastic transformation of the cells, thereby enhancing the SCC 
incidence in these patients. 
 
1.4.3 Treatment 
It is well established that chronic non-healing ulcerations, like those common in RDEB 
patients should be closely monitored for malignant change.  Multiple biopsies are essential 
as only part of the chronic ulceration may undergo malignant change, and further more the 
tumour may appear asymptomatic and are indistinguishable from chronic ulcerations of the 
RDEB phenotype. 
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The main treatment of RDEB associated SCC is surgical excision (Mallipeddi 2002).  
However, despite taking a large excision margin, malignant lesions can recur and 
metastases are often seen.  RDEB patients require frequent monitoring of chronic wounds 
for malignant changes, as they are often indistinguishable from normal RDEB phenotypic 
blistering and multiple biopsies are taken.  Treatment by surgical excision is attributed to 
the fact that there is often difficulty in distinguishing premalignant lesions from non-
malignant lesions and accurate diagnosis requires histological analysis (Mallipeddi 2002). 
 
Some combination therapies have been used; however they have shown minimal 
effectiveness (Mallipeddi 2002).  There are a few reports of radiotherapy being used to 
treat SCC in DEB patients (McGrath et al. 1992; Bastin et al. 1997).  Bastin and colleagues 
reported the use of radiotherapy in 12 DEB patients delivering a total dose between 12-
60Gy over 9-47 days (Bastin et al. 1997).  Only 54% of irradiated tumours in the study 
showed a partial response, and poor wound healing and skin erosions were apparent at a 
total dose of around 45Gy (Bastin et al. 1997).  Furthermore, the use of chemotherapy is 
generally avoided due to the risk of systemic toxicity.  One report documents two DEB 
patients treated with Cisplatin which produced a partial response in relation to the 
reduction in axillary lymphadenopathy, the patient then went on to have a lesion on her 
chest surgically excised and the patient was alive 1 year after treatment (Lentz et al. 1990).  
The second patient chose to withdraw from the treatment and died just under 4 weeks 
later (Lentz et al. 1990).  The few reports that document combination therapies and the use 
of radio- and chemo- therapy suggest that there is a narrow therapeutic index in the 
treatment.  Further evidence of this is documented by Fine and colleagues who used 
Isotretinoin to treat DEB patients with SCC, this caused several patients to have increased 
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mechanical skin fragility when a sustained dose of Isotretinoin was administered (Fine et al. 
2004). 
 
1.5 Other patient groups with higher risk of SCC 
1.5.1 Other EB subtypes with increase SCC risk 
JEB and DDEB patients have exhibited SCC but metastasis or death was not observed.  Up 
until 2004, there had been 6 reported cases of SCC in non-Herlitz JEB patients (Mallipeddi 
et al. 2004).  Although this patient group are not presented with as great a risk as the RDEB 
patients, it is important to note that other EB types do develop SCC, so that they are aware 
of changes to blisters and erosions which may be indicative of malignant transformation.  
Kindler syndrome patients have a 20% increase in SCC.  
 
1.5.2 Immunosuppression is implicated by a higher incidence of NMSC in OTRs 
It has long been established that immunosuppression in the setting of solid organ 
transplantation has been implicated as the main etiological factor for an increased risk of 
developing non-melanoma skin cancer in organ transplant recipients (OTRs) (Penn and 
Starzl 1972; Preciado et al. 2002).  There is a strong predisposition specifically for renal 
transplant patients to have a higher incidence of cutaneous SCC  (Euvrard et al. 2003), with 
up to a 100 fold greater risk of developing SCC in comparison to the general population of a 
comparable age range (Penn and Starzl 1972; Jensen et al. 1999). 
 
Unlike the general population, and in parallel to RDEB patients tumours that develop in 
OTRs have much earlier onset with studies showing the mean age of development of 
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epithelial tumours being 35 years old (Penn and Starzl 1972).  There have been varying 
reports of the average lag time of tumour development after transplantation including; 
between 3-5 years after transplantation (Blohme and Larko 1990), followed with a more 
recent study identifying a 8.4 year interval (Preciado et al. 2002).  A long-term retrospective 
study evaluating the risk of cancer in 1098 renal OTRs, indicated a 7% risk of tumour 
development after 1 year of immunosuppression therapy, which is significantly increased to 
75% risk after 20 years (Preciado et al. 2002).   Although there is a prevalence of cutaneous 
SCC in OTRs, there is also a 3 fold, 84 fold, and 20 fold increased incidence of melanoma, 
Kaposi’s sarcoma and SCC of the lip, respectively (Jensen et al. 1999). 
Although immunosuppression has been eluded to be the leading cause of SCC development 
in this patient group, the exact pathogenesis is unknown.  Suggestions have been that the 
immunosuppressing agents themselves are carcinogenic or that they potentiate the effect 
of environmental carcinogens such as UV light in these patients.  Parallels can be drawn 
between SCC development in OTRs and RDEB patients when compared to the general 
population.  Firstly they both develop earlier in life, secondly both groups can present with 
multiple primary tumours, with an Australian study demonstrating an average of 7.5 
primary tumours being presented per patient in their cohort of OTRs (Bouwes Bavinck et al. 
1996).  Further still, like SCCs associated with RDEB patients, these tumours tend to be 
more aggressive (Stasko et al. 2004).   
 
The increased incidence of SCC in OTR, and together with an decreased T cell population in 
EB patients (Chopra et al. 1992) implies that although the oncogenic mechanisms in these 
patients are undoubtedly multi-factorial a lowered immune surveillance could aid the 
carcinogenesis in both subsets of patients.  A reduction in immunological function could 
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lead to poorer efficiency in immune mediated destruction of tumour cells.  Consistent with 
the theory that poor immune surveillance leads to cancer susceptibility, is supported by 
increased incidence in patients suffering from immunodeficiency diseases such as HIV 
(Veness 2006). 
 
1.5.3 Increased risk of SCC in burn scars 
SCC commonly occurs in the background of chronically injured and diseased skin, the SCC 
that develops in RDEB patients is a prime example.  Skin affected by; long term ulcers, 
radiation dermatitis and vaccination scars all provide cutaneous defects that are more liable 
to become SCCs (Alam and Ratner 2001).   
 
Further to this, epidermoid cancers that develop in non healing scars, known as Marjolin’s 
ulcers (Sabin et al. 2004) are a rare occurrence but present another subset of patients with 
higher risk of aggressive SCC development, with a high tendency for local recurrence, 
lymphatic metastasis (Sabin et al. 2004; Kadir 2007) and general metastatic rate of 
approximately 30-34% compared to only 0.5-3% in the general population (Novick et al. 
1977; Moller et al. 1979).  One case study, of a 47 year old woman, following the excision of 
a septic ischial bursa sinus, 20 years later presented with a keratinized squamous carcinoma 
which was excised but unfortunately recurred, metastasized and caused death 8 months 
after diagnosis (Cruickshank et al. 1963), demonstrating a 27 year lag period in cancer 
development and then the aggressive and rapidly invasive nature of these SCCs.  There are 
varying reports about the average latency period after the initial ulceration; with reports of 
between 20-40 years (Kowal-Vern and Criswell 2005), which is higher than that of OTRs but 
similar in some respects to the interval seen in RDEB patients.  A recent report of 16,903 
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Danish patients presents a conflicting report that no increased risk of cutaneous 
malignancies is seen in their burns patient cohort (Mellemkjaer et al. 2006).  This could be a 
direct result of improved initial treatment and management of burns. 
 
Although SCC is the most common malignancy in burns patients, other cancers can develop 
as a result of scarring including BCC, melanoma, liposarcoma and adenocanthoma (Kadir 
2007).  Various etiologies have en implicated in the malignant transformation of burn scars 
including; toxin production from tissue damage, immunological factors, poor 
vascularisation, weaker lymphatic systems which may lead to poorer immunological 
defence and DNA mutations (Lindelof et al. 2008).  A prolonged wound healing 
environment which can lead to increased proliferation of cells and abnormal keratinocyte 
behaviour has also been implicated in burn scar malignant transformation; this is similar to 
the circumstances of keratinocyte cell biology associated with SCC development in RDEB 
patients. 
 
1.5.4 Xeroderma Pigmentosum patients have a high frequency of cSCC 
Mutations of DNA repair machinery predispose to many cancers (Yuspa and Epstein 2005).  
A rare recessive genodermatoses known as Xeroderma Pigmentosum (XP) is characterised 
by amplified sensitivity to UV light with exaggerated sun burning and a high susceptibility to 
cutaneous malignancies (Kraemer et al. 1987).  It is now known that this disorder is caused 
by defective DNA repair due to aberrations in the Nucleotide Excision Repair (NER) pathway 
in most patients (van Steeg and Kraemer 1999).  XP sufferers develop malignancies at very 
high frequency; with a 2000 fold increase in incidence compared to the general population 
(Kraemer 1993). 
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A comprehensive literature review of XP patients between 1974 and 1982 showed 45% of 
XP patients developed SCC or BCC.  Contrasting to RDEB associated SCC, the tumours that 
develop in XP patients do develop earlier with the median age of 8 years, but they generally 
have good prognosis with a 70% probability of survival and metastasis is rare (Kraemer et 
al. 1987).  The molecular pathology behind the development of SCC is known in this patient 
group, as mentioned earlier the NER pathway is defective.  Tumours occur mainly on sun-
exposed sites and damage to the DNA via UV radiation is ineffectively repaired leading to 
the development of a mutant population of cells.   
 
Other conditions exist that have a higher malignancy incidence, including some 
inflammatory disorders such as discoid lupus erythematosus, lichen sclerosis, lichen planus 
and cutaneous tuberculosis which have all been reported to predispose patients to 
development of skin tumours (Alam and Ratner 2001).  
 
Although the process of cancer initiation which seems to be activated in all these 
conditions, and for reasons that remain unknown in a number of skin diseases, it is possible 
to theorise that this is due to a complex array of aberrations and interplay involving 
genetics, tumour microenvironment and immune function.  Whilst these diseases share 
similarities in incidence of cutaneous SCC and parallels to RDEB in terms of pathophysiology 
of chronic wound environments and a compromised immune system, no similarities in the 
molecular pathogenesis of cutaneous malignancies in these patient groups have been 
identified. 
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1.5.5 Other malignancies in RDEB SCC 
Malignant melanoma is uncommon in RDEB but still poses significant risk (Mallipeddi 2002), 
one report outlined an RDEB patient with melanoma (Chorny et al. 1993).  National EB 
Registry (NEBR) data analysis between 1986 and 2006 revealed melanoma arose in 2% of 
DDEB patients and 2.1% of sev-gen RDEB (Fine et al. 2009). 3 RDEB patients with melanoma 
were between 2 and 12 years of age.  This study shows a total cumulative risk of melanoma 
development in RDEB patients of 2.5% by age 12  (Fine et al. 2009), compared to a risk of 
1.15% in the US general population (Rigel et al. 1996).  
 
Basal cell carcinoma (BCC) is the most common NMSC in the general population; but 
remains relatively low risk in EB patients.  NEBR demonstrated between 1986 and 2006 
there were no reported cases of BCC in sev-gen RDEB but 2 cases in RDEB-O (Fine et al. 
2009).  Within EB diseases, BCC is most common in EBS patients with a cumulative risk of 
8% by the age of 40 (Fine et al. 2009).  No significant risk is posed for RDEB patients to 
develop of internal malignancies (Fine et al. 2009). 
 
1.6 Aims of Thesis 
As of yet, no distinct biomarkers of RDEB SCC development or progression have been 
identified.  New investigative methods such as higher resolution expression arrays and next 
generation sequencing will hopefully move this research forward.  Signalling pathways 
already implicated in sporadic SCC include epidermal growth factor receptor, mitogen 
activated protein kinases, phosphotidylinositol 3-kinase (Featherstone 2007).  One 
similarity of RDEB SCC and non-RDEB SCC manifestations is the up-regulation of the 
transmembrane glycoprotein MUC1 (Cooper et al. 2004; Rodeck et al. 2007).  It is necessary 
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to continually strive to identify the key pathways involved in the initiation of SCC 
development in these patients in the hope of targeting these pathways for potential 
preventative and combative therapies.  
 
One initial aim of this thesis is to investigate TP53 expression in RDEB.  In light of recent 
research on the p53 gene and the identification of beta, gamma and delta isoforms 
(Bourdon et al. 2005) along with only a few studies on TP53 status in RDEB SCC, this 
outlines an interesting avenue to establish for the first time the TP53 isoform status in 
RDEB SCC.  If present, mutation analysis would enlighten as to whether they are fully 
functional or abnormal proteins in these tumours. 
 
Microarrays have been utilised in thousands of studies to compare expression profiles 
between diseased and normal tissues.  To determine genetic pathways implicated in 
initiation, progression and maintenance of disease, the aim of this project is to utilise the 
results from a global gene expression array performed by previous members of Dr Andrew 
South’s laboratory using RDEB SCC keratinocytes, Normal Human Keratinocytes and non-
RDEB SCC keratinocytes to establish candidate therapeutic targets of RDEB associated SCC.  
All SCC cell lines were generated from primary tumours and SNP mapping confirmed the 
samples were of neoplastic origin rather than normal untransformed cells.  The initial 
hypothesis being that RDEB SCC represents a distinct phenotype of SCC compared to 
sporadic non-RDEB SCC due to the clinical presentation of the disease and its aggressive 
nature.   
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Knowing which genes are expressed and at what levels are key questions in understanding 
many diseases at the molecular level.  Microarrays provide a platform that can give an 
insight into the expression profiles of many disease states to help decipher the cause and 
consequence of genetic aberrations, identify therapeutic gene targets and the effects of 
drugs on cells.  This is a versatile method which is capable of analysing the mRNA 
expression levels of thousands of genes simultaneously thus giving a global view of a 
sample’s transcriptome in a single experiment.  This method, and in fact this microarray 
study has been used to investigate changes between SCC (including UV-induced and RDEB 
associated SCC as one sample group) and NHK (grouped including RDEB keratinocytes), 
which has ultimately derived a 435 gene signature of SCC and identified 2 definitive 
therapeutic targets of SCC; PLK1 and c20orf20 (Watt et al. 2011).  Thereby validating the 
use of this array as a suitable method for discovering real genetic differences between 
RDEB SCC keratinocytes and non-RDEB SCC keratinocytes, in the quest to identify 
therapeutic targets of the aggressive SCC that develop in RDEB patients.  Validation of the 
genes identified by the microarray as being differentially regulated between RDEB SCC 
keratinocytes and non-RDEB SCC keratinocytes were then subjected to further analysis to 
establish if they are affected by the expression of Type VII Collagen, which thereby implies 
whether or not dysregulation of certain genes are a direct consequence of the RDEB 
phenotype or as a result of the genetic instability associated with cancer cells.  One 
particular gene of interest; SLCO1B3; which encodes an organic anion transporter; 
OATP1B3 was carried forward and interrogated on its suitability as a target of RDEB SCC 
and is discussed in detail in Chapter 5.  The ultimate aim of this investigation was to identify 
potential therapeutic targets of RDEB associated SCC. 
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1.7 Significance of Research 
Clinical data suggest there is a defined pathology unique to RDEB SCC yet numerous studies 
imply only similarities via molecular and histological studies (Arbiser et al. 2004; Cooper et 
al. 2004; Mallipeddi et al. 2004; Kivisaari et al. 2008).  To date no single study has identified 
a distinct difference in histology or expression of markers both at the mRNA or protein level 
when comparing RDEB to non-RDEB SCC.   SCC is the greatest cause of death in RDEB 
patients.  Although huge resources are being spent on research into the treatment of EB, it 
is only recently that better treatment strategies providing long term therapies against the 
primary disease RDEB have become available, but these treatments which target the 
blistering phenotype have not yet been used for long enough to establish if they reduce the 
risk of SCC in the long term in this set of patients.  Furthermore, the generic squamous cell 
carcinoma treatment strategies used to deal with sporadic SCC in the general population 
have proved of little use in the treatment of SCC that arise in the background of RDEB, with 
surgical treatment being primarily palliative (Uitto et al. 2010) and 41.9% of sev-gen RDEB 
patients having to undergo surgical amputation of part of their affected limbs due to the 
regional spread of SCC (Fine et al. 2009).  Therefore effective treatment strategies are a 
substantial clinical need which remains unmet for these patients.  Whilst we are still unable 
to prevent the development of SCC or to prevent the metastatic potential of the mutagenic 
keratinocytes in RDEB patients it is unequivocally of utmost importance to identify 
therapeutic targets of RDEB SCC and to ultimately develop treatment modalities that 
provide patients with a better prognosis if not cure for their cancer.  
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Chapter 2 
Material and Methods 
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2.1 General Materials 
2.1.1 Specialised materials  
3mm Whatman paper      Whatman 
Filter flasks       Nunc, Denmark 
Hybond ECL nitrocellulose membrane    Amersham, UK 
NuPage 4-12% Bis-Tris gels      Invitrogen  
NuPage novex Tris-Acetate mini gels     Invitrogen  
Top10 One Shot electrocomp cells     Invitrogen 
Cryo 1°C freezing container     NalGene, USA  
CryoVials       Nunc, Denmark 
 
2.1.2 General reagents 
100bp DNA ladder       Invitrogen, UK 
1kb DNA ladder       Invitrogen, UK 
Alkaline phosphatase (AP)     Roche, Germany 
Calcium Chloride       Fluka Biochemika, 
Switzerland 
COL7A1 Taqman probes     Applied Biosystems 
Dulbeccos modified Eagles medium    Life Technologies, UK 
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ECL plus western blotting detection reagent    Amersham, UK 
EDTA  Fluka Biochemika, 
Switzerland 
EDTA-free protease inhibitor cocktail tablets   Roche, Germany 
Electrophoresis grade agarose      Invitrogen, UK 
Hepes        Fischer Scientific, UK Ltd 
Human genomic DNA      Roche, Germany 
Human liver total RNA       Clontech, CA, USA 
Isopropanol       Fischer Scientific, UK Ltd 
Lipofectamine  2000       Invitrogen, UK 
M-MLV reverse transcriptase     Promega, USA 
Rainbow marker       Invitrogen, UK 
Random primers      Invitrogen, UK 
RNase-free water       Invitrogen, UK 
RNasin plus RNase inhibitor      Promega, USA 
Set of dNTPs       Promega, USA 
Taqman universal PCR master mix, no UNG   Applied Biosystems 
T4 poly nucleotide kinase      Invitrogen, UK 
Trypsin        GibCo BRL 
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Phosphate buffered solution      Fischer Scientific, UK Ltd 
Sodium Chloride      Fischer Scientific, UK Ltd 
Tris-Base        Fischer Scientific, UK Ltd 
Triton X-100        Fischer Scientific, UK Ltd 
Versene       GibCo BRL 
 
2.1.2 Assay kits 
Cell titer 96 AQeous One solution cell proliferation assay Promega, USA 
Dual luciferase reporter assay system     Promega, USA 
ECL advance western blotting detection kit   Amersham, UK 
FastStart high fidelity PCR System    Roche, Germany 
QIAquick gel extraction kit      Qiagen, Germany 
QIAquick maxi prep kit       Qiagen, Germany 
RNeasy mini kit       Qiagen, Germany  
TOPO TA cloning kit      Invitrogen, UK 
Wizard plus mini preps DNA purification system   Promega, USA  
 
All other chemicals used in the following experiments were purchased from Sigma Aldrich 
(Poole, Dorset, UK) unless otherwise stated. 
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2.1.3 Antibodies 
All primary antibodies used for the detection of proteins are listed in Table 2.1, secondary 
antibodies used and their appropriate dilutions for each method are listed in Table 2.2. 
 
 Antibody Host  Supplier 
Anti-Collagen 
Type VII 
Rabbit Polyclonal 
IgG 
Calbiochem, Darmstadt, Germany 
Beta-Actin 
Mouse 
Monoclonal IgG 
Abcam 
OATP8 
Rabbit Polyclonal 
IgG 
Professor B. Steiger, 
 University Hospital, Zurich 
OATP8 C14 
Goat Polyclonal 
IgG 
Santa Cruz 
OATP8 D16 
Goat Polyclonal 
IgG 
Santa Cruz 
OATP8 H-52 
Rabbit Polyclonal 
IgG 
Santa Cruz 
OATP8 MDQ 
Mouse 
Monoclonal IgG 
Novus Biologicals, 
Littleton, CO, USA 
p16 (c20) 
Rabbit Polyclonal 
IgG 
Santa Cruz  
p53 (DO-1 SC126) 
 Mouse 
Monoclonal IgG 
 Santa Cruz 
Table 2.1 Table of primary antibodies (Ab) used for investigating protein expression 
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Antibody Dilutions Supplier 
Donkey-anti-goat IgG 
HRP (H&L) 
WB/IMF 
1:2000 
Jackson 
ImmunoResearch, 
Suffolk, UK 
AlexaFluor 594 goat-
anti-rabbit 
1:800 
IMF 
Molecular 
Probes, Eugene, 
USA 
AlexaFluor 488 goat-
anti-mouse 
1:250 
IMF 
Molecular 
Probes, Eugene, 
USA 
Polyclonal rabbit-
anti-mouse 
 WB 
1:2000 
 Dako, Denmark 
Polyclonal swine-
anti-rabbit 
WB 
1:4000 
Dako, Denmark 
Table 2.2 All secondary antibodies used, their dilutions and suppliers 
 
2.1.4 General buffers 
10x Phosphate Buffered Saline (PBS)  
0.2M phosphate buffer (1 part 0.2M NaH2PO4H2O and 4 parts 0.2M NaHPO42H2O) + 
1.5M NaCl, pH 7.4 
10X TBE 
104g Tris Base + 55g Boric Acid +40ml 0.5M EDTA 
Tris tween buffer solution (TTBS)  
50mM Tris/HCl (ph8.0), 0.1% (v/v) tween, 150mM NaCl 
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Transfer Buffer  
14.4g glycine + 3.03g tris (hydroxymethyl) methylamine dissolved in 400ml dH2O 
then make up to 800ml with dH2O and add 200ml methanol 
RIPA buffer 
150 mM sodium chloride +1.0% Triton X-100 + 0.5% sodium deoxycholate + 0.1% 
SDS (sodium dodecyl sulphate) + 50 mM Tris, pH 8.0 
 
2.1.5 Fixatives 
4% (w/v) paraformaldehyde (Merck, Darmstadt, Germany) made up in PBS.  The powder 
was dissolved in water by stirring at 60°C and adding drops of NaOH until the solution had 
cleared.  
 
Methanol Acetone made up from 1:1 ratio of methanol (VWR, France) and acetone (VWR, 
France). 
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2.2 Methods 
2.2.1 Cell Culture 
2.2.1.0 SCC Cell Lines 
A list of SCC cell lines used for all experiments performed in this thesis, are listed in table 
2.1. 
 
2.2.1.1 Maintenance and storage of cell lines 
Maintained at 37°C, 5% humidified atmosphere with 5% CO₂.  Cells were grown in 
keratinocyte medium containing; 300ml DMEM with 100ml Ham F12, 40ml FBS and 4ml 
RM+ (growth factors). Cells are maintained in 75cm2 Nunc filter flasks (Nunc, Roskilde, 
Denmark), and grown to approximately 75% confluency before routine passaging.  Growth 
media was changed approximately every 2 days. 
 
Phoenix cells were used as a packaging line for retroviral transfections and were maintained 
at 37°C, 5% humidified atmosphere with 5% CO₂ in media containing only 90% DMEM and 
10% FBS. 
 
2.2.1.2 Cell passaging 
Cells were passaged by aspirating off media and washing cells with 5ml PBS.  Cells were 
then incubated with 1.5ml Versene and 1.5ml dH2O for 2-3 minutes to remove any 
contaminating fibroblasts, cells were then washed again in PBS and dissociated from the  
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Sample Patient Age Sex 
Tumour 
Location 
Differentiation 
State 
Metastasis 
RDEB 
SCC 1 
RDEB COL7A1 
c.3832-1G>A 
54 M n/a 
Poorly 
differentiated 
No 
RDEB 
SCC 2 
RDEB COL7A1 
p.R525X; p.R578X 
36 F 
Left 
forearm 
Moderately 
differentiated 
No 
RDEB 
SCC 3 
RDEB COL7A1 
c.8244insC 
32 F Shoulder Unknown n/a 
SCC 1 Renal Transplant unknown M Forearm 
Well 
differentiated 
No 
SCC 2 Cardiac Transplant unknown M Hand 
Well 
differentiated 
No 
SCC 3 Renal Transplant unknown M Hand 
Moderately 
differentiated 
Yes 
SCC 4 Renal Transplant unknown M Ear 
Poorly 
differentiated 
Yes 
SCC 5 Immunocompetent unknown M 
Right 
temple 
Moderately 
differentiated 
Yes 
 
Table 2.3 SCC cell lines use for experiments. RDEB SCC refers to SCC cell lines generated from 
Recessive Dystrophic Epidermolysis Bullosa Patients; SCC refers to cells lines from non-RDEB 
individuals. 
 
plastic surface by incubation with 3ml Trypsin. Cells were centrifuged at 1200rpm for 3 
minutes. Media was aspirated off the cell pellet which was then re-suspended in 
approximately 5ml of fresh keratinocyte media.  Approximately, 106 cells were plated into a 
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new 75cm2 Nunc filter flask containing 10ml Keratinocyte media, and maintained in culture. 
Remaining cells were prepared for cryostorage. 
 
2.2.1.3 Cryostorage of cells 
Cells were resuspended at a concentration of a minimum of 1 million cells per ml in 
Freezing media (FBS + 10% DMSO).  Cells were aliquoted in 1ml volumes into cryovials 
(Nunc), and placed in a Cryo 1°C freezing container (NalGene, Rochester, NY, USA) and 
placed at -80°C for a few days before to slowly bring down the temperature prior to long 
term storage in liquid nitrogen. 
 
To bring up cells from cryostorage, vials were thawed quickly in a 37°C water bath and 
added to 5ml of cold keratinocyte media, as the DMSO in the freezing media is toxic to cells 
at room temperature.  Cells were then centrifuged at 1200rpm for 3minutes, then 
aspirating of the media.  Cells were re-suspended in fresh keratinocyte media and plated 
out in either 25 or 75cm2 filter flasks and maintained in culture.  
 
2.2.1.4 Cell counting 
Experiments which required cells to be plated out at specific densities, cells were counted 
using a Casy Counter (Roche Diagnostics Ltd, West Sussex, UK); a cell counting machine 
which utilises multiple channel technology to give highly accurate cell counts. 100μl of cell 
suspension is diluted in 900μl CasyTon and placed under the capillary.  Readings were given 
in cells/ml. 
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2.2.1.5 siRNA Transfections 
SLCO1B3 knockdown experiments were performed by transfecting RDEB SCC keratinocytes 
with siRNA using Lipofectamine 2000 (1mg/ml) (Invitrogen, UK), following the 
manufacturers’s protocol.  Briefly, the day before transfection cells were plated out in 6-
well plates at a density of 300,000 cells per well in 2ml of keratinocyte medium.  Generally 
for high transfection efficiencies it is recommended that cells are transfected at 
approximately 90-95% confluency to minimise toxicity to cells.  The most important aspect 
of transfecting cells is maintaining the correct ratio of DNA:Lipofectamine2000 when 
preparing each complex.  For each well, the following volumes of reagents were used; 5μl 
of Lipofectamine2000 diluted in 250μl of Opti-Mem I reduced serum media (Opti-Mem) and 
incubated for 5 minutes, whilst a total of 5μg DNA was diluted in 250μl Opti-Mem. Both 
complexes were mixed together and incubated at room temperature for 20minutes. The 
total 500μl complex was added to the well, and cells incubated at 37° in CO2 humidified 
incubators for 6 hours, before changing the media for 2.5mL fresh keratinocyte medium 
and maintained in culture for 48 hours. 
 
2.2.1.6 Cell fixation 
Cells were plated out onto glass cover slips in 24 well plates, at a density of 0.5 million cells 
per ml of media, and 1ml of cell suspension was added to each well.  Cells were grown for 2 
days prior to fixation. To fix cells using methanol acetone, first the media was aspirated and 
cells washed with 1ml PBS.  500μl of ice-cold methanol acetone was added to each well and 
placed at -20°C for 20 minutes.  Methanol acetone was removed and cells were washed 3 
times for 5 minutes with 1ml of PBS.  24-well plates contained fixed cells were stored at 4°C 
in PBS until needed.  
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2.2.2 RNA/DNA Manipulations 
2.2.2.0 RNA isolation 
Keratinocyte cell lines were grown to 2 days post-confluency in 75mm dishes, washed in 
phosphate buffered saline (PBS), and detached from the culture dish by adding 2ml of RNA-
Bee (Biogenesis, Poole, England) and physically removing cells with a cell scraper (Sarstedt, 
Newton, NC, USA).  Cell lysates were then collected and aliquoted 1ml into two 1.5ml 
microcentrifuge tubes.  20% chloroform (200μl/ml) was added to each aliquot and shaken 
vigorously for 30 seconds.  Tubes were placed directly on ice for 5 minutes, prior to being 
pelleted via centrifugation at 13,000rpm, at 4°C for 15 minutes.  The aqueous phase was 
collected and removed to a fresh microcentrifuge tube and an equal volume of isopropanol 
was added. RNA was then precipitated overnight at 4°C or stored at -80°C for long term 
storage. RNA was pelleted at 13,000rpm, for a further 15 minutes, and the pellet was 
washed in 70% ethanol (ETOH) followed by air drying for 5 minutes. RNA was resuspended 
in 100μl dH20, and quantified using the Nanodrop. Approximately, 50μl of RNA was purified 
using the Qiagen DNaseI treatment protocol followed by the Qiagen RNA mini kit, no more 
than 100μg of RNA can be added to a single RNA mini column, therefore volumes of 
starting RNA may vary. RNA was eluted from the column in 50-100μl dH20.  RNA was re-
quantified using the Nanodrop, and stored at -80°C in single use aliquots to prevent 
freezing thawing which may cause degradation of the RNA. 
 
2.2.2.1 RNA isolation from tissue 
RNA was extracted from tissue samples by the Tayside Tumour Bank (Ninewell’s Hospital, 
Dundee, UK). Poor quality RNA can greatly hamper and compromise gene expression 
results and differences between the sample qualities can cause misinterpretation of results.  
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The tumour bank tested the quality of each RNA using the Agilent 2100 Bioanalyser, to 
electrophoretically separate the sample which is then detected via laser induced 
fluorescence. This method of examining RNA quality is by far the most accurate.  Principally,  
good quality RNA will have high 18S and 28S peaks and low 5s peaks (Figure 2.0), the RIN 
(RNA integrity number) is then derived from the electropherogram curve and samples are 
assigned a number from 1-10; with 1 showing the most degradation of RNA and 10 showing 
the least (Fleige and Pfaffl 2006). 
 
 
 
 
Figure 2.0 RNA integrity electropherogram 
An example of an RNA integrity electropherogram for one of the RDEB SCC tissue samples, this 
particular sample shows high 18S and 28S peaks and was assigned a RIN of 8.4 
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2.2.2.2 cDNA synthesis 
2.5ug of total RNA was used as a template for first strand cDNA synthesis. Briefly, RNA was 
diluted in up to 20μl of dH20. Next, the following components were added to the RNA prior 
to incubating at 65°C for 10 minutes: 
7μl 5 x M-MLV RT-buffer (Promega, Madison, WI) 
4μl 10mM dNTPs (Promega, Madison, WI) 
1μl RNasin (Promega, Madison, WI) 
1μl random primers (OD 90, Invitrogen) 
Heating the reaction denatures the RNA and allows the dNTPs and random primers to bind 
to the single stranded RNA.  After initial incubation period, reactions are placed directly on 
ice.  2μl of M-MLV reverse transcriptase (equivalent to 400 units) (Promega) was added or 
in the case of control samples, 2μl of dH20 was added to a duplicate sample. Samples were 
then incubated at 42°C for 90 minutes. cDNA was then quantified via spectrophotometry 
and its purity tested by running a standard RT-PCR reaction using the desmoplakin (DSP) 
gene to identify if samples are contaminated by genomic DNA (gDNA) prior to its use in 
further investigations.  The primer sequences for DSP were; Forward: 5’-CTG AGG TCT TCT 
TCA ATC CC-3’ and Reverse 5’-TGC GGA TGG CAT CTG AAT G-3’ and had an annealing 
temperature of 57°C. PCR products were visualised on an agarose gel and as the primers 
are able to amplify cDNA and gDNA with amplicons of 178bp and 1.25kb, respectively, as 
seen in Figure 2.1.  
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Figure 2.1 Genomic contamination identified by AGE of cDNA and –RT samples. Desmoplakin 
amplification in SCC 2 should produce a product of 178bp as seen in the cDNA lane, whilst the 
control cDNA; -RT (without reverse transcriptase) showed an amplified band of approximately 
1.25kb signifying genomic contamination of this sample. 
 
2.2.2.3 Spectrophotometry 
DNA and RNA were both quantified using the Nanodrop 2000 (Labtech, International, UK).  
dH20 was used as a blank to adjust for any background.   
 
2.2.2.4 Primer design 
Oligonucleotide primers were manually designed for all genes tested for gene expression, 
unless otherwise stated.  Primer pairs were designed to amplify a product that spanned an 
exon-exon boundary to reduce the risk of amplifying genomic DNA.  All primers were 
designed in a 5’ to 3’ orientation from the plus to minus strand of DNA and the following 
parameters were taken into account to design the most efficient primer sets: 
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 Primers ranged between 18-24 nucleotides in length, which was dependent on GC 
content within each sequence.  Where possible >4 consecutive GC’s were avoided. 
Ideally 50% GC content was achieved to give greater stability but still maintains a 
unique sequence.  A range of 40-60% GC could be used if necessary. 
 Primer pairs were designed to amplify a product of 80-200bp, which is the range 
that is most easily amplified using standard PCR thermal cycling parameters. 
 All primer pairs were searched for in the BLASTN (Altschul et al. 1997), to locate 
similarities between sequences, and to identify homologous matches.  This ensures 
the specificity of the primers to amplify a single product.  
 Primers designed to amplify genes identified by the microarray, were made 
specifically to pick up the same transcript variant(s) that the Illumina array probe 
sequence would hybridise to. 
Finally, all primers were ordered in a lyophilised format from MWG eurofins (Germany), 
and reconstituted in dH2O at a concentration of 1nm/μl stock concentration. Primer 
annealing temperatures could be calculated manually; if the recommended temperature 
was not successful in amplifying a product, in which case the following formula was used: 
69.3 (0.41(GC%)) – 650/oligo.length 
 
2.2.2.5 Reverse transcriptase PCR 
Standard PCR (RT—PCR) was carried out in 25 or 50μl reaction volumes.  Each 50μl reaction  
contained; 5μl 10x PCR Buffer (HT Biotechnology), 1μl forward primer (20pMol/μl), 1μl 
reverse primer (20pMol/μl), 1μl dNTPs (10nM), 3μl of cDNA, 0.5μl SuperTaq (HT 
Biotechnology) and 38.5μl dH2O.  If performing a number of PCR reactions, make a master 
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mix for number of reactions you will use plus one, to reduce pipetting errors.  Standard 
cycling conditions were used and can be found in Table 2.4 and were performed on the 
DNA Engine Tetrad 2 (BioRad, Nottingham, UK).   
 
Step Temperature Time (seconds) Number of Cycles 
Enzyme Activation 94°C 2minutes 1 
DNA Denaturing 94°C 10 
 
 
 
Annealing 55-65°C* 10 34 
Extension 72°C † 
 
Final Extension 72°C 5minutes 1 
Table 2.4 Standard PCR cycling parameters.  *Annealing temperatures were determined uniquely 
for each primer set used and was dependent on length and GC content of primer sequences.  
†Extension times could vary depending on the length of amplicon, generally 1kb products required 1 
minute for extension. 
 
2.2.2.6 Agarose gel electrophoresis 
PCR products were ran on an agarose gel, where they were subjected to a voltage that 
caused the migration of DNA from the cathode to anode and visualised under ultraviolet 
(UV) light in a method called agarose gel electrophoresis (AGE).  The percentage of agarose 
used is dependent on the size of products being visualised, usually larger products require a 
lower percentage gel to allow easier migration of fragments through the gel matrices. As a 
general rule; a 2% agarose gel is adequate for 0.1-1kb fragments, whilst 1-5kb fragments 
are better ran on 0.8-1% agarose gels. Briefly, electrophoresis grade agarose was mixed 
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with 100ml 0.5% Tris-borate-EDTA-acid (TBE) buffer and heated until the agarose has 
dissolved, before cooling prior to adding 6μl ethidium bromide (0.1mg/ml), a DNA 
intercalating dye.  Agarose solutions were poured in gel trays and allowed to set.  PCR 
products were prepared with 10x loading buffer containing glycerol and bromophenol blue, 
subsequently 5-10μl of sample was loaded per well.  Gels were run at 70 volts (v) for 
approximately 1.5 hours and visualised using a UV light transilluminator.  The GeneGenius, 
(Synergy) gel imaging machine was used to document the results if required (Figure 2.2)  
 
 
 
 
Figure 2.2 Example of an agarose gel.  Gel was loaded with 6.5μl 100bp DNA ladder, followed by 
10μl of each sample and run at 70 volts for 1.5 hours.  All samples show an amplified product of 
correct size at approximately 125bp and no contamination is present in the no template control 
(NTC).  
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2.2.2.7 Direct sequencing 
Prior to direct sequencing, PCR products were purified using an ExoSap protocol, which 
utilises two hydrolytic enzymes; Exonuclease I (ExoI) and Shrimp alkaline Phosphatase 
(Sap).  ExoI is used to remove residual single stranded primers and DNA whilst Sap 
eliminates unused dNTPs from PCR products.  Briefly, both ExoI and SapI were diluted in 
their corresponding buffers at a ratio of 1:50 and 1:20, respectively.  Then, equal volumes 
of ExoI and Sap were mixed to create the ExoSap solution, of which 2μl was added to each 
purification reaction containing 5μl of PCR product. Reactions were incubated at 37°C for 
15 minutes, followed by heat inactivation at 80°C for 15 minutes. Samples were aliquoted 
and sent to the DNA Analysis Facility at Dundee University (Ninewells Hospital, Dundee) for 
direct sequencing by Capillary Electrophoresis using the 3730 DNA Analyser (Applied 
Biosystems, UK). Both PCR products and plasmid preps were sequenced by the DNA 
Analysis Facility, and the concentrations required for the different samples are listed in 
Table 2.5. 
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Template Quantity/μl 
PCR Products 
100-200bp 1-30ng 
200-500bp 3-10ng 
500-1000bp 5-20ng 
1000-2000bp 10-40ng 
>2000bp 20-50ng 
Plasmid DNA 
Double Stranded  150-300ng 
 
Table 2.5 Required template concentrations for DNA sequencing 
 
 
2.2.2.8 High fidelity PCR 
The SLCO1B3 ORF and promoter fragments were amplified using the FastStart High Fidelity 
PCR Kit (Roche, Germany).  Each 50μl PCR reaction was setup using each component listed 
in Table 2.6.  Reactions were then run on the DNA Tetrad 2 (BioRad) using the cycling 
conditions outline in Table 2.7 
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Reaction Component 
Volume 
Required 
cDNA template 1μl 
High Fidelity Reaction Buffer 5μl 
dNTPs (10mM) 2μl 
Forward Primer (20pMol/μl) 1μl 
Reverse Primer (20pMol/μl) 1μl 
High Fidelity Enzyme 0.5μl 
dH2O 39.5μl 
Table 2.6 High Fidelity FastStart PCR reaction components and required volumes 
 
 
Step Temperature Time  
Number of 
Cycles 
Enzyme Activation 95°C 5mins 1 
DNA Denaturing 95°C 30sec 
 
 
 
Annealing 55-65°C* 30sec 40 
Extension 72°C 2.5minsᵻ 
 
Final Extension 72°C 5mins 1 
Table 2.7 Cycling conditions for High Fidelity PCR reactions * Annealing temperature was 
dependent on the primer set used, †Extension times varied on the length of the amplified product, 
approximately 1kb is extended in 1 minute 
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2.2.2.9 SYBR Green qRT-PCR 
There are 3 stages of any PCR amplification: the baseline, exponential and plateau phase 
(Figure 2.3).  Quantitative Real-Time PCR (qRT-PCR) allows the entire amplification process 
to be observed unlike in standard RT-PCR in which the end point, or plateau phase which 
occurs when all reagents are exhausted is examined by AGE.  Therefore qRT-PCR which 
measures expression during the early exponential phase is able to detect smaller changes in 
gene expression.  qRT-PCR was used to determine and validate the relative gene expression 
levels of all the genes identified by global gene expression array analysis using the DyNAmo 
SYBR green PCR kit (Finnzymes, Finland). 
 
SYBR green is a DNA intercalating dye which, upon binding to dsDNA, fluoresces.  Basically, 
primers extend the target DNA sequence, then multiple molecules of SYBR green bind to 
the dsDNA product and emit fluorescence.  The fluorescence is dependent on the amount 
of DNA and therefore longer products will generate great fluorescence.  This provides a 
versatile and inexpensive method for investigating gene expression. 
 
Primers for all genes used in this investigation are listed in Table 2.8.  To examine the gene 
expression levels using qRT-PCR: 10μl 2x SYBR Green Master Mix was mixed with 8pmol of 
each primer and 5μl cDNA (80ng/μl) in a total volume of 20μl.  Reactions were performed in 
triplicate for each sample and primer set, alongside an endogenous control which was EF1α 
and ran on the MiniOpticom Real-Time PCR System (BioRad, Hertfordshire, UK).  Cycling 
parameters are outline in Table 2.9 and follow the recommended DyNAmo SYBR Green Kit 
conditions.  Data was collected in “real-time” by measuring the fluorescent signal at the 
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end of each cycle, and in this case was taken at two points 72°C and 80°, followed by the 
generation of a melting curve to identify non-specific products by ramping the temperature 
 
 
Figure 2.3 PCR amplification plot. Three stages of amplification baseline, exponential and plateau 
phase. qRT-PCR readings are taken during the exponential phase whilst standard RT-PCR only gives a 
reading from the final plateau phase 
 
from 70°C to 90°C and collecting data every 4 seconds.  The cycle threshold (Ct), which is 
the number of cycles it takes for the fluorescence to cross the threshold on the 
amplification plot and was determined by setting the baseline to subtract the background 
fluorescence seen in the initial PCR cycles prior to the detection of an increase in 
fluorescence from a PCR product amplification, then manually setting the threshold level in 
the log view of the amplification curve in during exponential phase.  Relative expression 
was determined using the ΔΔCt method (Livak and Schmittgen 2001). 
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Table 2.8  
Gene Primer Sequence 5’ – 3’ Tm (°C) 
AAMP 
F: GTG GAG TCC TTG GGC TTC TG 
R: GCC TAA GAG TCT GCG TAG CC 
61 
ADFP 
F: GCT CTA CCT CTC ATG GGT AG 
R: CCT TGG ATG TTG GAC AGG AG 
59 
BCS1L 
F: CCT GGT TGC GGA AAG AGC AG 
R: GCT CAG CAG GTG GTT GAG TC 
61.4 
C14orf156 
F: CAG CCG GTT GCT TTT GTG AG 
R: CTC TGT GAA AGC CAG TCT CC 
59 
C1orf135 
F: GCA TTG CTT CCT TCT TCA CC 
R: GGA TCA AAT GGT CTA GCT GG 
57.3 
C7orf27 
F: CCT GAG AGT TAT GTC CGA GC 
R: GAG TCT ACG GAG AGG ATGTG 
59 
CCNA1 
F: GAC CTC AGC AAG CAA TTA GG 
R: GAA GTT CTG GAA GTG CTT CC 
57 
DNAJB14 
F: GAT GCC TGT ATA CTG GGT ATG 
R: GCC ACC CTA TCT AGC ATT CTC 
57.9 
DNMT3B 
F: CAG ATG AGA AGT CTG CTA CC 
R: CCT GTC ATC TCT CAG ATG TG 
57 
DUSP23 
F: CTT CGT GCA GAT CGT GGA C 
R: CTT CAC CAG GTA ACA GGC C 
59 
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ERH 
F: GAT GAT CTG GCA GAC CTC AG 
R: CAC TAC AGC ACG CTG TAC AC 
60 
FST 
F: GGA ATG ATG GAG TCA CCT AC 
R: GCA CTG GAT ATC TTC ACA GG 
57 
FTH1 
F: CTT GGC ATA TCT CTT TG 
R: GAA ATT AGC CCG AGG CTT AG 
56.3 
G3BP2 
F: GAC TCT GAA CCA GTT CAG AG 
R: CAT TGC GCC TAA TAT CCC TG 
57 
GSDMDC1 
F: GGC ACT GAC CAT GCT GAG TG 
R: CAC TCT GCT CCA AGA GGC TG 
58.2 
HOXA5 
F: CGC AAG CTG CAC ATA AGT C 57 
R: GAG AGG CAA AGA GCA TGT G 
 
HSPC244 
F: GAG CTG TGC TAT ACC TGT CC 
R: GTT GTG GAA CTC AGT CTC CG 
59.4 
IFITM1 
F: CTT CTT GAA CTG GTC CTG TCT G 
R: GAA TCC AAT GGT CAC GAG GATG 
60 
ITGB1 
F: GTG CTT TCT GTC ACC TCT TC 
R: CAA AGT AAG ACT CGC GTA GG 
57.3 
KRT8 
F: CCT CCA GGG CCG TGG TTG 
R: CCG CAG CTG TTC ACT TGG 
60 
LOC116412 
F: CAA CGC TCC AAC CTC AAC 
R: GTT ACA AAC GTT GGT GGG 
54.9 
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MGAT4B 
F: GAG AGG TGG ACC CAG CCT TCG 
R: CAG GGT ACC CTC AGA AGC CCG 
60 
MXD4 
F: GCA GCA GGA GCA TCG TTT CC 
R: CAC CAG GGC CAA ACT CCA TG 
61 
OAS3 
F: CAT CTG CCC TGT GCT GCA TG 
R: GGG CTG GTG TCC ATC TTC TC 
61 
POFUT1 
F: CCC AGT CGG TCT ACG TTG C 
R: GAC CTG TAC ATC CTC GGC C 
61 
PPP1R3E 
F: GTT CAA GAT CGC ACA GCT AG 
R: CAT CAT GGT TAC ACA GAG GC 
57.3 
RPL23 
F: CCA GTG TCC TTT GAA TCG AC 
R: GAA ATC CGG AAT TTC GCA CC 
57.3 
SLCO1B3 
F: GTT CTC TGC AAC AGG AGG TAC 
58 
R: GGA GCT AGA ATT CCT CCT AG 
SLC25A11 
F: GAA TCC AGA ACA TGC GGA TG 
R: CGT AGC GGA CAA CTT TGA AC 
63.7 
SNRPN 
F: GGA TCG CTT ACA CCT GAG AC 
60 
R: GCA CCG GAG GAA GAA AGA GG 
SNURF 
F: GGA GAT GCC TGA CGC ATC TG 
R: GGT GTA AGC GAT CCC TTG CC 
61.4 
STOML2 
F: GAT AAA TGA GGC AGC AGG AG 
R: CAG TGA AGC TGC TGC ATC TC 
58 
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TJAP1 
F: CTGGAAGAGCTCAATGAGCG 
R: CGAACCATGTCCTGTAGCTC 
59 
TTC7B 
F:GCA CTG TCG GAA GTG GCT TC 
R: CTG TGG CTT CTG CAG GCT TC 
61.4 
VWA1 
F: GGC AAC TTC CTG GAG CTG TC 61 
R:  CAT CGC GTC AAT GGA GC 
 
EF1α 
F: GAG AGC TTC TCA GAC TAT CC 
R: GTC CAC TGC TTT GAT GAC AC 
58 
Table 2.8 List of all primers used for qRT-PCR.  All primer sequences and recommended annealing 
temperatures. 
 
Table 2.9 DyNAmo Sybr Green qRT-PCR cycling parameters *Annealing temperature was specific to 
each primer set 
Step Temperature Time (mins) 
No. 
 of Cycles 
Enzyme 
Activation 
95°C 10 mins 1 
DNA Denaturing 94°C 10 secs 
 
 
 
Annealing 55-65°C* 20 secs 40 
Extension 72°C 30 secs (Plate Read) 
 
2nd Extension 80°C 2 secs (2nd Plate Read)   
Final Extension 72°C 5 mins 1 
Melting Curve  70-95°C Read every 4 secs, hold for 2 secs 1 
Incubation 72°C 5 mins   
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2.2.2.10 TaqMan qRT-PCR 
TaqMan reagents utilises 2 primers and a probe which must hybridise to the target and is 
therefore considered a highly sensitive and has greater specificity and accuracy than 
standard gene expression assays.  This method uses an assay mix specific to a particular 
gene of interest which consists of a non-extendable DNA probe which is labelled with both 
a fluorescent reporter and 3’ quencher.  The quencher prevents the Taq polymerase from 
extending along the DNA. Once both the primers have attached, they are extended by the 
5’ to 3’ exonuclease activity of the polymerase, which also hydrolyses the probe causing the 
fluorophore and quencher to dissociate from the target DNA.  This spatial separation of the 
reporter/quencher disrupts their ability to absorb energy emitted by the reporter and 
therefore creates an increase in the reporter dye fluorescence which is measured during 
the extension of each cycle. The more abundant a gene target, the more binding occurs 
thus the higher the fluorescence emission. 
 
qRT-PCR for COL7A1 (5’ and 3’) and GAPDH was performed using TaqMan probes sets 
Hs001574739_g1, Hs00982422_g1 and Hs001922876_u1 (Applied Biosystems, UK), 
respectively.  These assays all contained a probe which had a minor groove binder (MGB) at 
the 3’ end of the probe, as well as a FAM reporter dye at the 5’ end and a non-fluorescent 
quencher at the 3’.  For each reaction 2.5μl (25ng/μl) cDNA was added to 12.5μl 2x TaqMan 
master mix (AbiGene, UK), 1.25μl assay primer and probe mix and made up to 25μl dH2O, 
on ice.   Reactions were carried out in 96-well plates, in triplicate for each sample and assay 
set.  PCR reactions were carried out by the DNA Analysis Facility at the University of Dundee 
(Dundee, UK), using the 7900HT Fast Real-Time PCR System (Applied Biosystems, UK). 
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2.2.3 Gene Cloning 
2.2.3.0 Transformations into E.coli 
Electrocompetent E.coli (similar to DH10B strain) were electroporated, a method in which 
foreign DNA is introduced into host cells by applying high voltage electric pulses which 
create a pore like structure in the cell wall of the host cells, this increases the permeability 
allowing for easier uptake of DNA.  Briefly, 0.5μl DNA was added to 20μl Top10 
electrocompetent cells (similar to DH10B strain) (Invitrogen, UK) in a 2mm electroporation 
cuvette (PeqLab, Germany) on ice.  The cuvette was then dried and placed in the 
GenePulser (BioRad, Hemel Hempstead, UK) and electroporated at 20v. The time constant 
was checked after each electroporation and should equate to ~4.6.  Cuvettes were 
immediately placed on ice after electroporation and 750mL LB broth was added.  The LB 
broth was then aliquoted into a microcentrifuge tube and placed in a shaking incubator at 
37°C for 45 minutes to recover.  
 
The transformed E.coli was then spread on to agar plates containing 0.1mg/ml Ampicillin 
using aseptic technique.  Plates were incubated overnight at 37°C. 
 
2.2.3.1 Inoculation of colonies 
Colonies that had grown on agar plates were inoculated by using a pipette tip to pick single 
colonies (perfectly circular colonies, with no other colonies around) and placed in 5ml LB 
broth containing 0.1mg/ml Ampicillin.  Cultures were grown at 37°C o/n before creating 
glycerol stocks and purifying DNA using small scale plasmid DNA purification protocol (see 
section 2.2.3.2). 
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2.2.3.2 Small scale purification of plasmid DNA 
To purify DNA from small 5ml plasmid cultures, 1.5ml of LB Broth was aliquoted into two 
microcentrifuge tube and centrifuged at 9,500rpm for 5 minutes.  The supernatant was 
removed and then the Wizard Plus Prep DNA purification system (Promega) was used by 
following the manufacturers instruction to fully lyse and clear cells and effectively use a 
column to bind the DNA and purified by multiple wash steps.  The DNA was eluted in 30μl 
of dH2O, quantified by spectrophotometry (see section 2.2.2.4) and finally run on a 0.8% 
agarose gel to confirm size after restriction enzyme digestion (see section 2.2.3.4). 
 
2.2.3.3 Large scale purification of plasmid DNA 
Using the QIA maxi prep kit (Qiagen) and following the manufacturer’s protocol, DNA was 
purified from plasmid cultures of between 50-100mL in volume.  The kit utilizes a 
“QIAcatridge” and “HiSpeed Maxi Tip” along with lysate cleaning of cell debris and 
isopropanol precipitation of DNA which is then bound to the HiSpeed tip to wash and lyse 
cells, and remove cell debris and bind DNA prior to further wash steps and final elution of 
DNA from the Maxi tip with 1mL of dH2O, which delivers a yield of approximately 500μg 
DNA. 
 
2.2.3.4 Restriction enzyme digestions of plasmid DNA  
Restriction enzymes are endonucleases that recognise specific sequences of DNA and 
cleave dsDNA.  These enzymes are often used in cloning experiments in the preparation of 
target DNA and vector DNA, prior to ligating the DNA of the two fragments together.  RE 
digestions are also useful and quick tools for confirming the size of constructs by creating 
linear DNA which can migration evenly through an agarose gel, unlikely supercoiled DNA, 
and the use of multiple enzymes in a reaction can create specific fragment lengths that can 
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be used to confirm the orientation of an inserted piece of DNA in a vector.  In brief, 10μl 
reactions were set up using a maximum of 10% enzyme in each.  The following components 
were added to a 0.2mL PCR tube: 
1μl RE Buffer (specific to each enzyme) 
1-8μl  DNA 
0.5-1μl RE 
Make up to 10μl with dH2O 
Reactions were incubated at 37°C for 1 hour for a quick digest or for complete digestion; 
o/n, unless otherwise stated by the RE datasheet.  Table 2.10 lists all RE used for the 
experiments discussed in this thesis.  If using only one RE for the digestion of a vector which 
will subsequently be used in a ligation reaction, it was necessary to incubate the digested 
vector with alkaline phosphatase (AP) (Roche), a hydrolase enzyme that removes the 
phosphate groups from DNA which prevents the re-annealing of the vector DNA.  In brief, 
0.5μl of AP plus 1μl AP buffer and 8μl dH2O were added to the digested vector DNA and 
incubated at 37°C for 2 hours, then heat inactivated at 85°C for 30 minutes.  
 
2.2.3.5 DNA purification by gel extraction  
PCR products and plasmid digestions that required purification were loaded onto agarose 
gels of appropriate percentage for the size of product and ran at 100v for approximately 1 
hour, or until bands had completely separated.  Half of the gel lane containing the product 
of interest was visualised using a UV light transilluminator and then aligned with the 
remaining gel where the fragment of interest was excised using a sterile scalpel.  The gel 
remaining gel can then be viewed to establish is complete excision of the fragment was 
achieved.  The whole gel was not viewed under UV light to prevent DNA degradation and 
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damage by the UV light.  Excised products were then purified following the standard 
protocol of the QIAquick Gel Extraction Kit (Qiagen) and DNA was eluted in 30μl dH2O. 
 
Restriction 
Enzyme 
Recognition Sequence 
Temperature 
(°C) 
Supplier 
BsmI 
   GAATG  CN▼ 
65 
New England 
Biolabs, Hertforshire, 
UK CTTAC▲GN 
    
BstXI 
CCAN  NNNN▼NTGG 
50 
New England 
Biolabs, Hertforshire, 
UK  GGTN▲NNNN   NACC 
    
HindIII 
A▼AGCT   T 
37 Invitrogen, UK 
T   TCGA▲A 
    
PvuI 
CG AT▼CG 
37 
New England 
Biolabs, Hertforshire, 
UK GC▲TA GC 
    
SacI 
G  AGCT▼C 
37 
New England 
Biolabs, Hertforshire, 
UK C▲TCGA  G 
    
XhoI 
C▼TCGA  G 
37 Invitrogen, UK 
G  AGCT▲C 
Table 2.10 Restriction Enzymes used for cloning experiments. Closed triangles in the recognition
 
sequences show where the DNA is excised on each strand in a 5’ to 3’ direction. 
 
2.2.4.6 Ligations 
Ligation reactions of previously digested and purified vector and insert DNA were setup 
according to the manufacturer’s protocol for the Sigma ligation kit.  A ratio of 1:10 for 
vector to insert was used in a total volume of 10μl and incubated overnight at 16°C.  
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Reactions were then electroporated in Top10 electrocompetent cells and grown overnight 
at 37°C on Ampicillin agar plates.  Appropriate controls were performed including using the 
vector alone, insert alone and vector minus ligase.   
 
2.2.4.7 Retroviral transduction 
Using healthy phoenix cells, 3.5x106 cells per T25 flask per transfection and leave to settle 
and grow over night. Next day, change the media to 2.5ml pre-warmed phoenix cell media.  
Using the standard Lipofectamine2000 (Lipo2000) transfection protocol, make up the 
following components; 230μl OptiMem mixed with 20μl Lipo2000, and 2.5μg DNA 
(SLCO1B3 ORF in pBabe puro vector) in 250μl OptiMem.  Mix Lipo2000 and OptiMem and 
incubate at room temperature for 5 minutes. Both complexes were then mixed together 
and incubated for a further 20 minutes at room temperature. The 500μl mix was then 
added to the phoenix cells and incubated overnight. The next day, the media was replaced 
for fresh phoenix cell media and incubated overnight.  The following day, the transfected 
phoenix cells were split into a larger T150 flask and left to expand and grow. Two days later 
the media was replaced for 16ml of keratinocyte media and collect the media overnight at 
32°C.  Meanwhile RDEB keratinocytes were seeded at a low density of 2x104 cells per well 
of a 6 well plate and grown over night at 37°C. 
 
The following day, conditioned media from the phoenix cells was collected and replaced 
and continued to grow 32oC.  The collected conditioned media was filter through a.4.2μM 
Nalgene syringe filter (Thermoscientific, Leicestershire) to removed cells, and 8μg/ml 
polybrene was added. The media on the RDEB SCC keratinocytes was replaced with 2ml of 
the conditioned media, centrifuged at 300g for 1 hour at 32oC. After which cells were 
94 
 
immediately place the cells at 32oC for another 1 hour before replacing the media with 
fresh-pre-warmed 37oC media and incubated at 37oC overnight.  Infection cycles were 
repeated for 3 days, and then 48 hours later the cells were selected for recombinant 
expression by adding 2μg/ml puromycin. If cells express the recombinant protein they 
should also express the puromycin resistance gene encoding in the vector DNA, and 
therefore only cells expressing the vector will survive after puromycin selection. 
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2.2.4 Protein Expression 
2.2.4.0 Whole cell lysate extraction 
Cells were grown in 25mm filter flasks to until 2 days post confluence (see section 2.3).  To 
isolate whole cell lysates firstly, the growth media was aspirated and cells were washed in 
3ml of PBS.  After removing all PBS, 3ml of Trypsin was added and flasks were incubated at 
37°C for 3 minutes to dissociation adherent cells from the plastic surface.  An addition 2ml 
of media was added to the flask and the cell suspension was aliquoted into a falcon tube 
and centrifuged at 1200rpm for 3 minutes.  Cell pellets were re-suspended in1ml of ice-cold 
PBS and aliquoted into a fresh 1.5ml microcentrifuge tube. Cell suspensions were 
centrifuged at 10,000rpm for 1 minute and the supernatant removed. Cell pellets were re-
suspended in 100μl RIPA buffer containing complete mini protease inhibitors, and mix well 
by aspirating up and down.  Solutions were then incubated on ice for 30 minutes to obtain 
completely lysed cells, prior to centrifugation at 13,000rpm for 15 minutes at 4°C.  The 
supernatant was then collected in a fresh microcentrifuge tube and stored at -80°C. 
 
 
2.2.4.1 Protein quantification 
Concentration of protein in cell lysates was quantified using the Bradford assay.  In brief, 
bovine serum albumin (BSA) standards of known protein concentrations between 0.1-
1.4mg/ml were prepared; 5μl of each standard was then added to separate wells of a 96 
well plate.  Unknown samples were diluted in RIPA buffer, to be approximately within the 
range of 0.1-1.4μg/ml.  Five microlitres of each unknown sample was added to the 96-well 
along with triplicate wells of RIPA buffer alone to act as a blank to enable the background 
to be subtracted.  To each well, 250μl of Bradford reagent (Invitrogen, UK) was added, and 
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the plate was mixed briefly on a shaker for 30 seconds.  Samples were then incubated at 
room temperature for 5minutes prior to measuring the absorbance of each well at 595nm 
using the VersaMax tuneable microplate reader (Molecular Devices).  A standard curve of 
the net absorbance versus the protein concentration was generated from the BSA 
standards, and used to extrapolate the protein concentrations of all unknown samples, 
taking into account the original dilution factor. 
 
2.2.4.2 Immunoblotting 
For analysis OATP1B3 that has a molecular weight of 120kDa was ran on a 10% Bis-Tris gel 
(Invitrogen). Samples were prepared in a total volume of 20μl to the required concentration 
(20-50μg), and mixed with 4x NuPage LDS sample buffer (Invitrogen) plus and incubated at 
95° for 5 minutes.  Samples were centrifuged briefly before loading onto the gel, gel tank 
was filled with running buffer (14.4g Glycine, 3.03g Tris (hydroxymethyl) methylamine, 
800ml dH2O and 200ml methanol) and run at 120V until the rainbow marker (Invitrogen) 
had ran through the gel and separated completely.  The gel was removed and sandwiched 
into a cassette along with materials pre-soaked in transfer buffer and layered in a specific 
order, see Figure 2.4.  Air bubbles were removed by gently rolling over the layers as the 
sandwich was assembled, before firmly securing into a cassette which was placed in a 
transfer tank (BioRad, Hertfordshire, UK) and ran over night at a current of 25mA.  This is 
known as a wet transfer, in which the proteins migrate from the gel onto the nitrocellulose 
membrane due to the negative charge of particles and the current applied.  
 
Following transfer, the membrane was removed and placed in a tray containing 5% dried 
non-fat milk (Marvel, Dublin, ROI) in PBS with 0.1% tween20 (PBS-T) for 1 hour on a rocking 
97 
 
platform to block non-specific binding.  The primary OATP1B3 antibody (Ab) was diluted to 
the appropriate dilution in 5% milk PBS-T and incubated overnight at 4°C.  After incubation 
with the primary Ab, the membrane was washed 3 times for 5 minutes each in 5% PBS-T 
prior to incubating for 1 hour with the appropriate secondary Horse Radish Peroxidase 
(HRP) linked antibody that was made up in 5% PBS-T.  The membrane was then placed in 
5% PBS-T for 2 minutes on a rocking platform, and then washed 4-5 times for 10 minutes 
each in PBS-T at room temperature on a rocking platform.  The membrane was placed on 
cling film and excess PBS-T was removed with tissue, 1ml of ECL advance western blotting 
detection kit was incubated for 1 minute, which is a  chemiluminescent detection system 
based on peroxide oxidation of the lumigen substrate to produce light.  Excess ECL was 
removed with tissue and the clingfilm folded over. The membrane was place into a dark 
cassette and exposed for autoradiography, using Hyperfilm autoradiography film (GE 
Healthcare, Little Chalfont, UK). 
 
 
Figure 2.4 Immunoblotting transfer setup. The figure represents the order in which the transfer 
cassette for western blotting is set up, and the direction of current. 
 
 
Gel 
Sponge 
2 x Whatman paper 
2 x Whatman paper 
Hybond ECL Nitrocellulose Membrane 
Sponge 
Current 
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2.2.4.3 Immunofluorescent staining of cells 
Parafilm was taped down onto the work surface and cover slips with previously fixed cells 
were rehydrated in 8μl of PBST (Tween 20 0.1%) for 5minutes.  Cover slips were then 
incubated on 8μl of PBST with 3% BSA for 20 minutes. Primary antibodies were made up in 
PBST-BSA, and cover slips were incubated on 10μl of appropriate Ab for 1 hour in a 
humidified atmosphere, control samples were incubated in 10μl of PBST-BSA.  Cover slips 
were then washed 3 times in 8μl PBS, for 5 minutes each time.  Each cover slip was then 
incubated on 10μl of secondary antibody for 45 minutes in a dark container, prior to 
another three PBS washes each of which was 5 minutes and slides were incubated in a box 
to prevent exposure to the light. Each cover slip was then placed on a 4μl drop of Mounting 
(Invitrogen) on a glass slide and the edges of each cover slip were coated with nail varnish 
to prevent movement of the cover slips. Cells were then viewed for immunofluorescent 
staining of specific proteins using a fluorescent microscope. 
 
2.2.4.4 Immunofluorescent staining of tissue sections 
Frozen tissue sections were fixed onto glass slides by placing them in a slide holding 
containing ice-cold methanol acetone and placed at -20°C for 5 minutes.  Slides were then 
air dried for 2 minutes in a humidified atmosphere. Each section was then outlined using a 
wax pen and each slide appropriately labelled with the name of sample, antibody, Ab 
dilution and date.   
 
Sections were rehydrated with PBS for 2 minutes, and then covered with BSA, a protein to 
prevent non-specific binding and incubated in a humid atmosphere for 20 minutes.  Primary 
antibodies were reconstituted in BSA solution to the required dilution.  10μl of primary 
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antibody was added to appropriate sections, and BSA solution was added to negative 
controls, and incubated for 1 hour.  Antibodies and BSA were removed from the sections, 
and slides were subjected to 3 washes in PBS each for 5 minutes.  The appropriate 
“AlexaFluor” secondary antibodies were made up to the required dilutions and 10μl was 
added to all sections, and incubated for 45 minutes in a dark container.   Slides were then 
subjected to 3 more PBS washes.  2 drops of Mountin (Invitrogen) containing Dapi nucleic 
stain was added to each section and then each section was covered with a square glass 
cover slip and left in a dark container until set.  Tissue sections could then be examined for 
protein expression using a fluorescent microscope. 
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2.2.5 Functional Assays 
2.2.5.0 Cell viability assays 
Microcystin-LR (MC-LR) a cyano-bacterial toxin was purchased from Alexis Biochemical’s 
(Nottingham, UK) and was used to investigate if SCC keratinocytes could be selectively 
killed based on the expression of OATP1B3.  A colorimetric assay was used to determine 
changes in cell viability after exposure to MC-LR using the cell titer 96 aqueous one solution 
cell proliferation assay (Promega, Madison, CA) which is an MTS-based assay, which 
basically utilises the ability of living cells to produce NADH and NADPH which is able to 
reduce the tetrazolium 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl0-2-(4-
sulfophenyl)-2H-tetradzolium, inner salt (MTS) product to a soluble formazan in culture.  
When cells die, they lose their ability to reduce the MTS, and therefore the amount of 
formazan produced in proportional to the number of viable cells.   
 
To perform the assay, cells were plated at 3000 cells per well in 50μl of keratinocyte media 
and seeded into 96-well plates. The following day, 50μl of media containing various 
concentrations of MC-LR (0.001-1μM) were added to each well. Appropriate controls were 
performed and included; adding 50μl media alone and 50μl media containing the drug 
vehicle (1% DMSO). Cells were then grown for 24-48 hours at 37°C.  Cell viability was 
determined at time of seeding (T0) and after 24 and 48 hours by adding 20μl MTS solution 
and incubated for 3 hours, prior to reading the absorbance at 495nm in the VersaMax 
tuneable microplate reader (Molecular Devices, UK). 
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2.2.5.1 siRNA knockdown 
The expression of SLCO1B3 was knocked-down by transfecting RDEB SCC 2 cells with a pool 
of 3 SLCO1B3 specific siRNAs (Sigma Aldrich, UK).  Transfections were optimised and carried 
out in 6-well plates. Each well required 5μl of Lipofectamine2000 to be diluted in 250μl 
Opti-Mem and incubated for 5 minutes, followed by diluting a total of 4.0μg siRNA (1.33μg 
of each siRNA) in 250μl of Opti-Mem. Each complex was then mixed together gently and 
incubated for 20 minutes prior to adding to the appropriate well of the 6-well plate. 3 
controls were performed for this experiment and included; control cells with just 500μl 
Opti-Mem added, mock transfected cells which only had the Lipofectamine complex added 
to an addition 250μl Opti-Mem and a final control, known as a non-targeting siRNA in which 
a scrambled siRNA was diluted in Opti-Mem and complexed with Lipofectamine.  Cells were 
maintained in culture for 6 hours prior to changing the media for 2.5mL fresh keratinocyte 
medium.  RNA was then isolated at specific time points after transfection, and converted 
into cDNA using the same method outlined in section 2.2.2.0 and 2.2.2.1, followed by 
determining if knock-down of SLCO1B3 expression was successfully achieved via qRT-PCR 
using the protocol in section 2.2.2.9. 
 
2.2.5.2 Fluo-3 Uptake Assay 
The fluorescent calcium indicator; 1-[2-Amino-5-(2,7-dichloro-6-hydroxy-3-oxo-3Hxanthen-
9-yl)]-2-(20-amino-50-methylphenoxy)ethane-N,N,N0N0-tetraacetic acid tetra ammonium 
salt (Fluo-3) (Invitrogen, Carlsbad, CA)  is a substrate of OATP1B3 and was used to 
investigate the transport activity of OATP1B3 in SCC keratinocytes. 
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Briefly, SCC keratinocytes were grown in culture and plated at as density of 400,000 cells 
per well in 24-well plates.  Cells were grown at 37°C in a humidified 5% CO2 atmosphere for 
24 hours prior to the start of the uptake experiment.  Cells were washed in 0.5mL of pre-
warmed (37°C) and filtered Fluo-3 uptake buffer composed of 142mM NaCl, 5mM KCl, 
1mM KH2PO4, 1.2mM MgSO4, 1.5mM CaCl2, 5mM glucose and 12.5mM HEPES, pH 7.4. 
Then, 1ml Fluo-3 uptake buffer was added to each well, with or without 50μM of the 
inhibitor Rifampicin and incubated at 37°C in a humidified 5% CO2 atmosphere for 1 hour. 
After 1 hour, the uptake before was removed and replaced by 1ml of fresh uptake buffer 
containing various concentrations of Fluo-3, ranging from 0.125 to 50μM. Cells were 
incubated for 1 hour at 37°C.  After the incubation period, uptake was stopped by removing 
the uptake buffer containing the substrate and washing cells 3 times using ice-cold uptake 
buffer followed by adding 500μl 10% SDS in 1mM CaCI2 to lyse the cells. Uptake was the 
determined by measuring the fluorescence in a HT synergy 2 multi-mode microplate reader 
(BioTek, USA) at an excitation wavelength of 485nm and an emission wavelength of 530nm. 
 
2.2.5.3 Tritiated β-estradiol Uptake Assay 
Radiolabelled [3H] estradiol-17β-glucuronide (39.8Ci/mmol) was purchased from 
PerkinElmer Life Sciences (Boston, MA). SCC keratinocytes were grown at 37°C in a 
humidified 5% CO2 atmosphere, and plated at 80,000 cells per well on 24-well plates, 24 
hours later the cells were used in the uptake assay. 
 
Initially, cells were washed 3 times in 0.5mL pre-warmed uptake buffer containing 
116.4mM NaCl, 5.3mM KCl, 1mM NaH2PO4, 0.8mM MgSO4. 5.5mM D-Glucose and 20mM 
Hepes, pH7.4.  Uptake was initiated by adding 200μl of uptake buffer containing the 20nM 
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[3H]-estradiol-17β-glucuronide, in the presence or absence of OATP8 substrates; 
Clotrimazole and Rifampicin. Cells were incubated for 1 hour at 37°C in a humidified 5% 
CO2 atmosphere.  Uptake was stopped by removing the uptake solution, and washing cells 
4 times with 0.5ml of ice-cold uptake buffer.  Cells were then lysed using 500uL 1% Triton X-
100, and physically removing the cells of the plastic using a cell scraper. Lysates were 
homogenized by pipetting up and down.  Finally, 300μl of cell lysate was added to 
emulsifier (PerkinElmer, Buckinghamshire, UK) and used for liquid scintillation counting.   
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Chapter 3 
TP53 Expression and Mutation Status in SCC 
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3.1 Background 
3.1.1 Tumour Suppressor Genes 
Tumour suppressor genes (TSGs) encode proteins that protect cells from damage which can 
cause cancer to development.  When TSGs become mutated this may result in loss of 
phenotypic function and if accompanied by several other genetic changes the cell can 
undergo cancerous transformation.  TSGs generally operate to prevent cellular damage by 
promoting cell cycle arrest and apoptosis.  The general dogma regarding dysfunctional 
tumour suppressor genes is that of Knudson’s “two-hit hypothesis” in which both alleles 
that encode a TSG must be affected for an effect to be apparent (Knudson 1971).  The 
reason being that the mutated alleles of a TSG are most commonly recessive and therefore 
if only one allele is mutated the other allele is still capable of producing a functional 
protein.  Although there are exceptions to this rule, examples of which are talked about in 
greater detail when discussing TP53 mutations further on in this chapter. 
 
3.1.1.1 Gatekeeper TSGs 
TSGs can be divided into 3 distinct classes; gatekeepers, caretakers and landscapers 
(Macleod 2000). Gatekeepers include all genes that act directly to inhibit cell growth, 
whether that is by suppressing cell proliferation, the induction of apoptosis or by promoting 
differentiation.  This category can be further divided into initiation, progression and 
metastatic gatekeepers, depending on the stage at which the genes act to prevent tumour 
growth (Macleod 2000).  There are two main points that can define a gatekeeper TSG.  
Firstly they act directly to prevent tumour growth; loss of function of a particular 
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gatekeeper is a rate limiting step in tumourigenesis and finally the restoration of the 
function of these TSGs in tumour cells can suppress neoplastic growth (Macleod 2000). 
 
3.1.1.2 Caretaker TSGs 
Caretakers act indirectly to suppress growth by certifying the fidelity of the DNA through 
effective repair of DNA damage or prevention of genomic instability.  This group of TSGs 
include many genes involved in DNA repair, such as MSH2, MLH1 and ATM protein kinase 
which respond to ionizing radiation by activating p53 (Giaccia and Kastan 1998).  The 
functional loss of a caretaker TSG can predispose to cancer by increasing the DNA mutation 
rate and thereby increasing the risk that the function of gatekeeper tumour suppressor 
genes will be lost as more mutations occur.  By restoring the function of these genes 
tumour growth is not prevented, as mutations of gatekeeper genes may have already 
occurred as a consequence of the original caretaker function loss (Kinzler and Vogelstein 
1998).  Interestingly, the TP53 gene can be classified as both a gatekeeper and caretaker 
TSG.  As p53 induces apoptosis, it would appear to act as a gatekeeper, however whilst 
acting as “guardian of the genome” it prevents genomic instability and therefore would 
then be referred to as a caretaker TSG (Lane 1992).   
 
3.1.1.3 Landscaper TSGs 
Finally, landscaper TSGs are predicted to act by controlling the microenvironment in which 
tumour cells grow.  The term landscaper TSG was first described following observations in 
juvenile polyposis syndrome (JPS) a disease characterised by polyps in the gastrointestinal 
tract that occur in childhood whereby initiating lesions were found in stromal cells 
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surrounding the tumour rather than directly in the tumour cells (Kinzler and Vogelstein 
1998; Whittle et al. 2010).  Landscaper TSGs can act by directly or indirectly regulating 
extracellular matrix proteins, cell surface markers, adhesion proteins, or secreted growth 
factors.  The loss of function of these TSGs can result in irregular microenvironment growth 
and function, thus promoting transformation of the epithelia in which it surrounds. 
 
3.1.2 TP53 
TP53 is a tumour suppressor gene that encodes the protein p53, it was discovered over 30 
years ago through the interaction of p53 with the oncogenic T antigens from the SV40 virus 
and has since become one of the most widely studied genes (Lane and Crawford 1979).  
Initially, TP53 was thought to be an oncogene, this discrepancy in classification was due to 
initial studies being inadvertently carried out using a mutant form of TP53.  Later studies 
revealed that the primary function of p53 was that of a TSG (Levine and Oren 2009).  It is 
reported that 40% of human tumours express the mutant form of p53 (Goh et al. 2010).  
However, the role in which it plays in RDEB SCC is somewhat little understood and has only 
been reported in two papers (Slater et al. 1992; Arbiser et al. 2004).  However, it has been 
well studied in cutaneous SCC, and has been reported to be mutated in up to 90% of 
tumours and deep sequencing of micro-dissected skin has revealed 14% of all epidermal 
cells harboured accumulated p53 mutations (Brash et al. 1991; Stahl et al. 2011).  The p53 
protein is normally expressed at low levels under normal conditions but its expression is 
induced in response to cellular stress.  Many different stress signals can activate the 
expression of p53, where the protein undergoes post translational modification thereby 
stabilising the protein and allowing it to accumulate within the nucleus of cells where it can 
activate downstream target genes that are involved in cell cycle control, maintenance of 
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genetic integrity, proliferation and differentiation (Figure 3.0) (Giaccia and Kastan 1998; 
Giglia-Mari and Sarasin 2003; Goh et al. 2010).  
 
 
 
 
Figure 3.0 p53 expression is induced by many stress signals and as a result initiates a response to 
prevent cellular damage.  The schematic diagram above depicts the stress signals that can activate 
p53 expression which is usually low under normal conditions.  Activation causes the protein to 
accumulate in the nucleus and form stabilised tetramers whereby it can then bind to co-factors and 
induce a stress response. 
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3.1.2 1 p53 structure 
Over the past few years it was established that there are as many as 9 p53 protein isoforms 
encoded by the TP53 gene through splicing and an alternative transcriptional initiation site 
(Bourdon et al. 2005), the structure of which is shown in Figure 3.1.  The expression of the 
p53 isoforms is not well studied in either RDEB SCC or non-RDEB SCC and it is interesting to 
investigate the expression of these isoforms in our sample cohort, to establish if mutations 
are present and to identify if there is a specific mutation spectrum in the RDEB SCC samples 
that could lead to higher rates of cell proliferation or if common mutations are found this 
could be used as a target in the development of RDEB SCC cancer therapies.  It has been 
reported that p53 isoforms are expressed in normal tissue but in a tissue dependent 
manner suggesting the expression of the isoforms can be selectively regulated and have 
been reported to be differentially expressed in various cancers including breast tumours 
and head and neck squamous cell carcinoma (Bourdon et al. 2005; Boldrup et al. 2007).  
Presence of multiple splice variants is a probable cause for discrepancies in research 
showing difficulty in linking p53 status to the mechanisms and sensitivities of different 
human cancers (Bourdon et al. 2005). 
 
3.1.2.2 TP53 mutations 
TP53 mutations are the most frequent genetic aberrations in human cancer (Kato et al. 
2003).  TP53 aberrations are reported to be the most frequent genetic mutations in 
cutaneous SCC, with 50% incidence (McGregor et al. 1997; Boukamp 2005).  They are also 
considered to be an early event in cutaneous SCC, due to a study showing that over 50% of 
AKs harbour TP53 mutations (Nelson et al. 1994).  Germline mutations of TP53 have been  
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Figure 3.1 Schematic diagram illustrating that p53 can encode at least 9 protein isoforms  
(A) Shows the intron/exon structure of p53 containing 11 introns.  The wild-type p53, p53β, p53γ 
and Δ40 proteins are encoded by P1 and P1’ promoters, whilst Δ133 protein isoforms are encoded 
by the P2 alternative promoter.  The C-terminus can be alternatively spliced to produce 3 isoforms, 
denoted by red, blue and black arrow above the intron/exons boxes.  (B) The top band shows the full 
length wild-type p53, followed by β and γ gamma isoforms produced by splicing of intron 9. Then the 
three Δ40 isoforms produced by alternative splicing of intron 2 and alternative initiation of 
translation sites. Finally the last three isoforms are produced by use of an alternative promoter in 
intron 4 to create Δ133 isoforms. 
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definitively linked to a predisposition to cancer development; such is the case in an 
autosomal dominant hereditary disorder known as Li-Fraumeni syndrome (Malkin 1993).   
 
The majority of mutations, approximately 80%, occur within the DNA-binding domain which 
is important for the folding and stabilization of the tertiary structure of p53 (Kato et al. 
2003; Marcel and Hainaut 2009; Peltonen et al. 2010). Within this domain 6 “hotspot” 
mutations have been identified (Petitjean et al. 2007).  Most of the mutations occurring in 
the TP53 coding sequence are predominantly missense mutations; these are point 
mutations which results from the substitution of a single nucleotide within the DNA 
sequence.   
 
Many different mutations within this gene can result in very different consequences to the 
function of the protein; some studies have worked solely on establishing the effects of 
particular mutations on p53 function in mice models (Lozano 2007).  The consequences of 
mutations can cause loss of tumour suppressor function (LOF) (Blagosklonny et al. 1997); 
gain of oncogenic function (GOF) (Dittmer et al. 1993) and furthermore, some mutant TP53 
alleles can exhibit a dominant-negative effect over the wild-type copy (de Vries et al. 2002). 
 
3.1.2.3 Dominant-negative TP53 Mutations 
Studies using knock-in mouse models have demonstrated the ability of mutant p53 to drive 
tumour formation, invasion and metastasis through dominant-negative inhibition of wild-
type p53 (Goh et al. 2010).  The concept of dominant-negative inhibition is just one 
example of the complexity of mutant p53 in driving tumour progression.  Dominant-
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negative effects occur due to the fact that p53 binds to form functional tretramers, which 
when wild-type and mutant p53 bind they show weakened DNA association and reduced 
transcriptional activity (Milner and Medcalf 1991), thus the mutant p53 prevents the 
function of the wild-type protein. 
 
3.1.2.4 Gain of function TP53 mutations 
TP53 also has ‘gain of function’ properties which is an oncogenic effect.  To test p53 
mutants which exhibit GOF effects, mutant p53 alleles can be introduced into mice which 
do not express endogenous p53, and then test for an acquired tumour phenotype.  Using 
this basic model, Dittmer and colleagues (1993) were able to show mutant p53 tumours 
confered a gain of function that provided these cells with a growth advantage over p53-null 
tumours.  Some GOF properties may also be attributed to mutant p53 being able to inhibit 
the function of p53 family member’s p63 and p73 (Strano et al. 2002). 
 
Mutant p53 can also acquire additional functions that allow it to interact with other 
proteins, eliminating or altering their activities (Lozano 2007).  Many of the proteins 
targeted by GOF are those which are part of the general transcriptional machinery, such as 
kinases and acetylases that modify p53, and others are negative regulators of p53 itself 
(Appella and Anderson 2001).  p53 mutants that possess new functions that are not shared 
by the wild-type p53 protein can be defined as GOF mutants.  Rather than transactivating 
normal p53 target genes, GOF mutant p53 activates a different subset of genes, such as 
MDR1 and MYC (Vousden and Prives 2005), these newly activated proteins provide survival 
and growth advantages for to tumour cells.  For example MDR1 is a multi-drug resistance 
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protein which provides a transport mechanism in tumour cells that causes efflux of anti 
cancer drugs and effectively pumps the drug back out of the cell making them resistant to 
certain treatments.   
 
3.1.3.5 Effect of UV radiation on TP53 
It has been clearly demonstrated that UV radiation of the skin by exposure to both UVA and 
UVB light causes skin cancer (Brash et al. 1991).  This is evident from skin tumours which 
occur mainly on sun-exposed sites, and occur at a higher frequency in fair skinned 
individuals (Salasche 2000).  It is common to find UV molecular signatures in the DNA of 
SCCs.  These signatures mutations are specifically caused by UV and are common in the 
TP53 gene.  It is thought that sunburnt skin harbours cells with TP53 mutations and that 
these mutant cells undergo clonal expansion and can give rise to a tumour.  Molecular 
signature mutations can also be found in premalignant conditions such as Actinic Keratoses 
(AK), which can develop into SCC.  Studies have shown that 1 in 1000 AKs progress into a 
SCC (Marks et al., 1996).  Together this suggests that TP53 mutations are an early event in 
SCC development.  Xerodermo Pigmentosa (XP), is a nucleotide excision repair (NER) 
deficient condition, predisposes patients to a 4000-fold increased risk of developing skin 
cancers and these tumours have a high frequency of molecular signatures found in the 
TP53 (Benhamou and Sarasin 2000). 
 
3.1.4 TP53 in RDEB SCC 
Only 2 studies have investigated p53 expression in RDEB SCC.  Neither of which have 
investigated the expression of the different p53 isoforms.  The first study showed 26% of 
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RDEB SCC samples labelled positively for up regulation of the p53 protein (Slater et al. 
1992).  Furthermore, 12 out of 15 of the well differentiated tumours within the sample 
cohort were negative.  Whilst 63% of the moderately to poorly differentiated tumours had 
positive labelling.  This study concluded that mutant p53 protein expression correlates with 
poorer tumour differentiation states.  Differentiation refers to the state of the tumour cells 
and how much they resemble the surrounding normal tissue.  Those with poor 
differentiation are likely to be mature tumour cells or highly invasive metastatic tumour 
cells which lack the morphological structure and function of normal healthy cells.  The 
second paper, demonstrated 3 of 8 tumours had TP53 mutations, however this study only 
investigated exons 3-8 of the DNA sequence and not the whole open reading frame (Arbiser 
et al. 2004).  In our sample cohort, p53 protein expression has been previously reported 
and over-expression can be seen in 5 of 8 SCC samples (Figure 3.2). 
 
 
 
Figure 3.2 p53 protein expression by western blotting (Watt et al. 2011) 
Western blotting performed by Dr Carol Hogan, shows the protein expression of p53 in the same 
samples used throughout this thesis.  The immunoblot shows amplification of p53 protein in 5 of 8 
SCC samples, and complete loss in 1 of 8 SCC samples. 
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3.1.5 Single Nucleotide Polymorphisms in RDEB SCC 
Single nucleotide polymorphisms (SNP) are variations in a single base within the DNA code.  
SNP mapping is a high-throughput, rapid and accurate technique that utilises microarray 
technology to provide whole-genome wide analysis of allelic alterations within the DNA of a 
given sample (Purdie et al. 2007).  Arrays have been used to detect SNP and identify disease 
related chromosome loci, including those in several human cancers.  Such as the 
identification of frequent 3p11-p12 loss in oral tongue SCC (Zhou et al. 2005) and conserved 
loss of heterozygosity (LOH); which is the loss of a normal functional allele at a 
heterozygous locus (Tischfield 1997) at 9p21and 6p23-27 in BCC (Teh et al. 2005).  Only one 
published study has reported SNP mapping in cutaneous SCC, in which their results showed 
LOH at 9p, in 81% of samples; along with recurrent but less frequent changes at 3p, 2q, 8p 
and 13 (Purdie et al. 2007). 
 
Unpublished data from a SNP mapping experiment from Dr Andrew South’s laboratory has 
identified recurrent LOH of chromosome 17p13 (5 of 12 RDEB SCC and 6 of 12 SCC) this 
chromosomal loci is known to harbour the TSP; TP53.  SNP results showing allelic losses, 
gains and uniparental disomy (UPD) which results from the inheritance of both homologous 
chromosomes from one parent, for each of the samples used within this study are 
summarized in Table 3.1.  
 
3.1.6 Aim  
The aim of this chapter was to identify the mRNA expression status of the main tumour 
suppressor gene TP53 in RDEB SCC samples and evaluate whether there is a difference 
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between TP53 mutation status in RDEB SCC compared to non-RDEB SCC.  This is brought 
about by identification of SNPs in RDEB SCC and non-RDEB SCC samples and the increased 
p53 protein expression in our samples cohort (Figure 3.2) (Purdie et al. 2007; Watt et al. 
2011).  Identifying a different mutational spectrum between the two SCC types could 
identify different molecular origins of these tumours and would allow specific RDEB SCC 
therapies to be developed by targeting mutations that are common in RDEB SCC tumours. 
 
In this study, the mRNA expression of full length wild-type (wt) p53, p53β, p53γ and the 
Δ133 p53 isoforms was investigated followed by mutational analysis of the amplified 
products.  Results suggest that no distinct mutational spectrum was identified in either SCC 
type.  Whilst all tumour samples harboured at least one mutation, each was a 
heterogenous mutation which was not observed in the other samples. 
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Table 3.1 Overview of chromosomal aberrations as identified by SNP mapping 
Summary of SNP locations identified by SNP array (Dr Andrew South), and previously reported by 
Purdie and colleagues (2007) for UV induced SCC samples.  Chromosome locations showing loss, gain 
and/or uniparental disomy (UPD) are noted for each sample used throughout this thesis.  p and q 
refers to the arm of the chromosome where SNPs were identified. 
 
  
Sample Loss Gain UPD 
RDEB SCC 1 
4p, 4q, 8p, 10p, 11p, 
13q, X 
8q, 11p, 12q, 22q 
3q, 4p, 4q, 9p, 12p, 
13q, 17p, 18q 
RDEB SCC 2 
3p, 4p, 4q, 5q, 6p, 7q, 
8p, 10p, 21p, X 
14p, 14q, 22p, 22q 
1p, 1q, 2q, 4p, 5q, 8q, 
9p, 9q, 11q, 13q, 15q, 
17p 
RDEB SCC 3 3p, 4p, 4q, 8p, 13q 5q 
2p, 4p, 5q, 6q, 7p, 7q, 
8q, 9p, 10p, 10q, 12p, 
12q, 14q, 17p, 19q, 
21q, X 
SCC 1 3p, 8p, 18p 1q, 3p, 7p, 8q, 9q 8p, 9q 
SCC 2 3, 9p, 18q 3q, 9p - 
SCC 3 
3p, 5q, 8p, 9p, 11p, 
17p 
3q, 5p, 7p, 8q, 11p, 
17q 
7q, 9p, 9q, 17p 
SCC 4 
1q, 2q, 7q, 9q, 10p, 
11q, 14p, 22p, 22q 
13p, 13q, 17p, 17q 
1p, 6p, 6q, 9q, 14q, 
20q, X 
SCC 5 
2q, 9p, 18p, 18q, 19p, 
19q 
8q, 11p, X - 
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3.2 Methods and Results 
Nested RT-PCR was used to amplify the p53 isoforms.  Briefly, 50μl reactions were setup 
using standard RT-PCR protocol as outlined in Chapter 2 Section 2.2.2.5.  The first PCR 
reaction used primers E2.1 and RT1 to amplify the TP53 ORF using the following conditions 
outlined in Table 3.2, using the DNA Tetrad 2.  A second PCR reaction was then performed 
using the 1μl of the PCR product from the first reaction as the template. The following 
primer combinations were used; E2+RT2, E2+p53b and E2+p53g to amplify wtp53, p53β 
and p53γ, respectively.  Δ133p53 variants were also amplified using nested PCR.  The initial 
reaction utilised primers i4f1 and RT2, followed by a second reaction using the following 
combinations of primers; Δ133p53: i4f2 and RDNp53, Δ133p53β: i4f2 and p53β and 
Δ133p53γ: i4f2 and p53γ.  All primer sequences are outlined in Table 3.3. 
 
Step Temperature Time  Number of Cycles 
Enzyme Activation 94°C 3mins 1 
DNA Denaturing 94°C 
30sec  
  
Annealing 64°C 45sec 35 
Extension 72°C 1.5mins 
 
Final Extension 72°C 8mins 1 
Table 3.2 Cycling conditions p53 nested RT-PCR 
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Primer Name Primer Sequence (5'---3') 
E2.1  GTC ACT GCC ATG GAG GAG CCG CA 
RT1 GAC GCA CAC CTA TTG CAA GCA AGG GTT C 
E2 ATG GAG GAG CCG CAG TCA GAT 
i4f1 CTGAGG TGT AGA CGC CAA CTC TCT CTA G 
RT2 AAT GTC AGT CTG AGT CAG GCC CTT CTG TC 
i4f2 GCT AGT GGG TTG CAG GAG GTG CTT ACA C 
p53β TTT GAA AGC TGG TCT GGT CCT GA 
p53γ TCG TAA GTC AAG TAG CAT CTG AAG G 
RDNp53 CTC ACG CCC ACG GAT CTG A 
Table 3.3 TP53 nested RT-PCR primers  
 
3.2.1 TP53 isoforms are expressed in cutaneous SCC 
The expression of TP53 mRNA isoforms in SCC was investigated using nested qPCR.  No 
previous publications have documented the expression of TP53 isoforms in cutaneous SCC.  
RNA was extracted from cultures of 3 independent RDEB SCC, 1 normal human keratinocyte 
(NHK) and 5 non-RDEB SCC keratinocyte samples 2 days post confluence (for methodology 
see Chapter 2.2.2.2).  NHK was used to determine the normal expression pattern of the 
isoforms in keratinocyte cells.  Primer sets, have been previously published and were used 
to amplify isoforms of TP53 cDNA (Bourdon et al. 2005).  Nested PCR revealed expression of 
full length TP53 in NHK, all 3 RDEB SCC and 4 out of 5 non-RDEB SCC samples.  An example 
of the amplified products is seen in Figure 3.3. 
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PCR amplification showed mRNA expression of the p53β in NHK and all 8 SCC keratinocyte 
samples.  The expression of the isoform at the mRNA level for each sample is summarized 
in Table 3.4.  Interestingly, SCC 4 showed only expression of the β-isoform.  Whilst p53γ 
mRNA expression wasn’t present in NHK, but was present in all 3 RDEB SCC samples and 3 
of 5 non-RDEB SCC samples.  The Δp53 and Δp53β were both expressed at the mRNA level 
in NHK, but not Δp53γ.  The Δp53 mRNA isoforms were all expressed in RDEB SCC 
keratinocyte samples, apart from RDEB SCC 2 which showed no expression of any of the 
three Δp53 isoforms.  Δp53 isoforms were expressed in the majority of non-RDEB SCC 
samples, with the exception of Δp53γ which was not detected in SCC 1 and again only the 
Δp53β isoform was detectable in SCC 4. 
 
 
 
 
 
 
 
Figure 3.3 Agarose gel showing PCR amplification of full length p53, p53β, and p53γ  
TP53 isoforms were amplified by nested PCR.  wt represents amplified full length p53, followed by 
beta, for the beta isoform, and y for the gamma isoform, for each of the 6 samples used which are 
labelled above the 3 corresponding lanes.  NHK represents normal human keratinocytes used as a 
control samples and NTC is a no template control used to identify any contamination.  All other gel 
photos can been seen in appendix 1.0. 
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3.2.2 RDEB SCC keratinocytes express mutant p53 transcripts 
All amplified PCR products were purified using an ExoSap protocol followed by direct 
sequencing to identify mutations within the ORF of TP53 isoforms.  Sequencing of the PCR 
products revealed single point mutations in all 3 RDEB SCC samples.  Chromatographs of 
each mutation can be seen in Figure 3.4, all mutations are homozygous missense mutations 
that occur within the DNA-binding domain.  Codon 173 is mutated in RDEB SCC 1 in which 
the original valine amino acid is changed to a leucine once the first G nucleotide of the 
codon is substituted by a T nucleotide.  In RDEB SCC 2 the second nucleotide of codon 273 
is changed from a G to A nucleotide resulting in a histidine amino acid residue being 
produced instead of an arginine residue.  Finally, RDEB SCC 3 contained a double CC to TT 
substitution of the first two nucleotides of codon 152 resulting in the proline residue being 
replaced by a leucine amino acid residue.   
 
Interestingly, repeated PCR reactions duplicate RNA from these samples sometimes 
demonstrated different results.  One a number of occasion’s samples which showed 
expression in one PCR run didn’t necessarily demonstrate expression of the same isoform 
on a second run.  In these cases, at least 3 independent PCR reactions were performed and 
if the expression was seen in 2 out of 3 runs then the results were recorded as that isoform 
was expressed in the sample.   
 
It is intriguing to note that the p53γ isoform is expressed in RDEB SCC samples and not non-
RDEB SCC samples suggesting a possible gain of function phenotype may be acquired in 
these cells.  But NHK also showed expression of this isoform, however in retrospect the use 
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of only one NHK control limits the conclusions which can be drawn directly from this 
experiment.  Therefore it would be necessary to repeat this experiment with a greater 
number of NHK samples, so establish a greater understand of the normal isoform 
expression in normal human keratinocytes. 
 
 
 
 
Table 3.4 Summary of the SCC samples which express the TP53 mRNA isoforms 
The table shows which TP53 isoforms were expressed in each of the SCC samples. A “yes” indicates 
an amplified product was observed when samples were run on agarose gels whilst an “x” means no 
amplified products were seen. 
 
 
Sample p53 p53β p53γ Δp53 Δp53β Δp53γ 
NHK Yes Yes X Yes Yes X 
RDEB SCC 1 Yes Yes Yes Yes Yes Yes 
RDEB SCC 2 Yes Yes Yes X X X 
RDEB SCC 3 Yes Yes Yes Yes Yes Yes 
SCC 1 Yes Yes X Yes Yes X 
SCC 2 Yes Yes Yes Yes Yes Yes 
SCC 3 Yes Yes Yes Yes Yes Yes 
SCC 4 X Yes X X Yes X 
SCC 5 Yes Yes Yes Yes Yes Yes 
123 
 
 
 
Figure 3.4 RDEB SCC keratinocytes harbour missense mutations in p53, p53β and p53γ 
Direct sequencing of PCR amplified TP53 products revealed homozygous missense mutations in each 
of the RDEB SCC samples.  The arrow indicates the mutated nucleotide(s) and each codon affected is 
underlined. (A) Codon 173 is mutated in RDEB SCC 1, in which the first base is changed; C>T. (B) 
Codon 273 is mutated in RDEB SCC 2, in which the second base is changed; G>A. (C) Codon 152 is 
mutated in RDEB SCC 3, in which the first two bases are changed; CC>TT. Each of the mutations were 
present in full length p53, p53β and p53γ. 
  
A 
C 
B 
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3.2.3 SCC express mutant TP53 transcripts 
Non-RDEB SCC keratinocyte samples (SCC 1-5) all express mutant TP53 transcripts, 
chromatographs of each mutation are shown in Figure 3.5.  SCC 1 contained a single 
heterozygous mutation at codon 234, which results in the amino acid being changed to a 
serine residue on one allele.  SCC 2 contained a homozygous CC to TT mutation that results 
in a phenylalanine amino acid being produced instead of a proline residue.  SCC 3 also 
contained a homozygous mutation, although this alteration in the DNA sequence was 
present in codon 216 in which the original valine residue is changed to a methionine due to 
the first G nucleotide of the codon being substituted for an A nucleotide.  SCC 4 contained a 
single nucleotide deletion, in which the first T nucleotide of codon 91 is absent from the 
DNA sequence.  Lastly, SCC 5 was the only sample to contain more than one mutation, and 
harboured 3 heterozygous mutations.  Firstly; codon 179 contained a C to T transition 
which results in the amino acid being changed to a tyrosine, codon 247 also contained a C 
to T substitution which was a silent mutation in which the mutation resulted in a codon 
encoding the same asparagine amino acid as the original codon and finally, codon 248 
contained a C to T substitution resulting in a tryptophan residue instead of an arginine.   
 
Both heterozygous mutations occurred in samples with no apparent LOH at chromosome 
17 (Table 3.1 and Figure 3.5A and E).  Also, SCC 1 was the only non-RDEB SCC sample to 
show normal p53 protein level (Figure 3.2).  SCC 2 also showed no abnormalities of 
chromosome 17 by SNP mapping, but did show over-expression at the protein level (Table 
3.1 and Figure 3.5) indicating that p53 may be mutated, which was the case. SCC 3 showed 
some loss of 17p and UPD, and over-expression at the protein level, and so it was expected 
to be mutated.  SCC 4 showed some gain of 17p, and no protein expression (Table 3.1 and 
Figure 3.5)  This sample contained a single nucleotide deletion in codon 91 of the proline-
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rich domain resulting in a frameshift of the DNA sequence immediately after the deletion 
and subsequently alters all codons after the original mutation.  This would be an 
explanation for why no protein is seen when western blotting is performed to look for p53, 
although it could also be due to non-sense mediated decay of the transcript.  It is important 
to note that the western blot seen in Figure 3.2 was conducted using a p53 antibody which 
does not distinguish between different protein isoforms. After the deletion the subsequent 
frameshift results in the generation of four STOP codons (Figure 3.6), which are likely to 
cause non-sense, mediated decay of the transcript, thus, preventing the expression of the 
protein. 
 
3.2.3 Mutation spectrum is unique to each tumour sample 
Each of the samples contained different mutations, suggesting that the mutation spectrum 
in the SCC samples in our cohort is unique to the each tumour.  From this study it is 
impossible to distinguish between RDEB SCC and non-RDEB SCC based on the expression or 
mutations of TP53.  The majority of mutations detected were homozygous, and probably 
result from loss of one TP53 allele and a mutation occurring in the other.  All but one of the 
mutations occurred within the DNA-binding domain, with the other mutation occurring 
upstream in the proline rich domain (Table 3.5).  Intriguingly, two mutations; codon 273 in 
RDEB SCC 2 and codon 248 in SCC 5 are the two most commonly reported mutations out of 
all the mutations identified in this study. 
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3.2.4 UV signature mutations are most prevalent in sporadic SCC rather than RDEB 
SCC 
As expected, more UV signature mutations were identified in the non-RDEB SCC samples, 
where 57% (4 of the 7) of mutations identified in non-RDEB SCC are classed as UV signature 
mutations as they occur at dipyrimidine locations within the DNA sequence, whereas only 1 
of the 3 mutations identified in RDEB SCC is classified as a UV signature mutation.   
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Figure 3.5 Non-RDEB SCC keratinocytes harbour mutations in p53, p53β and p53γ 
Direct sequencing of the PCR amplified p53 products revealed homozygous mutations in 3 of the 5 
SCC samples and heterozygous mutations in 2 of 5 SCC samples.  The arrow indicates the mutated 
nucleotide(s) and each codon affected is underlined. Each of the mutations was present in wtp53, 
p53β and p53γ, unless otherwise stated. (A) Codon 234 is mutated in non-RDEB SCC1, in which the 
second base is changed; A>C. (B) Codon 278 is mutated in non-RDEB SCC2, in which the first two 
bases are changed; CC>TT, a classic UV signature mutation. (C) Codon 216 is mutated in non-RDEB 
SCC3, in which the first base is changed; G>A. (D) Codon 91 is changed in non-RDEB SCC4 in which 
only the p53β isoform is expressed, this is a deletion of the first base TGG>*GG. (E) Codons 179, 247 
and 248 show heterozygous mutations in non-RDEB SCC. Each codon displays a C>T substitution 
A B 
D 
E 
C 
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Figure 3.6 mutant expression of p53β in SCC4 is caused by a deletion of nucleotide 271  
Deletion of nucleotide 271 in the coding sequence of p53β results in an altered amino acid sequence. 
The deletion of the T nucleotide occurs at the position denoted by the red arrow, after which the 
new codon sequence is shown in blue writing along with the generation of 4 STOP codons 
highlighted by the red writing and *. 
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Sample 
Type of 
Mutation 
Coding 
Sequence 
Exon Domain 
Protein 
Sequence 
Mutation Effect 
Structural 
Motif 
CpG Site 
No. Of Mutation 
Reports 
RDEB SCC 1 Homozygous c.517G>T 5 
DNA Binding 
Domain 
p.V173L Missense L2 No 65 
RDEB SCC 2 Homozygous c.818G>A 8 
DNA Binding 
Domain 
p.R273H Missense S10 Yes 812 
RDEB SCC 3 Homozygous 
C454-
455CC>TT 
5 
DNA Binding 
Domain 
p.P152L Missense L No 3 
SCC1 Heterozygous c.701A>C 7 
DNA Binding 
Domain 
p.Y234S Missense S8 No 7 
SCC 2 Homozygous 
c.832-
833CC>TT 
8 
DNA Binding 
Domain 
p.P278F Missense H2 No 10 
SCC 3 Homozygous c.646G>A 6 
DNA Binding 
Domain 
p.V216M Missense S7 No 76 
SCC 4 Homozygous c.271del1 4 Proline Rich Domain N/A Frameshift S3 No 2 
SCC 5 Heterozygous c.535C>T 5 
DNA Binding 
Domain 
p.H179Y Missense H1 No 107 
SCC 5 Heterozygous c.741C>T 7 
DNA Binding 
Domain 
p.N247N Silent L3 No 15 
SCC 5 Heterozygous C742C>T 7 
DNA Binding 
Domain 
p.R248W Missense L3 No 707 
Table 3.5 Summary of all TP53 mutations.   
The table summarises all mutations identified in all SCC samples.  The number of mutations reported was provided by the IARC p53 mutation database (Petitjean et al. 
2007). 
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3.3 Discussion 
3.3.1 TP53 isoforms are expressed in SCC 
The expression of TP53 isoforms at the mRNA level was investigated to determine the 
pattern of expression in RDEB SCC and non-RDEB SCC compared to NHK (Table 3.4).  No 
previous publications have reported expression of the TP53 isoforms in cutaneous SCC, 
although full length TP53 has been investigated in; pre-cancerous lesions AKs and Bowen’s 
disease, cutaneous SCC and in two reports in RDEB SCC (Brash et al. 1991; Slater et al. 1992; 
Campbell et al. 1993; Arbiser et al. 2004).   TP53 isoform expression has been investigated 
in head and neck SCC in which they concluded that all TP53 variants except the Δp53 were 
expressed in some tumour samples and in normal epithelium (Boldrup et al. 2007), this is 
concordant with no expression of Δp53 in NHK, suggesting that in 6 of the 8 SCC samples 
transcription of Δp53 is activated. 
 
3.3.2 Internal hotspot mutations present in RDEB SCC 
A single point mutation was identified in each of the RDEB SCC keratinocyte samples.  
Codon 173 was mutated in RDEB SCC1 (Figure 3.4A) this mutation occurs within the DNA-
binding domain, and more specifically within the L2 domain which is responsible for the 
correct folding and stabilisation of the central part of the protein (Cho et al. 1994).   
  
Interestingly, the mutation of codon 273 discovered in RDEB SCC2 (Figure 3.4B), has been 
reported to be a “hotspot” mutation often seen in internal malignancies (Khromova et al. 
2009).  Internal hotspots are generally situated where there is cytosine methylation which 
blocks the formation of (6-4) photo products and are therefore generally not associated 
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with UV (Ziegler et al. 1993).  Hotspot mutations are classified as amino acid residues 
involved in either making direct contact with DNA or in supporting the structural binding 
surface of the DNA.  According to the IARC p53 database, this mutation has been reported 
on 636 occasions and in several cancers (Petitjean et al. 2007), reports identified in the 
database suggest mutation R273H possesses oncogenic gain of function in which mutant 
p53 is able to transactivate reporter genes suppressed by wt-p53.  This particular mutation 
changes the amino acid from an arginine to histidine has been reported to increase 
angiogenesis of colon cancer xenografts harbouring this hotspot mutation identified by 
having a higher number of blood vessels which is correlated with accelerated tumour 
growth (Khromova et al. 2009).  Given that this TP53 mutant is classed as a “contact” 
residue it is possible to expect that this mutant retains the overall structure of the DNA 
binding domain but directly interferes with p53’s ability to bind to DNA and thus 
transactivate target genes (Joerger and Fersht 2007; Olivier et al. 2010).   
 
Intriguingly, the mutation of codon 152 identified in RDEB SCC 3 is a classic example of a 
UV-signature mutation (Figure 3.4C).  This is an interesting mutation, as RDEB patient’s skin 
is bandaged for prolonged periods of time due to chronic blistering.  This would suggest 
that they are not exposed to high levels of UV light and therefore you would not expect to 
see UV induced mutations in these samples.  However, it is most likely that this mutation 
was caused through other means than by UV-exposure, but as this mutation involves the 
substitution of two nucleotides it would be interesting to see if photoproducts were 
generated at this location within the DNA of these cells.  This can be done by measuring the 
cyclobutane pyrimidine dimers and pyrimidine-pyrimidone (6-4) photoproducts in the DNA 
to establish if indeed photoproducts were generated and demonstrating if this was a UV 
induced mutation (Douki and Cadet 2001; Kim et al. 2010).    
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3.3.3 Heterozygous mutations present in SCC with retained heterozygosity at 17p 
Unlike the RDEB SCC samples which contained only homozygous mutations, two of the non-
RDEB SCC keratinocytes samples contained heterozygous mutations.  In SCC5 3 
heterozygous mutations were present; all three mutations are UV signatures as they are C-
T substitutions at dipyrimidine locations in the DNA sequence (Figure 3.5E).  The mutation 
at codon 179 occurs within the DNA-binding domain at zinc binding residue, in yeast based 
functional assays its transactivation activity is reported as partially functional (Kato et al. 
2003).  Mutant codon 247 is a silent mutation, in which the single base pair substitution 
which still codes for the same amino acid as the original codon and therefore results in 
wild-type protein being translated rather than a mutant protein, this is also known as a 
synonymous mutation.   
 
The final mutation in SCC 5 is another example of a contact “hotspot” mutation, in which 
the residue is required for direct interaction of the DNA.  This mutation is a hotspot of both 
internal and UV associated malignancies (Ziegler et al. 1993). The IARC database documents 
that this mutation has been observed 597 times and allows reporter genes repressed by wt-
p53, whilst inhibiting the actions of p63 and p73 (Petitjean et al. 2007; Goh et al. 2010).  
There are two mouse models available for this mutant; one constructed in BALB/c genetic 
background transgenic mice with mutant p53 G245W the mice equivalent to human 
mutant p53 R248W, which fused with a haemagglutinin (HA)-tag to allow it to be 
distinguished from wt-p53 (Krepulat et al. 2005) and a more recent model by Song and 
colleagues (2007) in which they introduced the R248W allele into humanized p53 knock in 
(HUPKI).  The HUPKI model showed abolished tumour suppressor activity and evidence to 
indicate these p53 mutants have acquired GOF by the interaction with the nuclease Mrell 
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and suppression of binding which leads to impaired activation of Ataxia-telangiectasia 
mutated (ATM) (Song et al. 2007).   
 
Interestingly, the identification of only heterozygous mutations in this samples correlates 
with SNP mapping data showing no alterations and retained heterozygosity at 17p.  SCC1 
also contained a heterozygous mutation which also showed no alteration on chromosome 
17 (Figure 3.5A). 
 
3.3.4 A single nucleotide deletion in p53β of cutaneous SCC 
One of the ten mutations identified in this study was a deletion of a single T nucleotide in 
SCC 4 a non-RDEB SCC sample, in the p53β isoform (Figure 3.5D).  A single deletion (or 
insertion) of any nucleotide ultimately results in a frameshift of the remaining nucleotide 
sequence after the mutation.  Under normal conditions, the majority of non-sense 
transcripts, such as those which result from an insertion or deletion of a nucleotide are 
recognised and degraded by the cell in a process known as non-sense mediated decay 
(NMD) (Frischmeyer and Dietz 1999).  Our results indicate that at the mRNA level only the 
p53β and Δp53β isoforms were detectable and furthermore, Dr Carol Hogan was only able 
to demonstrate expression of the p53β variant at the protein level via immunoblotting 
(Appendix 1.1).  This conforms to the hypothesis that the full length p53, p53γ and the 
corresponding Δp53 isoforms undergo NMD as a result of the deletion of the T nucleotide 
in codon 91 which is predicted to be detected by the cell during proof-reading of the mRNA 
transcript and identified as a non-sense transcript.   
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3.3.5 Further Work 
Our results imply that the p53 isoforms are expressed in NHK and in cutaneous SCC.  In 
accordance with other reports that suggest approximately 75% of p53 mutations are 
classified as missense, our study demonstrated that 100% of RDEB SCC samples contained 
missense mutations whereas only 85% of the non-RDEB SCC harboured mutations.  The 
higher percentages of missense mutations in our study are likely to be due to the small 
sample size, and a more representative percentage could be acquired by investigating the 
mutations of a greater number of samples.  Arbiser et al., (2007) identified only 3 of 8 RDEB 
SCC by single-strand conformation polymorphism (SSCP) analysis using an electrophoresis 
unit in which a mutation was identified by a shifted band pattern, samples indicating 
mutation were then further analysed by direct sequencing of the PCR products.   
 
The only other study that has investigated p53 in RDEB SCC is that by Slater and colleagues 
(1992), in which, they used anti-serum to p53 protein to detect for up-regulation of the 
protein in 26 SCC samples from 6 patients.  Only 26% of these labelled positively for mutant 
p53 protein, they speculated that the low percentage of mutant p53 identified was due to 
most tumours in the cohort being well differentiated and showed no p53 staining.  Our 
study has shown that even samples which show normal p53 protein expression harbour 
mutations in the mRNA which supports Kusters-Vandevelde’s report that positive staining 
of p53 is not synonymous with p53 mutations (Kusters-Vandevelde et al. 2010).  Although, 
over-expression of the protein is indicative of mutation as missense mutations lead to the 
synthesis of a more stable mutant protein than the wild type-protein resulting in the higher 
levels detectable by the antibody. 
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As a therapeutic target of RDEB SCC, TP53 does not represent a unique pathway, although 
the mutations identified in TP53 of these samples were different to those in non-RDEB SCC, 
no common mutations were identified.  Having a common mutation within a sample set 
would allow an anticancer strategy to be developed, whereby p53 pathway is reactivated 
by targeting that specific mutation in a gene therapy approach.  However, it would be 
interesting to investigate these mutants further to elucidate the structural and functional 
consequences of each mutant.  To do this nuclear magnetic resonance (NMR) spectroscopy 
and x-ray crystallography could be utilised to examine the structure, followed by yeast 
based functional assays to predict the impact of the mutant on the protein function. 
 
All samples in this study harbour mutant TP53; therefore this suggests that SCC tumours in 
general could be selectively targeted based on this finding.  Given that p53 is mutated in 
over 40% of all cancers, it has been a popular target for therapeutic research.  Many 
strategies are being employed to treat cancers with aberrations of the p53 pathway (Lane 
et al. 2010).  Research currently ongoing in this area includes work on p53 vaccines (Roth et 
al. 1996; Nemunaitis et al. 2009).  Based on the high expression and frequent mutations of 
p53 in tumour cells the immune system could recognise it as an antigen, this has led to 
research into immunising patients with large peptides derived from p53 (Cheok et al. 2011).  
This is so far the only approved p53 therapy, with a vaccine known as Gendicine being 
permitted for use in China.  Other interesting therapeutic approaches include; using small 
molecules to inhibit MDM2 and p53 interactions.  A group of cis-imidazoline analog small 
molecules known as Nutlins are proving to be useful by inhibiting MDM2 and thus inducing 
p53 (Vassilev et al. 2004).  Specifically Nutlin-3, which competes to bind to MDM2 causing 
displacement of p53 and resulting in the induction of apoptosis in malignant cells (Kojima et 
al. 2005; Secchiero et al. 2008).  However, this treatment strategy is mainly effective in 
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tumours that do not harbour TP53 mutations such a haematological malignancies (Cheok et 
al. 2011).   
 
Having identified that all SCC samples harbour mutations in TP53, the generation of p53 
therapies that target mutant p53 and restore its activity are of particular interest (Brown et 
al. 2011).  This is potentially effective in tumours with inactive mutant p53, particularly 
those with mutations within the core DNA binding domain which accounts for 87.5% of the 
samples studied in this investigation, these mutations are known to cause the thermal 
destabilisation of p53 (Brown et al. 2011).  Peptides that stabilise mutant p53 can restore 
the biological conformation and potentially restore wt-p53 alleles, an example of this is 
p53C a peptide derived from the c-terminal domain that has a stimulatory effect on p53 
DNA binding activity.  In vitro this peptide has restored activity of some p53 DNA contact 
mutants and several destabilised mutants (Hupp et al. 1995).  As a therapy for SCC in 
general further experiments could be done to establish the effect of mutant p53 on the 
tumours, to provide further evidence to support the use of p53 targeted therapies.  Such 
models could initially include p53 knock-down in SCC cell cultures to evaluate the effect on 
tumour cell viability, this could be further supported by knock-out mouse models.  Another 
experiment to knock in specific p53 mutants could be used to establish the effect of certain 
mutants, with particular interest in the expression of p53γ and the possibility of a gain of 
function.   
 
SCC in RDEB patients arise in areas of severe inflammation (Mallipeddi 2002; Arbiser 2007), 
and studies have shown p53 to be mutated in other cancer-prone chronic inflammatory 
diseases.  An example of which is Barrett’s oesophagus whereby the normal squamous 
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epithelium of the windpipe transforms into intestinal columnar epithelium due to repeated 
attack from acid reflux from the stomach (Kong et al. 2010), and has been shown to be 
contain mutated p53 (Keswani et al. 2006; von Holzen et al.).  Together, with evidence of 
p53 mutations in premalignant conditions of the skin, as mentioned earlier, and owing to 
recent research revealing the accumulation of multiple non-synonymous p53 mutations in 
normal epithelial skin cells (Stahl et al. 2011) it would be of interest to investigate p53 in 
status in unaffected and affected (scarred) RDEB skin.   Another reason for doing this, along 
with investigating p53 expression in SCC tissue is that it is known that in culture p53 can be 
activated, and therefore the expression we see and subsequent mutation specific is an 
artefact of culturing the cells.  Therefore it would be crucial to evaluate whether p53 
expression is seen as a result of culturing. 
 
To conclude this study, TP53 and its isoforms are expressed in RDEB SCC and non-RDEB SCC. 
Furthermore, each sample contains at least one mutation, each sample hosts a unique 
mutation and no common alterations were identified.  The mutation spectrum of RDEB SCC 
was different to non-RDEB SCC.  Although TP53 does not have a unique mutation status in 
RDEB SCC, and therefore does not offer a specific target for RDEB associated SCC, it does in 
fact offer an abrogated pathway which could be targeted for SCC therapy in general.   
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Chapter 4 
 
Markers of RDEB SCC keratinocytes identified by global gene 
expression analysis 
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4.1 Background 
As already mentioned in Chapter 1, cancer originates from an accumulation of several 
genetic mutations (Hanahan and Weinberg 2000).  In studying the genetic alterations that 
occur in cancer cells it allows researchers to develop an understanding of the originating 
genetic changes that cause cancer growth, and to identify those changes that allow the 
metastatic spread of the disease.  Identifying expression changes of various genes can also 
identify pathways that are aberrantly regulated in cancer cells, which can then be used to 
directly target the cancer cells with therapeutics.  An example of a therapy developed to 
target genetic mutations is the discovery of the BCR-ABL fusion gene caused by a reciprocal 
translocation of two chromosomes and is responsible for the development of chronic 
myeloid leukaemia (CML) (Pane et al. 2002).  This mutant protein displays constitutive 
tyrosine kinase activity which is crucial for the transformation of haematopoietic cells and 
has led to the development of tyrosine kinase inhibitors used for CML treatment (Daley et 
al. 1990; Lugo et al. 1990; Druker et al. 2001).  One such inhibitor is Imatinib, which targets 
the oncogenic protein BRC-ABL and is routinely used for the treatment of CML, with studies 
showing 90% of low and 83% of high risk patients having 5 year progression free survival 
after this treatment (Hasford et al. 2011). 
 
Frequently in cancer cells, alterations occur in the expression of genes through the 
amplification and deletions of genomic DNA; resulting in over-expression and reduced 
expression of genes that may drive tumour development (Akkiprik et al. 2009; Medina et al. 
2009).  Global gene expression arrays can be used to investigate the RNA expression levels 
of thousands of genes (Schena et al. 1995; Shalon et al. 1996).  Over 15 years ago, DNA 
microarrays were developed which now provide a powerful tool capable of simultaneously 
analysing the expression of thousands of genes (Maskos and Southern 1992).  Microarrays 
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have become a mainstream technique for the study of gene expression in many disease 
states, not only cancer (Meltzer 2001; Mohr et al. 2002). 
 
4.1.1 Concept of Microarray Experiments 
The main principle of a microarray relies on the hybridization of two complementary DNA 
strands.  If there is a high degree of similarity between the two sequences, it allows strong 
non-covalent bonds to form between complementary base pairs.  The target samples are 
fluorescently labelled and these directly bind to the probe sequences which are attached to 
a substrate generally made from glass or silicon.  After binding, the substrates are washed 
to remove any non-specific binding.  The hybridized sequences generate a fluorescent 
signal which can vary in intensity depending on the amount of target sample binding to the 
probe.  Some arrays utilize two fluorophores, to create a two colour hybridisation which are 
detected by a fluorescent scanner allowing amplifications and reductions in gene 
expression to be synchronously measured (Shalon et al. 1996).  The raw values are given as 
a relative quantization intensity which has been compared to the intensity of the same 
feature under different conditions.  
 
4.1.1.1 Microarray Studies 
Many microarray studies have focused on detection of biomarkers capable of distinguishing 
disease stages (Bomprezzi et al. 2003), prognosis (Subramanian and Simon 2010; Cho et al. 
2011) and response to therapeutics (Maxwell et al. 2003; Chiaretti et al. 2004).  Also, 
countless studies have centred on the genetic alterations between disease and normal 
samples to identify genes and genetic pathways that are altered in cancer and could be 
used as targets for new therapies (Huang 1999).  The importance of this is just starting to 
become recognised, as a greater spotlight is focused on; individualised molecular 
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medicines, the capability of predicting an individual’s drug response, and targeting specific 
proteins and pathways within an individual’s tumour.  Microarray studies provide a solid 
foundation for these studies. 
 
In parallel to microarrays the emergence of next generation sequencing provides the only 
alternative platform to offer “global” identification of genetic changes (Schuster 2008; Reis-
Filho 2009).  This new technology offers simultaneous data collection on a cell’s genome; 
and provides identification of somatic mutations, accurate copy number analysis and 
information on any balanced or unbalanced chromosome rearrangements (Shah et al. 
2009; Stratton et al. 2009). 
 
4.1.1.2 Microarray Studies in SCC 
Many studies of SCC have utilised microarray technology (Daley et al. 1990; Dooley et al. 
2003; Hudson et al. 2011; Watt et al. 2011).  Microarrays used for the investigation of 
cutaneous SCC have identified increased expression of epidermal differentiation complex 
genes on chromosome 1q21, a hallmark of SCC (Hudson et al. 2011), and the use of both in 
vivo and in vitro conditions has demonstrated biomarkers of SCC common to both 
experimental conditions (Dooley et al. 2003).  Watt and colleagues (2011) used expression 
array analysis in an integrated approach to elucidate therapeutic targets of cutaneous SCC.  
The study used a microarray to identify markers of SCC in vitro and in vivo which were 
followed up by siRNA screening resulting in the identification of 2 genetic targets both of 
which have inhibitors that can reduced tumour volume in mice xenografts (Watt et al. 
2011).  This study demonstrated the robust use of gene expression analyses in the 
identification of biomarkers of disease and target identification.  
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4.1.2 Cancer therapy for RDEB SCC is limited 
As detailed in Chapter 1, cutaneous SCC is the leading cause of death in RDEB patients 
(Arbiser et al. 2004).  RDEB patients often die from the disease, unlike in the general 
population where SCC treatments for example Moh’s surgery provide a positive outcome 
and have a good cure rate in those who develop UV-induced SCC, including high risk 
tumours (Kwa et al. 1992; Fleming et al. 1995; Leibovitch et al. 2005).  
 
4.1.3 Microarray data comparing SCC to RDEB SCC 
Global gene expression array data from our laboratory, produced prior to the start of this 
investigation, made comparisons of RDEB SCC keratinocytes to non-RDEB SCC 
keratinocytes.  The array contained approximately 50,000 probes that are complementary 
to 40,000 genes.  Four groups of samples were hybridized to the array.  The samples 
originated from early passage primary cultured keratinocytes and the groups composed of; 
4 independent NHK, 3 EBK, 4 RDEB SCC and 5 non-RDEB SCC keratinocyte samples.  
 
For this investigation the array data was used to compare the gene expression profiles of 
RDEB SCC and non-RDEB SCC keratinocytes to identify differentially regulated genes 
between the two samples sets.  This comparison tested the following hypothesis that based 
on the clinical presentation and localisation of the SCC tumours that arise in RDEB patients, 
and their aggressive nature, these tumours are significantly genetically different to the SCC 
tumours that arise in the general population. 
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Initial findings, based on clustering analysis of the samples suggested that RDEB SCC and 
non-RDEB SCC cannot be distinguished base on the transcriptional profiles in culture, as 
seen in Figure 4.1, which demonstrates that the 4 different sample sets do not cluster 
separately which would have indicated that each group of samples could be distinguished 
based on their gene expression profiling. The closer two samples cluster the more 
similarities they share. 
 
4.1.3.1 Analysis of DNA microarray 
The microarray data was initially analysed using Illumina’s BeadStudio Data Analysis 
Software to generate normalized signal intensities for each of the probes on the array. 
These signal intensities were then analysed by performing the student’s T-Test using Excel 
(Microsoft). The array identified a total of 36 genes to be differentially regulated between 
RDEB SCC and non-RDEB SCC keratinocytes.  This is not a significant number of transcripts 
and only represents approximately 0.007% of the total number of transcripts tested on the 
array.  When comparing all SCC (grouped RDEB SCC and non RDEB SCC) samples in this 
experiment against to normal samples (NHK and RDEBK) identified a 365 gene signature for 
SCC which has been validated and is able to distinguish SCC samples from non-SCC samples 
in culture, thus validating the reliability of the array results (Watt et al. 2011).  The small 
number of genes identified as being differentially regulated between RDEB SCC and non-
RDEB SCC also conforms to clustering analysis of the array data shown in Figure 4.0, taken 
from study by Watt and colleague’s (2011) study which confirms that RDEB SCC and non-
RDEB SCC are not genetically different.  However, the genes that have been identified as 
being differentially regulated in RDEB SCC keratinocytes may prove to be useful targets for 
new therapeutics that specifically aimed at tumour cells that arise in RDEB patients and 
form that basis of this chapter.  
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The 36 genes were derived from the array used strict filtering criteria.  Initial interrogation 
of the data to expose the differentially regulated transcripts in RDEB SCC in comparison to 
non-RDEB SCC; derived 18 transcripts (Table 4.0) that were identified due to alterations in 
fold change, expression level and p value using the following 3 categories: 
1:  p value < 0.001, fold change >2.5  
2: p value <0.001, fold change >1.5, expression >100 
3: p value 0.001 – 0.005, fold change >2.5, expression >50 
 
Figure 4.0 Dendrogram showing clustering of RDEB SCC and non-RDEB SCC indicative of genetic 
similarties. Normalised array signal intensities were subjected to unsupervised clustering using (BRB-
ArrayTools v3.8.1).  The closer two samples are to one another on the dendrogen demonstrates 
more similarities between samples.  This provides evidence that samples clearly separate based on 
tumour status.  However RDEB SCC cannot be segregated from non-RDEB SCC based on their gene 
expression profiles. Adapted from ((Watt et al. 2011).   
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GI Number Gene Name Functional Name 
Chromosome 
Location 
Fold Change  
RDEB SCC vs Non-RDEB SCC 
p value  
RDEB SCC vs Non-RDEB SCC 
GI_4557228-S AAMP Angio-associated migratory cell protein 2q35 1.80 0.000877 
GI_34577058-S ADFP Adipose differentiation-related protein 9p22.1 0.08 0.004119 
GI_28559062-A DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta 20q11.2 2.81 0.000244 
GI_32261290-S DUSP23 Dual specificity phosphatase 23 1q23.2 0.14 0.001571 
GI_30148196-S FAM41C Family with sequence similarity 41, member C 7p15-14 0.21 0.000148 
GI_24497516-S HOXA5 Homeobox A5 1p36.33 0.37 0.003794 
GI_19923799-S HSPC244 HSPC244 11q13.1 0.27 0.004538 
GI_4504918-S KRT8 Keratin 8 5q35 4.45 0.004491 
GI_16915933-A MGAT4B 
Mannosyl (alpha-1-3)-glycoprotein beta-1,4-N-
acetylglucosamine transferase, isozyme B 
12q13 0.47 0.000320 
GI_10947033-S MXD4 MAX dimerisation protein 4 4p16.3 0.26 0.002232 
GI_45007006-S OAS3 2-5-oligodenylate synthetase 3, 100kDa 12q24.2 4.34 0.002258 
GI_27436888-I POFUT1 Protein O-fucosyltransferase 1 20q11 2.48 0.000491 
GI_34147649-S SLC25A11 Solute carrier family 25 member 11 12p12 1.60 0.000106 
GI_9790232-S SLCO1B3 
Solute carrier organic anion family, member 
1B3 
17p13.3 9.06 0.000115 
GI_29540556-A SNRPN Small nuclear ribonucleoprotein polypeptide N 15q11.2 0.15 0.001527 
GI_1302654-A SNURF SNRPN upstream reading frame 15q12 0.12 0.001920 
GI_18079315-S TJAP1 Tight junction associated protein 1 6p21.1 0.61 0.000997 
GI_37545980-S TTC7B Tetratricopeptide repeat domain 7B 14q32.11 2.74 0.001625 
Table 4.0 Microarray analyses based on three sets of criteria, identified 18 genes that are differentially regulated in RDEB SCC compared to non-RDEB SCC keratinocytes. 
3 sets of criteria taking into account p value and fold change were used as an indicator of statistically significance in regard to differentially regulated genes between the 
two sample sets.  Fold changes highlighted in red are up regulated in RDEB SCC whilst those in green are down regulated.
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18 transcripts is not a significant number of transcripts, and therefore suggests that the SCC 
that present in RDEB patients are not significantly genetically different to those that 
present in the general population.  Further interrogation of the data was performed to 
prevent any differences between the two sample sets being overlooked.  The three 
additional sets of filtering criteria used to identify differentially regulated transcripts in 
RDEB SCC, are listed below: 
1:  Further interrogation of microarray data using a modification of the Mann-Whitney U 
test, identified transcripts with wide variation but the expression value for the close sample 
from the Non-RDEB SCC sample group to the RDEB SCC sample group was higher than 50, 
which is the level of intermediate expression on the Illumina array, and at least 50% of the 
value (Table 4.1).  This was able to identify genes which showed a wide variation in 
expression levels in the samples which would be missed using the t-test which assumes a 
normal distribution. 
2:  Differentially expressed genes were identified based on differences between SCC versus 
normal between RDEB and non-RDEB samples.  P values for all genes are within the original 
filtering criteria for category C, and have p values below 0.005 (Table 4.2).  This derived 3 
genes that were not significantly different when comparing RDEB SCC to non-RDEB SCC but 
clearly showed significant expressional differences between tumour and normal samples 
for each SCC group. 
3: Non parametric ranking was used to identify genes with the highest level of 
dysregulation in RDEB SCC.  Each sample on the array was assigned a number from 1-16 
based on their level of dysregulation, 16 being highly dysregulated.  Genes showing the 
highest level of dysregulation in all RDEB samples were identified as markers of RDEB SCC 
(Table 4.3).   
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Gene 
Average 
Non-RDEB 
SCC 
Average 
RDEB 
SCC 
RDEB SCC 
Fold 
Change 
P Value 
SCC RDEB SCC 
Difference 
1 2 3 4 1 2 3 4 
FST 143 626 4.4 0.02 210 59 150 89 367 572 415 1149 157 
IFITM1 141 893 6.3 0.005 11 99 17 280 698 426 1291 1156 129 
Hs.448642 1076 600 0.5 0.004 946 874 1309 983 769 550 552 527 104 
FTH1 600 792 1.32 0.008 1246 1268 1521 1232 610 913 1146 499 87 
ITGB1 1440 950 0.6 0.016 1323 1266 1849 1239 801 1158 761 1081 81 
VWA1 109 582 5.3 0.006 50 195 73 31 269 513 658 888 74 
RPL26 1643 2430 1.5 0.009 1606 1753 1694 1989 2902 2494 2268 2055 66 
C14ORF156 1884 2704 1.4 0.007 1983 1673 2258 1824 3215 2428 2320 2854 62 
ERH 548 864 1.5 0.006 618 454 540 715 1031 775 779 870 60 
C7ORF7 245 135 0.55 0.001 219 246 264 279 165 157 90 129 51 
 
Table 4.1 Modified Mann-Whitney U test used to identify a further 10 markers of SCC 
Further interrogation of microarray data using a modification of the Mann-Whitney U test, identified transcripts with wide variation but the expression value for the closest 
sample from the Non-RDEB SCC and RDEB SCC sample group was higher than 50, which was the level of intermediate expression on the Illumina array and at least 50% of 
the value.  
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Gene Fold Change 
RDEB SCC vs Non-RDEB SCC 
Fold Change 
All SCC vs NHK 
Fold Change 
RDEB SCC vs EBK 
P Value 
RDEB SCC vs Non-RDEB SCC 
P Value 
All  SCC vs NHK 
P Value 
RDEB SCC vs EBK 
G3BP2 1.64 2.94 0.46 0.00649 0.00288* 0.00072* 
DNAJB14 1.92 1.49 0.28 0.00714 0.00386* 0.00387* 
PPP1R3E 5.82 13.42 0.18 0.011717 0.00806 0.00009* 
Table 4.2 Differentially expressed genes based on differences between SCC versus Normal comparing RDEB and Non-RDEB samples 
p values for the different groups were significant based on Category C of the original filtering criteria, and had values below 0.005. Significance denoted by * 
 
Gene SCC 1 SCC 2 SCC 3 SCC 4 SCC 5 RDEB SCC 1 RDEB SCC 2 RDEB SCC 3 RDEB SCC 4 
C1orf135 10 9 12 11 7 15 16 13 14 
BCSIL 10 7 12 8 11 15 16 13 14 
GSDMDC1 8 9 12 10 11 13 16 14 15 
STOML2 10 8 12 5 11 16 14 15 13 
LOC116412 9 12 8 5 11 15 13 14 16 
Table 4.3 Genes identified by level of dysregulation for all SCC samples 
Non parametric ranking was used to assign each sample with a number from 1-16 based on the level of dysregulation, 16 being the greatest level of dysregulation.  Those 
genes with the highest levels of dysregulation for all for RDEB SCC samples were derived as markers of RDEB SCC. 
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4.1.4 Aim  
As the array suggests that these genes are uniquely regulated in RDEB SCC, they could 
potentially hold the key to therapeutic pathways that are valuable targets in the treatment 
of SCC in RDEB patients, as these tumours are resistant to conventional cancer therapies, 
and elucidate the reasons why these tumours are more tolerable of conventional therapies.  
This small set of genes may also harbour dysregulated genes which encode proteins that 
provide a growth and survival advantage to neoplastic cells in RDEB patients, thus 
contributing to the aggressive and invasive nature of these tumours, the pathogenesis of 
which remains unknown.   
 
The aim of this chapter is to identify genetic targets of cutaneous SCC that specifically arise 
in RDEB patients that could potentially be objectified for therapeutic intervention.  The 
strategy for this investigation included; identifying common pathways among the 36 genes 
through gene ontology and pathway analysis.  Following on from microarray analysis, the 
36 genes identified as being significantly dysregulated in RDEB SCC were validated using 
replicate cultures of the RDEB SCC and non-RDEB SCC keratinocytes samples used for the 
original array experiment.  Concordant expression of genes from on the microarray and 
qRT- PCR validation experiment were followed up and the expression levels of each 
examined in vivo and in RDEB SCC keratinocyte cultures re-expressing Type VII Collagen. 
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4.2 Methods and Results 
4.2.1 Pathway analysis identifies HNF4A and TGFβ1 to be enriched in RDEB SCC 
The gene ontology (GO) of the 36 genes identified by the microarray was explored using the 
NCBI gene database (http://www.ncbi.nlm.nih.gov/gene) to look through the literature 
annotations and conserved protein domains to categorise the genes based on their 
biological functions.  Literature on each gene was explored and function was curated into 1 
of 16 functional processes.  Of the 36 genes 44.4% were previously reported to be linked to 
cancer (16 of 36 genes), showing an enrichment for tumour related genes. The biological 
function grouping revealed the two largest functional groups to be; firstly unknown 
function with 30.6% of the genes being within this category and secondly 13.9% of the 
genes were involved in the regulation of transcription (Figure 4.1). 
 
Ingenuity Pathway Analysis (IPA) software (Ingenuity, USA) was accessed in July 2008 and 
used to investigate the pathways predicted by the literature between the genes identified 
by the microarray.  Additionally COL7A1 although was not identified by the array as being 
dysregulated was added to the gene list to help identify pathways directly linked to RDEB.  
This software uses a database generated by published scientific reports to correlate and 
link proteins based on biological and chemical interactions.  No one specific pathway was 
indentified from the 36 genes (Figure 4.2).  However, 2 “hubs”; HNF4A and TGFβ1 were 
identified as being enriched with interactions associated with the genes identified by the 
array.  This suggests that these two pathways could be of importance in the development 
of cutaneous SCC in RDEB patients.   
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4.2.2 qRT-PCR Optimisation 
Quantitative real time-PCR (qRT-PCR) was performed using 1 NHK sample, 3 independent 
RDEB SCC and 3 non-RDEB SCC keratinocyte samples, to validate the array results of the 36 
genes identified as being differentially regulated in the microarray experiment.  This 
allowed real changes in RDEB SCC gene expression to be identified by reproducing the same 
results in an independent mRNA expression study.  Both the microarray and qRT-PCR 
experiments were performed using RNA harvested from primary SCC keratinocytes cultures 
2 days post confluence.  This model mimics in vivo cell-cell contact and interaction and 
reduces variation in expression levels caused by different rates of proliferation. 
 
Figure 4.1 Regulation of transcription is an enriched biological process in RDEB SCC. Categorising 
genes based on their biological function and processes, identified genes involved in regulation of 
transcription to be enriched in this gene group and over 25% to have unknown function.   
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        IPA - accessed July 2008 
 
Figure 4.2 IPA identified HNF4A and TGFβ1 as “hubs” involving genes dysregulated in RDEB SCC 
compared to non-RDEB SCC.  Two hubs were identified; TGFβ1 and HNF4A.  Each gene pathway is 
associated with several interactions.  Genes in green are those which are up-regulated in RDEB SCC 
and those in red are down-regulated in RDEB SCC.  The genes in white boxes are not identified as 
differentially regulated by the microarray analysis. The shape of each box represents a different 
functional class; solid lines indicate direct interactions whilst dotted lines are indicative of indirect 
interactions between proteins.  
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Primers were designed to amplify a 100-200bp amplicon for each of the 36 genes.  Primer 
design specifications are detailed in Chapter 2, Section 2.2.2.4.  Briefly, primers crossed an 
exon-exon boundary to prevent the amplification of genomic DNA and were located in the 
3’ region of the coding sequence of each gene so that they were in close proximity to the 
probes used on the Illumina microarray (Primer sequences are listed in Chapter 2, Table 
2.9).  Primers were tested first using RT-PCR to verify the correct product was amplified and 
to identify any non-specific products (Figure 4.3A).  Before running samples using qRT-PCR a 
temperature gradient was performed to optimise primer annealing temperatures for 
generating products with the highest yield whilst having low background and amplification 
of non-specific products (Figure 4.3B).   
 
Figure 4.3 Primer optimisation. A) Shows an example of an agarose gel used to visualise RT-PCR 
products using NHK as a template to test primer pairs.  Amplicons between 100-200bp were 
amplified for the 4 genes; EF1α, MXD4, AAMP and OAS3.  B) Demonstrates an ideal melting curve at 
60°C from the temperature optimisation gradient using EF1α primers for a qRT-PCR Run.  The 
melting curve shows a single product was amplified.    
B 
A 
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Accurate PCR analysis requires an internal control, such as a gene which is constitutively 
expressed in all cells at similar levels.  When designing the qRT-PCR validation experiment, 
using replicate samples as those used on the array, a reference gene was chosen by 
establishing the level of expression of a number of routinely used reference genes (Dheda 
et al. 2004; Radonic et al. 2004).  The average expression levels of several reference genes 
including GAPDH and β-Actin were explored in NHK, EBK, non-RDEB SCC and RDEB SCC 
keratinocytes on the microarray to elucidate a suitable control for qRT-PCR experiments.  
The EF1α gene was chosen as the most appropriate reference gene for this experiment due 
to having the lowest standard deviation as expressed as a percentage of the expression 
level (Figure 4.4). Therefore the level of expression of this gene varies the least between 
this particular sample cohort. 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 EF1α a suitable reference gene that shows the least change in expression  
Graph showing normalised microarray expression ratios for commonly used qRT-PCR reference 
genes, each value is given as an average expression level for the whole sample set (n=16) and error 
bars represent the standard deviation of the samples expressed as a percentage.  EF1α had the 
smallest variation in expression throughout all samples used on the microarray.   
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4.2.3 qRT-PCR confirms 14 genes to be differentially regulated between RDEB SCC 
and non-RDEB SCC keratinocytes in culture 
Quantitative RT-PCR validation identified 14 genes that showed the same pattern of 
expression as seen in the microarray analysis (Table 4.4), however only 5 of those were 
significantly different in the microarray experiment and the qRT-PCR confirmation screen.  
The 5 biomarker genes; SLCO1B3, DUSP23, TJAP1, SNRPN and SNURF are significantly 
differentially regulated between RDEB SCC keratinocytes and non-RDEB SCC keratinocytes 
at the mRNA level. 
 
4.2.4 Five genes are significantly dysregulated in RDEB SCC in vitro 
Microarray analysis identified a 9 fold increase in expression of SLCO1B3 in RDEB SCC 
keratinocytes.  Subsequent qRT-PCR validated the up-regulation of this gene, showing an 
average 7.8 fold increase in mRNA expression in RDEB SCC keratinocytes in comparison to 
both non-RDEB SCC and NHK (p value 0.035) (Figure 4.5A). 
 
DUSP23 mRNA expression was significantly reduced in RDEB SCC compared to non-RDEB 
SCC keratinocytes with a down regulation of expression by 0.39 fold in RDEB SCC (p value 
0.004) (Figure 4.5B). However, the actual dysregulation of DUSP23 is seen more so in non-
RDEB SCC keratinocyte samples in comparison to NHK, whereas RDEB SCC and NHK show 
similar expression of DUSP23.   
 
mRNA expression of TJAP1 is altered in opposing ways in RDEB SCC compared to non-RDEB 
SCC keratinocytes in relation to the normal expression seen in NHK (Figure 4.5C).  
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Table 4.4 Continued 
        
 
 
NHK 
RDEB SCC 
1 
RDEB SCC 
2 
RDEB SCC 
3 
SCC 1 SCC 2 SCC 5 
RDEB SCC 
avg. 
NHSCC 
avg. 
Fold 
Change 
p value 
AAMP 0.0138 0.0185 0.0201 0.0195 0.0228 0.0266 0.0310 0.0193 0.0268 0.7226 0.037453 
ADFP 0.0087 0.0030 0.0120 0.00329 0.0125 0.0135 0.0024 0.0061 0.0095 0.6418 0.500274 
BCSIL 0.0298 0.0337 0.0408 0.0733 0.0615 0.0648 0.0840 0.1479 0.2103 0.7033 0.213549 
C1orf135 1.2050 1.6600 1.1240 1.850 1.1980 1.1430 1.0940 1.5446 1.1450 1.3490 0.142651 
C7orf27 0.0205 0.0357 0.0198 0.02362 0.0321 0.3326 0.3785 0.0263 0.2477 0.1065 0.111502 
C14orf156 0.1188 0.1452 0.1924 0.2555 0.1369 0.2260 0.3774 0.1977 0.2467 0.8011 0.559243 
CCNA1 0.0181 0.0145 0.0142 0.0212 0.0129 0.0138 0.0092 0.0166 0.0120 1.3877 0.159653 
DNAJB14 0.0474 0.0329 0.0481 0.0350 0.0410 0.0363 0.0387 0.0387 0.0387 1.0001 0.999495 
DNMT3B 0.0036 0.0089 0.0069 0.0083 0.0063 0.0089 0.0035 0.0080 0.0062 1.2857 0.339987 
DUSP23 0.0608 0.0505 0.0876 0.0535 0.2125 0.1789 0.1049 0.0638 0.1655 0.38584 0.0401648* 
ERH 0.0100 0.0158 0.0147 0.0135 0.0130 0.0170 0.0270 0.0147 0.0190 0.7743 0.363765 
FST 0.0207 0.0089 0.0218 0.0456 0.0082 0.0584 0.1095 0.0254 0.0587 0.4337 0.345538 
FTH1 0.4431 0.3332 0.2268 0.2729 0.2786 0.2467 0.1673 0.2776 0.2308 1.2026 0.359377 
G3BP2 0.1561 0.0505 0.1419 0.1594 0.2034 0.1780 0.1133 0.1172 0.1649 0.7113 0.331318 
HOXA5 0.0127 0.0056 0.0101 0.0057 0.0086 0.0078 0.0114 0.0071 0.0093 0.7695 0.311479 
HSPC244 0.0120 0.0066 0.0088 0.0205 0.0136 0.0168 0.0109 0.0119 0.0138 0.8689 0.715753 
IFITM1 0.0131 0.0053 0.0070 0.0579 0.0026 0.0056 0.0387 0.0234 0.0157 1.4929 0.728239 
ITGB1 0.2874 0.0525 0.2017 0.0714 0.0972 0.1724 0.0842 0.1085 0.1179 0.9202 0.870941 
KRT8 0.2144 0.1677 0.3891 0.3188 0.0811 0.1140 1.125 0.2918 0.4400 0.6633 0.692823 
LOC116412 1.5410 1.5420 1.3230 1.4780 1.1510 1.0400 0.8530 1.4476 1.0146 1.4267 0.016289 
MGAT4B 0.0103 0.0100 0.0106 0.0059 0.0113 0.0128 0.0131 0.0088 0.0124 0.7123 0.084350 
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MXD4 0.0960 0.0424 0.0378 0.0460 0.0689 0.0638 0.0434 0.0421 0.0587 0.7172 0.111288 
OAS3 0.0108 0.0424 0.0651 0.1124 0.0803 0.0644 0.0350 0.0734 0.0599 1.2249 0.611863 
POFUT1 0.0069 0.0044 0.0042 0.0053 0.0049 0.0110 0.0087 0.0046 0.0082 0.5660 0.118385 
PPP1R3E 0.0157 0.0187 0.0128 0.0128 0.0237 0.0253 0.0119 0.0147 0.0203 0.7268 0.301884 
RPL23 0.0321 0.0487 0.0594 0.0533 0.0369 0.0636 0.1108 0.0538 0.0704 0.7641 0.488735 
SLC25A11 0.0305 0.0349 0.0276 0.0329 0.0379 0.0404 0.0832 0.0318 0.0538 0.5913 0.212705 
SLCO1B3 0.00006 0.00154 0.00055 0.00109 0.00018 0.00020 0.00009 0.0011 0.00014 7.8272 0.034401* 
SNRPN 0.0661 0.0051 0.0039 0.0094 0.0453 0.0317 0.0660 0.0061 0.0477 0.1281 0.014749* 
SNURF 0.0181 0.0003 0.0002 0.0007 0.0079 0.0129 0.0149 0.0004 0.0119 0.0330 0.005323* 
TJAP1 0.0029 0.0018 0.0021 0.0011 0.0068 0.0043 0.0036 0.0017 0.0049 0.3469 0.035004* 
TTC7B 0.0280 0.0376 0.0698 0.1204 0.0570 0.0421 0.0668 0.2278 0.1659 1.3736 0.895792 
VWA1 0.0106 0.0559 0.0372 0.0622 0.0243 0.0315 0.0624 0.0517 0.0393 1.3145 0.423633 
 
Table 4.4 36 genes validated by qRT-PCR. Values are relative to EF1α and p value based on student’s t-test comparing all RDEB SCC and all non-RDEB SCC 
samples. Genes highlighted by yellow, show the same trend of expression in qRT-PCR as in the microarray data, * denotes significant difference between 
mRNA expression in RDEB SCC and non-RDEB SCC keratinocytes. 
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In non-RDEB SCC the gene seems to be positively regulated and shows a slight although not 
significant increase in expression compared to NHK.  Whilst in RDEB SCC, the TJAP1 
expression is negatively regulated and a significant reduction is seen when compared to 
non-RDEB SCC keratinocytes, with a 0.35 fold decrease in expression (p value 0.035).  
However, this reduction in mRNA expression is not significantly different between RDEB 
SCC and NHK.  
 
SNRPN mRNA is consistently down regulated in all 3 RDEB SCC keratinocyte samples, 
compared to both NHK and non-RDEB SCC keratinocytes.  There is an overall reduction in 
the non-RDEB SCC samples compared to NHK although not significantly.  However, SNRPN 
mRNA expression is significantly reduced (p = 0.015) in RDEB SCC by a fold change of 0.128 
in RDEB SCC compared to non-RDEB SCC keratinocytes (Figure 4.5d), confirming a down 
regulation of SNRPN in both the microarray and qRT-PCR. 
 
The mRNA levels of SNURF are reduced in 2 of the 3 non-RDEB SCC keratinocyte samples 
compared to NHK.  The level of expression is negligible in all 3 RDEB SCC samples with an 
average 0.033 fold reduction and a significance of p 0.005 (Figure 4.5e), this conforms to 
microarray analysis also showing a reduction in mRNA expression. 
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Figure 4.5 Five genes are significantly differentially expressed in RDEB SCC 
qRT-PCR validation confirms 5 genes identified by microarray as being significantly differentially 
regulated in RDEB associated squamous cell carcinoma (RDEB SCC1-3) compared to non-RDEB SCC 
(SCC1,2 & 5) keratinocyte cultures. A) SLCO1B3 is has consistently higher mRNA expression in RDEB 
SCC by an average of 7.8 fold increase. B) DUSP23 has a significantly lower average mRNA expression 
in RDEB SCC as compared to non-RDEB SCC C) TJAP1 expression is reduced in RDEB SCC compared to 
non-RDEB SCC D) SNRPN has significantly decreased mRNA expression in RDEB SCC E) SNURF also  
has a significantly decreased expression in RDEB SCC compared to non-RDEB SCC.  Samples represent 
technical replicates (n=3). 
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4.2.5 RDEB SCC keratinocytes expressing COL7A1 show altered expression of the 5 
differentially regulated genes 
Dysfunctional Type VII Collagen is the protein responsible for causing RDEB, and it has been 
long since suggested the lack of COL7A1 expression is the reason why RDEB patients 
develop SCC.  Therefore it’s necessary to establish whether the dysregulation of the 5 
significantly differentially expressed genes is dependent on presence of Type VII Collagen.  
This would identify a direct relationship between the primary disease and the tumour cells.  
This was tested using mRNA from RDEB SCC keratinocytes that had been retrovirally 
transduced to re-express Type VII Collagen (Appendices 1.3 Type VII Collagen protein 
expression after transduction).  qRT-PCR results indicated that the mRNA expression of 
SLCO1B3 is reduced to relatively normal levels comparable to NHK (Figure 4.6A).  The 
expression of DUSP23 is reduced in comparison to the pBabe puro empty vector control 
cells (PB) by an average of 2.71 fold.  In all 3 cell lines the reduced expression is significant 
with p values of 0.005, 0.031, 0.007 in RDEB SCC1, 2 and 3, respectively (Figure 4.6B). 
 
In COL7A1 transduced RDEB SCC keratinocytes the TJAP1 expression is reduced in 2 of the 3 
RDEB SCC cell lines (Figure 4.6C).  Both RDEB SCC 1 and 3, after retroviral transduction to 
over-express COL7A1 show a significant decrease in mRNA expression of TJAP1, p value 
0.01 and 0.02 respectively.  However, in the case of RDEB SCC 3 the empty vector control 
has a much higher mRNA expression than NHK and somewhat different to what you would 
expect from the control, as the parental cell line showed a reduced expression in 
comparison to NHK.  RDEB SCC 2 showed no significant difference between RDEB SCC 
keratinocytes that express COL7A1 and those which do not, this could be as a result of 
continual evolution of tumour cells in culture or selection after transduction which favours 
clones that express more TJAP1. 
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COL7A1 re-expression in RDEB SCC keratinocytes reduces the expression of SNRPN mRNA 
further in comparison to empty vector controls (Figure 4.6D).  However, only significantly 
so, in RDEB SCC 3, which was the sample showing the highest level of SNRPN in the parental 
cell line during the original qRT-PCR analysis.  Re-expression of COL7A1 in RDEB SCC 
keratinocytes, reduces the SNURF mRNA expression in all 3 cell lines, but only significantly 
in one sample (Figure 4.6E).  RDEB SCC2 has a significantly decreased mRNA expression and 
shows a 0.11 fold change (p=0.016) when COL7A1 in re-expressed.  However, this value is 
against the empty vector control which showed unusually high expression of SNURF. 
Whereas it was expected to be expressed at a similar level in the control cells as the original 
parental cell line which demonstrated a much lower expression than NHK in the original in 
vitro qRT-PCR analysis.  In this qRT-PCR, interestingly all 3 pBabe controls have similar levels 
of expression to the SNURF mRNA expression in RDEB SCC compared to NHK, suggesting 
that the empty vector alone maybe affecting the expression of this gene.  Also, in all cases 
the presence of Type VII Collagen reduces the expression of all 5 genes.  Paradoxically, 
given that if this was the mechanism that causes the dysregulation then the re-expression 
of COL7A1 should switch back on the expression of these genes.   
 
In terms of re-expressing COL7A1 in RDEB SCC keratinocytes, it is important to consider if 
the changes seen in these 5 genes would be controlled by the COL7A1 production in normal 
skin.  In other words, another it is important to test the level expression in normal skin, 
normal skin keratinocytes in culture in comparison to the level of expression in the RDEB 
SCC keratinocytes after retroviral transduction of the cells.    
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Figure 4.6 SLCO1B3 mRNA expression is reduced when Type VII Collgan is re-expressed in RDEB 
SCC keratinocytes 
RDEB SCC keratinocytes retrovirally transduced to express Type VII Collagen were then subjected to 
qRT-PCR and the mRNA expression of the 5 candidate genes tested.  SLCO1B3 mRNA expression is 
reduced back to a normal level of expression in RDEB SCC when Type VII Collagen is expressed (C7) in 
comparison to the empty vector control cultures (PB). All 5 genes tested A) SLCO1B3, B) DUSP23, C) 
TJAP1, D) SNRPN, E) SNURF, the mRNA expression is reduced in cells expressing Type VII Collagen.  
Samples represent technical replicates (n=3). 
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4.2.6 In Vivo mRNA expression status of the 5 in vitro biomarkers of RDEB SCC 
To establish if the dysregulation of these 5 genes is an artefact of in vitro culturing of the 
RDEB SCC keratinocytes, RNA from normal human skin, non-RDEB SCC, RDEB skin and RDEB 
SCC were used to create cDNA and subjected to qRT-PCR to investigate mRNA expression 
levels of the in vitro biomarkers of RDEB SCC keratinocytes identified by the microarray and 
qRT-PCR analysis.  
 
RNA was isolated from fresh frozen tissues by the NHS Tayside Tumour Bank (Dundee, UK) 
and assigned a RNA integrity number (RIN) based on RNA quality and quantity analysis.  RIN 
numbers are an overall measure of RNA quality and is based on a scale of 1 to 10, the 
higher the number the greater the integrity of RNA.  The RIN of each tissue sample used is 
detailed in Table 4.5, RDEB SCC samples 3, 6, 7, and 8 were eliminated from the qRT-PCR 
due to their poor quality RNA.  
 
qRT-PCR using the tissue cDNA reveals SLCO1B3 is over-expressed in 5 of 7 RDEB SCC 
tissues used, thus confirming the findings of the in vitro microarray and qRT-PCR screens.   
Interestingly, in vivo mRNA expression analysis reveals increased expression in 2 out of 3 
non-RDEB SCC and RDEB skin samples (Figure 4.7A).   
 
Tissue analysis established that the mRNA expression of DUSP23 is higher in non-RDEB SCC 
in vivo as well as in vitro with all 3 non-RDEB SCC samples showing higher mRNA expression 
than NHK.  Whilst 2 of 7 RDEB SCC samples showed a slight decrease in expression of 
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DUSP23, most samples show concordance with the in vitro data showing little difference in 
expression in comparison to NHK in 5 of 7 RDEB SCC tissue samples (Figure 4.7B). 
 
 
Nomenclature of Tissue Samples RIN 
NH SKIN 1 8.4 
SCC 1 5.7 
SCC 2 6.9 
SCC 3 6.5 
RDEB SKIN 1 8.7 
RDEB SKIN 2 8.8 
RDEB SKIN 3 8 
RDEB SCC 1 7 
RDEB SCC 2 7.1 
RDEB SCC 3 n/a* 
RDEB SCC 4 7.5 
RDEB SCC 5 8.4 
RDEB SCC 6 1* 
RDEB SCC 7 n/a* 
RDEB SCC 8 1* 
RDEB SCC 9 8.4 
RDEB SCC 10 8.6 
RDEB SCC 11 6.8 
Table 4.5 Tissue Samples used for in vivo qRT-PCR screen 
Nomenclature and RNA integrity numbers (RIN) for each sample. Only 4 samples had extremely very 
low RNA quality, denoted by*  
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TJAP1 mRNA expression was increased in 1 of 3 non-RDEB SCC tissue samples and in 2 of 7 
RDEB SCC samples (Figure 4.7C).  A further 4 RDEB SCC samples showed reduced expression 
of TJAP1 and the final sample showed no difference.  RDEB skin shows a reduction in TJAP1 
expression, along with 1 non-RDEB SCC sample.  The in vivo study shows varied expression 
of TJAP1, with no particular pattern of expression being identified between the sample 
groups. 
 
Analysis of SNRPN mRNA expression in vivo identifies increased expression in 100% of non-
RDEB SCC samples.  Only 50% (3 of 6) of RDEB SCC samples showed reduced expression, 
whilst a further 2 samples showed an increase and the final sample demonstrated no 
difference in expression in comparison to normal skin.  Intriguingly, both RDEB skin samples 
showed a reduction in SNRPN expression in vivo (Figure 4.7D).  In vivo SNURF expression 
was unchanged in RDEB skin and non-RDEB SCC.  Only 2 of 7 RDEB SCC samples showed a 
reduced expression of SNURF in tissue (Figure 4.7E), whilst the majority of RDEB SCC 
samples did not conform with in vitro data and instead showed no difference in the mRNA 
expression of SNURF. 
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Figure 4.7 qRT-PCR revealed over-expression of SLCO1B3 in cutaneous SCC in vivo.   
A) SLCO1B3 has increased expression in 71.4% of RDEC SCC samples B) DUSP23 has higher mRNA 
expression in all non-RDEB SCC samples compared to NHK, and in 5 of 7 RDEB SCC samples C) TJAP1 
mRNA expression was increased in 1 of 3 non-RDEB SCC tissues and a reduction in 4 of 7 RDEB SCC 
samples and 2 of 3 RDEB skin samples.  D) SNRPN expression is down in RDEB tissue, as well as in 3 of 
6 RDEB SCC samples.  E) SNURF mRNA expression is down in 2 of 7 RDEB SCC tissues, and shows no 
difference in expression in RDEB tissue and non-RDEB SCC tissue.  Samples represent technical 
replicates (n=3). 
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4.3 Discussion 
36 genes were originally identified by microarray analysis as being differentially regulated 
between RDEB SCC and non-RDEB SCC keratinocytes in an experiment aimed at the first 
steps in identifying therapeutics targets of SCC that develop in RDEB patients and 
understanding SCC pathology in these patients.  This is a priority for research in this topic 
due to the aggressive nature of these tumours in RDEB patients and their resistance to 
conventional cancer therapies.  SCC presents as a life threatening condition in RDEB 
patients and causes mortality in 78.7% of patients by the age of 55 (Fine et al. 2009).  
 
The most common functional groups of genes were those involved in the regulation of 
transcription, which included 14.4% of the genes (Figure 4.1).  This includes HOXA5 and ERH 
both reported to be tumour related (Zafrakas et al. 2008; Yoo et al. 2010) and MXD4 and 
FST which are both negative regulators of transcription.   
 
4.3.1 TGFβ in cancer 
Pathway analysis of these genes identified the TGFβ1 to be an enriched pathway associated 
with several of the genes identified by the array (Figure 4.2).  This could suggest that the 
TGFβ pathway is implicated in the development of cutaneous SCC. However the analysis 
doesn’t determine if this pathway is more important in RDEB SCC or in non-RDEB SCC.  
 
The TGFβ pathway includes a superfamily of cytokines that include over 30 structurally 
related polypeptide growth factors (Gordon and Blobe 2008) (Figure 4.8).  This pathway has 
been implicated in many diseases including; development disorders, vascular diseases and 
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is the most commonly mutated signalling pathway in cancer (Akhurst 2004; Gordon and 
Blobe 2008).  More specifically, an increase in TGFβ has been implicated in pre-eclampsia, 
restenosis, and hypertension and interestingly, in connective tissue and fibrotic diseases 
that are associated with out of control wound healing.  This suggests a connection with the 
chronic wound healing environment and cancer develop in RDEB patients.  TGFβ signalling 
is essential for the regulation of several cellular processes; including proliferation, 
migration, differentiation and survival and many physiological processes including 
embryonic development, angiogenesis and wound healing (Massague et al. 2000; Gordon 
and Blobe 2008).  Therefore errors occurring within these pathways can lead to a diverse 
range of diseases.   
 
TGFβ is frequently studied in sporadic cancer, and data is often paradoxical in terms of its 
role in the pathogenesis of human cancer (Inman 2011).  In general, TGFβ acts as a tumour 
suppressor early on in the process of carcinogenesis, activating downstream targets such as 
p21, p27, and p15 and leading to growth inhibition, promotion of differentiation and 
apoptosis (Xu and Pasche 2007).  In the late stages of carcinogenesis, it has been reported 
that TGFβ becomes a tumour promoter and its action mimic that of an oncogene causing 
cell growth, increased survival, motility, invasion and metastasis (Gordon and Blobe 2008).  
Alterations and deletions in the TGFβ pathway often result in human disease development 
including; cancer, developmental disorders and vascular diseases, this is unsurprising given 
that this is superfamily of proteins and complex pathway are ubiquitous and essential 
regulators of many cellular processes.  
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Specifically as TGFβ1 was identified in the pathway analysis of differentially regulated genes 
in RDEB SCC, this protein is synthesized and secreted into the extracellular matrix as an 
inactive precursor protein containing a signal peptide; the latency associated peptide (LAP) 
and mature TGFβ1.  Activation of TGFβ1 is thought to involve the proteolytic cleavage of 
LAP  which can be induced by acidic environmental conditions or by an excreted 
extracellular proteases such as MMP2 and 9 (Wu et al. 2007). 
Figure 4.8 TGFβ super-family signalling pathways 
The TGFβ signalling cascade is initiated when TGFβ ligands bind to their respective type I and II 
receptors. Once activated the type I receptor’s kinase domain becomes activated by phosphorylation 
allowing the receptor to in turn phosphorylate Smad transcription factors. These transcription 
factors form complexes that accumulate within the nucleus of cells and interact with other 
transcription factors that affect the transcriptome.  This signalling pathway leads to the regulation of 
a range of cellular responses including growth, motility and cell death.  Figure taken from Gordon 
and Blobe, 2008. 
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The known paradoxical role of the TGFβ pathways in tumour formation and recent research 
into TGFβ inhibitors as cancer therapeutics would suggest the need for future work to 
establish if indeed the TGFβ1 pathway specifically plays a role in RDEB associated SCC; as 
the protein could potentially be acting as a mutant tumour suppressor or oncogene in these 
patients.  Further studies could initially include investigating the downstream targets of 
TGFβ1 to identify if there is any difference in expression, this would hopefully illuminate 
any changes to the pathway in this patient group.  An important factor to consider would 
be to test both RDEB skin and RDEB SCC cells to look for early mutations and aberrations in 
cancer development.  Furthermore, as TGFβ1 is known to play a role in wound healing this 
suggests there may be a direct link between the RDEB phenotype and this gene.  It has 
been proposed that TGFβ1 can induce epidermal keratinocytes to express cell surface 
receptors known as Integrins such as α5β1, that facilitate cell migration in re-
epithelialisation of wounds (Gailit et al. 1994).  The involvement of functionally relevant 
proteins in the skin that are regulated by TGFβ and its potential role as a tumour promoter 
supports the rationale for further studies of TGFβ1 in RDEB SCC to be carried out.    
 
4.3.2 HNF4A in cancer 
IPA has identified HNF4A as being highly associated with the gene list derived from the 
microarray analysis (Figure 4.2).  HNF4A encodes a transcription factor; hepatocyte nuclear 
factor 4α and has a key role in regulating the expression of components of cell-cell 
junctions, including those in adherens junctions, tight junction and desmosomes (Battle et 
al. 2006).  Therefore, this suggests that HNF4A plays a part in the epithelia organization and 
barrier function.  
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A knock-out mouse model with targeted deletion of Hnf4a in epithelial cells of the fetal 
colon die perinatally (Ahn et al. 2008).  There is increasing evidence in the literature that 
HNF4A could be involved in the pathogenesis of human cancer, however, the role in which 
HNF4A plays has not been elucidated as yet and literature reports are conflicting on the 
subject.  Firstly, in several cancer cell lineages including endothelial lung carcinoma cells 
(Chiba et al. 2005); HNF4A inhibits cell proliferation suggesting that the dysregulation of 
this pathway would be a self protective mechanism initiated by the cell to prevent tumour 
progression rather than promotion.  Whereas aberrations of upstream regulatory signalling 
cascades are associated with progression of rodent and human hepatocellular carcinoma 
via accelerated cell proliferation, loss of epithelial morphology, dedifferentiation and the 
ability to invade and metastasise (Lazarevich and Fleishman 2008).  
 
Partial reversion of a malignant phenotype can be obtained by re-expressing HNF4A in 
dedifferentiated hepatoma cells (Yin et al. 2008).  Suggesting that, if in fact this pathway is 
aberrant in SCC it could be used as a potential target for therapy in a similar way.  HNF4A is 
described to function in a network of transcription factors including HNF1A and HNF1β 
which control gene expression in embryonic and adult tissues, particularly those of the 
liver, pancreas and kidneys (Ferrer 2002; Lucas et al. 2005).  A 4.7 fold down regulation of 
HNF4A is seen in renal cell carcinoma compared to normal tissue (Lenburg et al. 2003).  The 
different responses of the HNF4A pathway in various cell types suggests that there is a 
tissue specific response, and HNF4A may respond differently in various tissues in response 
to carcinogenesis.  As mentioned earlier, HNF4A is associated with regulating expression of 
tight junction molecules, and as this chapter reports a dysregulation of TJAP1; a tight 
junction protein, this suggests a potential direct connection between these two genes in 
RDEB SCC.  Considering that TJAP1 is reduced in RDEB SCC is could suggest that this 
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expression may be controlled by HNF4A and therefore causes reduced cell-cell interactions 
and reduced barrier function this may have an effect of the tumour cells ability to break 
away from the tumours and therefore increase the risk of metastasis.   
 
The most interesting point from the IPA analysis and the identification of HNF4A as a hub, is 
its connection to SLCO1B3.  This link was initially missed when looking at the IPA analysis 
however the subsequent association of the nuclear receptor HNF4A being able to directly 
influence the expression of SLCO1B3, makes this an attractive target in the search for a 
genetic target of RDEB SCC.  HNF4A warrants further research to establish if it indeed 
effects the SLCO1B3 expression in RDEB SCC keratinocytes, this could be done using a 
reporter assay. 
 
4.3.3 SLCO1B3 is highly expressed in RDEB SCC and other malignant tumours 
SLCO1B3 is a member of a superfamily of sodium-independent uptake transporter proteins 
known as solute carrier proteins (SLCs) or Organic Anion Proteins (OATPs) (Meyer zu 
Schwabedissen and Kim 2009).  This study is the first to report over-expression of SLCO1B3 
in cutaneous squamous cell carcinoma. In vitro studies, including microarray analysis and 
qRT-PCR have identified that the SLCO1B3 transcript is over-expressed in 3 independent 
RDEB associated SCC keratinocyte samples compared to non-RDEB SCC and NHK (Figure 
4.5A).  In vivo analysis of expression also showed an up-regulation of SLCO1B3 RDEB SCC 
proving this aberration in gene expression is not merely due to the culturing of RDEB SCC 
keratinocytes (Figure 4.7A). 
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The SLCO1B3 gene encodes a protein known as OATP1B3.  This family of transporters are 
known to transport many endogenous and xenobiotic compounds across membranes 
within the liver, kidney, brain, and intestine; including thyroid hormones, steroid conjugates 
and anti-cancer drugs (Tirona and Kim 2002).   Both OATP1B1 and OATP1B3 are exclusively 
expressed in the liver and are localised to the basolateral membrane of hepatocytes where 
they are responsible for the transport of solutes from the blood to the bile via vectorial 
transport (Cui et al. 2001).  OATP1B1 and OATP1B3 share 80% amino acid identity and there 
is some overlap in their substrate specificity, both can transport bile acids, Methotrexate, 
and steroid sulphates (Konig et al. 2000; Kullak-Ublick et al. 2001).   
 
This investigation illustrated that COL7A1 expression directly influences the mRNA 
expression of SLCO1B3 (Figure 4.6A).  This suggests that in effect, a long term reduction in 
COL7A1 expression could cause the activation of transcription of SLCO1B3; however the 
mechanism responsible for SLCO1B3 expression in RDEB SCC is unknown as yet and 
requires further investigation.  It could be that SLCO1B3 expression contributes to the 
initiation of tumourigenesis in RDEB patients or it could potentially alter cell growth, 
migration, and invasion and thereby enhance the aggressive nature of these tumours and 
increase their metastatic potential within these patients.   
 
SLCO1B3 expression has been reported in several other cancers including gastric, colon and 
pancreatic cancers (Abe et al. 2001).  The functional transport of small molecule drugs via 
OATP1B3 has not been established but as it is able to transport anti-cancer drugs such as 
Methotrexate into cells it could be exploited as a pathway to directly target tumour cells 
with cytotoxic agents already in use.  Furthermore, as this gene is normally only expressed 
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in the liver it may be possible to use a low dose of chemotherapy to minimise the systemic 
toxicity to normal cells within the body, whilst targeting the cancer cells.  Xenograft mouse 
models would be an ideal model to determine whether this is possible. 
 
4.3.4 DUSP23 over-expressed in vitro and in vivo 
DUSP23 is a member of the Protein Tyrosine Phosphatase (PTP) family, which collectively 
cause reversible phosphorylation of tyrosine residues of proteins belonging to the MAPK 
family (Tonks and Neel 2001).  More specifically DUSP23 is part of the Dual Specificity 
Phosphatases (DSPs) subgroup of PTPs, which can dephosphorylate both serine/threonine 
residues as well as tyrosine residues (Nakamura et al. 1999; Takagaki et al. 2004).  The 
desphosphorylation of kinases is important for the regulation of mitogenic signal 
transduction in response to cellular stimuli and thereby controlling the cell cycle and cell 
proliferation (Tonks and Neel 2001; Takagaki et al. 2004). 
 
DUSP23 is located on chromosome 1q23, and has only two exons and 1 intron (Wu et al. 
2004), its dysregulated between RDEB SCC and non-RDEB SCC keratinocytes in two 
independent experiments (Figure 4.5).  However, the regulation of this gene between RDEB 
SCC and NHK is not significantly different.  The up-regulation of DUSP23 mRNA expression 
seen in vitro in 3 non-RDEB SCC keratinocytes lines, is also mimicked in vivo in 3 
independent SCC (Figure 4.7), thus establishing this is in fact a real change within the SCC 
cells and is not an artefact of culturing keratinocytes in vitro.  Furthermore, there is also 
evidence of increased DUSP23 mRNA expression in some RDEB SCC tissues.  Although, this 
gene does not provide an RDEB SCC specific target, it could be more significant as a generic 
genetic target of SCC, given its up-regulation both in vitro and in vivo.  The apparent mRNA 
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up-regulation in a tumourigenic environment could suggest that it is caused in response to 
cellular stress.  Given that DSPs are activated by specific cellular stimuli, potentially future 
work could investigate why DUSP23 is expressed at higher levels in SCC, and is this due to 
oncogenic stimuli in tumours or a result of genetic instability of cancer cells.  Kinase activity 
in SCC keratinocytes could be tested, to establish if this activity is affected by the DUSP23 
expression using an immune-complex assay to measure activity of kinases after the co-
transfection of DUSP23 with various MAPKs (Shen et al. 2001).  One study has shown over-
expression of DUSP23 can increase the proliferative potential of human cancer cells (Tang 
et al. 2010). 
 
When COL7A1 is re-expressed in the RDEB SCC keratinocytes there is a reduction of the 
DUSP23 mRNA expression, significantly so in comparison to the empty vector control cells 
in each of the 3 cell lines (Figure 4.6).  However, due to the NHK and RDEB SCC 
keratinocytes expressing similar levels of DUSP23 to begin with, the expression of COL7A1 
causes greater dysregulation of this gene in the RDEB SCC cells.  This suggests that in RDEB 
skin the reduced expression of functional Type VII Collagen is not a contributory factor to 
the deregulation of this gene. 
 
4.3.5 TJAP1 encodes a tight junction protein dysregulated in SCC 
Tight junctions (TJs) are present in epithelial cells, and form part of the physical contact 
between cells, creating cell-cell junctions.  They have a diverse range of functions within 
cells by playing an essential role in adhesion, growth and proliferation (Kawabe et al. 2001).  
Tight junctions also act as physical barriers between cells to prevent solutes and water from 
passing through the paracellular pathway and provide a fence between apical and 
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basolateral plasma membranes in epithelial cells.  These junctions are composed of 
transmembrane proteins such as claudin, occludin and JAM, peripheral membrane protein 
such as actin filament binding scaffold proteins and cell polarity molecules.  TJAP1 is a 
recently discovered gene which encodes a novel peripheral membrane protein identified 
from a cDNA library and its protein name Protein Incorporated later into TJs (PILT), aptly 
named as it becomes incorporated into tight junctions after the claudin-based junctional 
strands have been formed (Kawabe et al. 2001). However, its exact function has yet to be 
elucidated.  It is highly expressed in tissues such as skeletal muscle and the spleen which 
are not rich in TJs and is conversely low in tissues which are high in TJs. PILT also localizes to 
the golgi so could be involved in vesicle trafficking between golgi and TJ to establish and 
maintain cell polarity (Kawabe et al. 2001). 
 
PILT is incorporated in TJs at a very late stage in the wound healing process which could 
suggest that it is incorporated into RDEB keratinocytes more frequently as these patients 
have generalised skin trauma which produces chronic wound environment.  qRT-PCR 
results suggest TJAP1 is dysregulated in RDEB SCC however more so in non-RDEB SCC 
keratinocytes when compared to NHK (Figure 4.5).  Although there is a significant 
difference between the mRNA expression of TJAP1 in RDEB SCC when compared to non-
RDEB SCC, when the expression is compared to NHK the expression is similar and not 
significantly different suggesting TJAP1 is not the most appropriate target for an SCC 
therapeutic in RDEB specifically.  This is confirmed by the in vivo studies which show no 
specific pattern of expression in RDEB SCC or non-RDEB SCC; with increased expression in 1 
of 3 non-RDEB SCC samples and only 2 of 7 RDEB SCC samples, whilst 4 showed reduced 
expression of TJAP1 (Figure 4.7). 
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4.3.6 SNRPN and SNURF encoded by the same locus and down regulated in RDEB 
SCC 
SNURF and SNRPN transcripts are located within the same SNURF-SNRPN locus on 
chromosome 15.  Basically, these transcripts from the microarray are in fact one gene with 
10 exons, which is transcribed into a bi-cistronic mRNA transcript. Exons 1-3 encode the 
SNURF protein (Gray et al. 1999), whilst exons 4-10 encode SNRPN protein (Ozcelik et al. 
1992), but also has 2 alternative 5’ initiation of transcription sites and multiple untranslated 
upstream exons of unknown function (Dittrich et al. 1996).  They are positioned within a 
gene cluster which spans an imprinted domain where genes are transcribed either from the 
paternal or maternal chromosome only, and their expression can occur within all cells or in 
a temporal or spatial manner.  SNPRN is expressed only by the paternal allele in all tissues 
studied so far (Runte et al. 2001), and is functionally imprinted in both mice and humans 
(Leff et al. 1992; Reed and Leff 1994). 
 
RDEB SCC keratinocytes have a significantly reduced mRNA expression of both SNRPN and 
SNURF which are encoded by the same locus on chromosome 15.  It is also possible that 
these genes are simply deleted in RDEB SCC keratinocytes or perhaps a translocation has 
occurred, in which case this particular region of chromosome 15 has been swapped with 
another chromosome when the cells have divided through mitosis. This could be 
investigated via cytogenetic and FISH analysis to look for chromosomal abnormalities 
specifically in the RDEB SCC cells.  Studies by Barr (1995) identified that SNRPN is expressed 
in a variety of tissues; with the highest expression occurring in the brain, but has also been 
identified in the heart, lungs, liver, spleen, kidneys, testis and ovary (Bar 2005).  Our study 
identifies expression of SNPRN and SNURF in NHK, suggesting that it is expressed in vitro 
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and is also detectable in normal skin in vivo, as identified by the qRT-PCR screen using 
tissue samples (Figure 4.7). 
 
Two upstream exons were found in the SNRPN gene and the first exon designated alpha, 
lies within a CpG island likely to be the promoter (Sutcliffe et al. 1994).  This suggests that 
the reduced expression of SNRPN in RDEB SCC could be a result of hypermethylation of the 
promoter region.  Whether or not these genes are methylated could potentially be 
investigated by bi-sulphite PCR, a methylation specific PCR to identify genes which are 
hypo- or hyper-methylated.  Promoter methylation is often the cause of maternal silencing, 
whilst this occurs less frequently in paternal silencing as there is some evidence to suggest 
that the paternal genome is actively demethylated in the oocyte, and therefore other 
mechanisms occur to cause inactivation of the paternal chromosomes.  
 
This imprinted domain and the loss-of-function of genes within this region are associated 
with 2 distinct neuro-genetic diseases; Prader-willi syndrome (PWS) and Angelmen 
Syndrome (AS) (Runte et al. 2004).  Studies have shown uniparental disomy of chromosome 
15 can result in these two disorders; with 70-80% of PWS patients having a paternal 
deletion of chromosome 15q11-q13 (Nicholls et al. 1989; Robinson et al. 1991), whilst 70-
80% of AS patients result from the same deletion but of the maternal allele (Knoll et al. 
1989; Malcolm et al. 1991).  PWS results from loss of the genes expressed on paternal 
allele, whilst AS results from loss of genes expressed only from the maternally inherited 
chromosome.  The lack of maternal or paternal allele expression in both AS and PWS is very 
similar to the UPD seen in RDEB where certain chromosomes are inherited from only one 
parent.  Given this striking similarity between the genetic alterations between these 3 
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conditions it is noteworthy that AS and PWS patients do not show an increased cancer risk 
whilst RDEB patients do. 
 
Future studies could include the investigation of the genes within this locus to establish if 
the loss is apparent before or after the initiation of malignant transformation in RDEB 
keratinocytes within a chronic wound environment. As SCC is very hard to distinguish from 
the normal blistering and chronic erosions that RDEB patients have, this gene may allow for 
an alternative method for assessing the tissue and tumoural margins in patients who 
develop SCC, as both normal and RDEB skin have expression of at least one of these 
transcripts.  Further tests could be performed to establish how this gene is silenced in SCC.  
As the two upstream exons of SNRPN lie within CpG islands it is conceivable that 
methylation suppresses the transcription of this gene and this would be a plausible 
explanation of gene silencing.  UPD is present on chromosome 15q (Chapter 3 Table 3.1) in 
RDEB SCC 3 and therefore could be the reason for dysregulation of SNRPN and SNURF in 
this sample.  The other two samples could have reduced expression of these genes due to 
other genetic events, whereby perhaps there is a mutation in the transcript resulting in a 
premature termination codon and nonsense mediated decay of the transcript, or a 
microdeletion as mentioned in other studies surrounding PWS where part of the 
chromosome is simply deleted, however no losses were identified by the SNP array data on 
chromosome 15. 
 
  4.3.7 Cell types contributing to tissue samples  
One possible explanation for the varying mRNA expression levels for the 5 genes tested in 
the tissue samples is that tumour tissue samples may not contain only cancer cells.  It is 
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well known that a tumour’s cell population is heterogeneous.  Therefore the RNA isolated 
from tumour tissue samples for the experiments discussed in this chapter may also be from 
a combination of normal and tumour cells.  This is one advantage of using the keratinocyte 
cell culture model for initial experiments, as the gene expression levels were taken from a 
homogenous cell population.  One consideration for future experiments would be to 
microdissect tumour samples to reduce sample heterogeneity and therefore increase 
mRNA expression accuracy. 
 
4.3.8 SLCO1B3 is a potential candidate worth pursuing 
Although 5 transcripts were identified by the microarray and qRT-PCR screening as being 
differentially regulated between RDEB SCC and non-RDEB SCC, SLCO1B3 would seem to be 
the most intriguing gene to follow up initially due to its apparent reduction in mRNA 
expression when COL7A1 is re-expressed and thus reverting the expression back to the 
normal mRNA levels, as seen in NHK and non-RDEB SCC keratinocytes.  Furthermore, the 
expression is seen in some RDEB SCC tissues and some non-RDEB SCC samples but not in 
normal skin (Figure 4.7A).  This transporter gene, could present as genetic target which is 
regulated in a different manner in mainly in RDEB SCC and therefore could be exploited as a 
potential therapeutic pathway specifically aimed at treating SCC in RDEB patients.   
 
As SLCO1B3 encodes an organic anion transporter that is normally only expressed in the 
liver and functions to transport many endogenous and exogenous proteins into the liver 
where they can be excreted and metabolised, this protein represents a potential pathway 
to directly target tumour cells and thus allow the accumulation of anti-neoplastic drugs in 
the tumour.  OATPS have been subject to many investigations which predominantly aim to 
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evaluate drug disposition and metabolism in mouse models along with transport of various 
substrates into via these transporters (Cattori et al. 2000; Muto et al. 2007; Chen et al. 
2008).  Mouse models have been utilised to investigate several OATPs by knocking down 
their expression and then testing drug distribution in these mice (Cattori et al. 2000; Cheng 
et al. 2005; Chen et al. 2008). One limitation of these models in respect to OATP1B3 is that 
there is no ortholog in mice, the closest member is Oatp1b2 which shares a similar 
homology with both OATP1B1 and OATP1B3 in humans (Konig et al. 2000; Konig et al. 
2006).  Mouse models do however represent useful tools for understanding the role of 
OATPs in drug targeting and disposition in cancer cells. 
 
OATP1B3 is capable of transporting several chemotherapeutic agents including 
Methotrexate and Paclitaxel.  The use of chemotherapy for the treatment of SCC in RDEB 
patients is limited and only a few cases reports exist (Ayman et al. 2002; Arnold et al. 2009; 
Shivaswamy et al. 2009).  This is mainly due to the systemic toxicity caused by these agents, 
which can increase infection rate and perturb the skin further.  As OATP1B3 is only 
expressed in liver cells and also in tumours cells, this would theoretically allow 
antineoplastic drugs to be taken up by the SCC cells only in RDEB patients, and reduce the 
systemic toxicity as any circulating drug will be transported into the liver by OATP1B3 
where it would be metabolised and excreted, thus reducing systemic toxicity to patients.  
This hypothesis is supported by a study undertaken by Van de Steeg and colleagues who 
demonstrated knockdown of SLCO1B1 in mice drastically decreased uptake of 
Methotrexate and Fexofenadine and consequently increased systemic toxicity (van de 
Steeg et al. 2010).   
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Interestingly two studies have shown OATP1B3 expression to be correlated to prognosis 
(Muto et al. 2007; Hamada et al. 2008).  Muto and colleagues demonstrated that 51 breast 
tumours expressed OATP1B3 which was inversely correlated to tumour size and was 
significantly associated with decreased risk of recurrence and improved prognosis (Muto et 
al. 2007).  This is believed to be due to OATP1B3 being able to transport estrone 3 sulfate in 
to breast tumour cells in a growth dependent manner (Muto et al. 2007).  Whilst Hamada 
and colleagues showed that prostate tumours which express wild-type OATP1B3 have 
poorer prognosis that those expressing the OATP1B3 334T>G or 699G>A variants.  This is 
due to the variants having reduced transporter activity and therefore transport less 
testosterone into tumour cells, whilst those expressing wild-type OATP1B3 transport more 
testosterone into cells creating a growth advantage for the tumour cells (Hamada et al. 
2008).  OATP1B3 is capable of transporting estrogen into cells, which is known to be a 
regulator of connective tissue molecules; namely collagen (Schiffer et al. 2003).  This could 
suggest that OATP1B3 is expressed as a result of a compensatory mechanism whereby the 
lack of COL7A1 expression in RDEB patients promotes estrogen uptake by expression of 
OATP1B3 and thus increased collagen synthesis. 
 
In terms of therapies for RDEB SCC, this protein presents a direct transport mechanism for 
the movement of anticancer drugs into tumour cells and thereby enhancing the 
accumulation of these drugs in tumour cells and selectively killing them.  The next chapter 
will explore the expression of SLCO1B3 further in RDEB SCC keratinocytes. 
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Chapter 5 
OATP1B3 validation as a potential therapeutic target of RDEB SCC 
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5.1 Background 
This chapter covers the validation of SLCO1B3 as a potential therapeutic target in RDEB 
associated SCC.  The previous chapter demonstrated that the SLCO1B3 is one of five 
significantly differentially regulated genes in RDEB SCC compared to non-RDEB SCC at the 
mRNA level, both in vitro and in vivo.  Furthermore, when COL7A1, the gene mutated in 
RDEB is retrovirally expressed in RDEB SCC keratinocytes the mRNA expression of SLCO1B3 
is reduced, thus suggesting that the extracellular matrix protein Type VII Collagen may be 
able to regulate the transcription of this transporter gene in RDEB SCC keratinocytes.  
 
5.1.1 Conventional Cancer Therapies for Treatment of SCC 
Cutaneous SCC is often treated via electrodessication and curettage, surgical excision, or 
cryosurgery, in the majority of patients with primary tumours these techniques eliminate 
90% of local tumours with a low risk of recurrence and metastasis (Johnson et al. 1992).  
The most widely used treatment for SCC is surgical excision for patients with UV-induced 
SCC and is applicable to the treatment of SCC that develop in RDEB patients however even 
after treatment prognosis is poor.  Molecular treatments of SCC are not common, although 
the recent study by Watt et al., illustrates two genetic targets of SCC (RDEB and non-RDEB 
associated SCC) and corresponding inhibitors that are currently in clinical trials can 
effectively reduce tumour size in mice (Watt et al. 2011). 
 
Establishing the molecular basis of tumours is not a new concept, this research has been 
ongoing for decades, since the first characterisation of animal cancer viruses in the 1960s 
and 1970s (Huebner and Todaro 1969).  Closely followed by the identification of the first 
oncogenes and tumour suppressor genes in the 1970s (Stehelin et al. 1976; Collins and 
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Workman 2006). During the 1990s studies elucidated the concept of cancer genes causing 
irregular signal transduction pathways to occur.  Now in the 2000s the study of molecular 
oncology is enhancing cancer drug discovery and generating hypotheses driven by disease 
causing gene targets and allowing for mechanism based drug discovery. 
 
5.1.2 Validating the Functional Characteristics of a Genetic Target 
For a gene to be a true therapeutic target it must be verified as a clinically effective 
pathway for the delivery of anti-cancer drugs to tumour cells (Workman 2003; Collins and 
Workman 2006).  Consequently, having identified SLCO1B3 to be significantly differentially 
regulated in RDEB SCC and its expression being linked to COL7A1, it calls for further 
research to examine its potential as a therapeutic target.  The natural progression of this 
study required these changes in expression to be confirmed and to investigate the 
functional and physiological consequences of SLCO1B3 expression. 
 
5.1.3 Drug Transporters  
Cells express different types of drug transporters, which can be classified into primary, 
secondary and tertiary active transporters (Mizuno et al. 2003).  Primary transporters are 
driven by ATP hydrolysis and consist of a group of ATP-binding cassette proteins which 
include multi-drug resistance proteins (MDR); Multidrug Resistance associated Protein 
(MRP) and the Breast Cancer Resistance Protein (BCRP) (Mizuno et al. 2003).  These 
proteins are most abundantly expressed on the canicular membrane in human liver 
hepatocytes where they are responsible for biliary excretion of drugs and their metabolites 
(Hooiveld et al. 2001). 
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Secondary and tertiary active transporters include the following families of proteins;  
Organic anion Transporters (OAT), Organic Anion Transporting Polypeptides (OATP), Na+-
taurocholate cotransporting polypeptide (NTCP), Organic Cation Transporters (OCT), Novel 
Organic Cation Transporters (OCTN), and Peptide Transporters (PEPT) (Burckhardt and 
Wolff 2000; Dresser 2001). The transport of compounds by these proteins is driven by the 
exchange or co-transport of intracellular or extracellular ions.  Secondary transporters 
expressed on the sinusoidal membrane of the liver and are liable for the uptake of drugs 
from the blood into hepatocytes (Meier et al. 1997).  
 
5.1.4 Organic Anion Transporting Polypeptides (OATPs) 
SLCO1B3 encodes the protein OATP1B3 which is a member of the OATP superfamily that 
include a large group of uptake carriers encoded for by SLCO genes (Konig et al. 2000; Abe 
et al. 2001; Cui et al. 2001).  Whilst some OATPs are expressed in single organs, others are 
expressed ubiquitously (Hagenbuch and Gui 2008).  These transporters are expressed in a 
variety of tissues including the liver, kidneys, intestine and brain where they are responsible 
for the Na+ independent movement of a broad spectrum of endogenous and xenobiotic 
compounds (Yamaguchi et al. 2008).  
 
In humans, several isoforms of the OATP family have been functionally characterised 
(Hagenbuch & Meier 2004).  They are known to mediate the transport of a range of 
endogenous substrates including bile acids and steroid hormones (Smith et al. 2005; Sekine 
et al. 2006).  Of particular interest to this study are the transporters present within the 
liver, as OATP1B3 is a liver-specific protein and under normal circumstances is exclusively 
190 
 
expressed on the basolateral membrane of hepatocytes around the central vein (Muto et 
al. 2007).  
 
5.1.4.1 Key functions of transporters in the Liver 
Transporters present within the liver are responsible for the elimination of xenobiotics and 
endogenous catabolites from the systemic circulation.  Once compounds have been taken 
up into hepatocytes, they are biotransformed into phase I and II reactions before being 
subsequently excreted into the bile.  Bile formation is driven by vectorial secretion of bile 
acids from the blood, which is efficiently retained within the enterohepatic circulation by 
active absorption in the ileum and extraction from portal blood by hepatocytes.  The major 
hepatocellular uptake system for bile acids is the sodium-taurocholate co-transporting 
polypeptide (NTCP) although there is some involvement of OATPS.  
 
5.1.4.2 Two liver specific OATPs – OATP1B1 and OATP1B3 
OAT1PB1 is the main Na+ independent bile salt uptake system in hepatocytes and is 
capable of transporting non-bile salt organic anions such as conjugated steroids (Abe et al. 
1999; Hsiang et al. 1999; Konig et al. 2000; Kullak-Ublick et al. 2001).  OATP1B1 and 
OATP1B3 share 80% amino acid identity and have one ortholog representing both proteins 
in rodents; Oatp4 (Hagenbuch and Meier 2004).  OATP1B1 and OATP1B3 have overlapping 
substrate specificities; with some common substrates that have differences in the affinity 
to the transporter (Abe et al. 2001; Cui et al. 2001; Ismair et al. 2001; Kullak-Ublick et al. 
2001).  They are both capable of transporting bile acids such as the amphipathic steroid 
molecule; Chenodeoxycholic Acid (CDCA), a derivative of cholesterol catabolism which acts 
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as a ligand for the nuclear receptor FXR and the antifungal agent Rifampicin which inhibits 
transport by both proteins at varying levels (Yamaguchi et al. 2006).  
 
5.1.4.3 OATP1B3 expression and functional characteristics 
OATP1B3 is a protein of 702aa, which under normal circumstances localises to the 
basolateral membrane of hepatocytes (Konig et al. 2000).  It has also reported to be 
expressed in several cancer cell lines derived from solid organ tumours including gastric, 
colorectal, pancreatic and hepatocellular carcinomas (Letschert et al. 2004; Smith et al. 
2005) and lung, breast and colon cancer tissues  (Muto et al. 2007; Lockhart et al. 2008). 
 
OATP proteins have multiple substrate binding sites which can affect the affinity of their 
substrates and the compounds which they are capable of transporting.  OATP1B3 is 
involved in the cellular uptake of steroid anions such as estradiol-17β-glucuronide and 
estrone-3-sulfate (Gui et al. 2008); xenobiotics  including digoxin and pravastatin;  
oligopeptides such as cholecystokinin and thyroid hormones into hepatocytes from the 
portal blood (Abe et al. 2001; Kullak-Ublick et al. 2001; Jung et al. 2002; Seithel et al. 2006). 
 
Many studies have looked at the transcriptional regulation of SLCO1B3.  It is a polymorphic 
gene with 2 common SNPs, occurring at base pair 334T>G and another in 699G>A which 
occur as a consequence of the non-random association of alleles at two loci across 
chromosomes which results in the alanine residue changing to serine at amino acid 112 
(S112A) and a methionine to isoleucine change at amino acid 233 (M233I), respectively 
(Tsujimoto et al. 2006; Smith et al. 2007).  It has been shown that the polymorphic variants 
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of SLCO1B3 have variable transport characteristics for some substrates (Letschert et al. 
2004; Smith et al. 2005; Konig et al. 2006).  The SLCO1B3 promoter contains several 
hypoxia-responsive elements suggesting that up-regulation of SLCO1B3 in tumours may 
also be related to anoxic conditions (Abe et al. 2001). 
 
5.1.4.4 OATP1B3 in cancer 
Research into the transport of substrates into cells via the OATP1B3 transporter is of 
particular interest to many research groups due to its documented over expression in 
tumours, and its ability to mediate uptake of many anticancer drugs including; 
Methotrexate, Paclitaxel, Docetaxel, SN-38 and Irinotecan (Ichihara et al. 2010).  The 
physiological significance of OATP1B3 expression in tumour cells is unclear, but is an 
ongoing question for many researchers.  Interestingly, in most tumours expressing 
OATP1B3 the change in expression is due to the induction of transcription of this gene, 
whilst in hepatocellular carcinoma (HCC) originating from cells where this protein is 
normally expressed, it has been reported to have reduced expression of OATP1B3 in 60% of 
HCC (Vavricka et al. 2004).   
 
Hamada’s data suggest that the over-expression of OATP1B3 is part of a complex stepwise 
process of cancer progression, which in the case of prostate cancer allows the cells to gain a 
biological advantage by up-regulating testosterone uptake and proliferation through 
increased androgen import (Hamada et al. 2008).  They show no detectable expression of 
SLCO1B3 in normal prostate tissue or benign hyperplasia, but marked expression in 
prostatic cancer and a statistically significant association of a specific SLCO1B3 haplotype 
with survival of patients (Hamada et al. 2008).   
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Azathioprine has been reported to increase the transport of Methotrexate, one study 
showed that treatment of cancer cell lines with Azathioprine, an inhibitor of DNA 
methyltransferase, significantly increased the mRNA expression of OATP1B3 in HepG2 and 
Caco-2 cells by 18 and 14 fold, respectively (Ichihara et al. 2010).  This provides a strategy 
that would enhance the expression of SLCO1B3 in tumour cells prior to treatment with 
antineoplastic drugs that have been specifically targeted to be taken up into cells via 
OATP1B3 in tumours.  Over-expression of OATP1B3 in RDEB SCC provides a specific 
pathway to deliver drugs to a specific tissue, avoiding distribution of drugs to other organs 
and thereby reducing the risk of toxic side effects to healthy cells.  As a transporter protein 
it may also provide more control of drug elimination processes (Mizuno et al. 2003). 
 
5.1.5 Aim 
In any experiment conducted to identify a target suitable for therapeutic invention it is 
importance to prioritise the research in terms of pursuing the best target.  To do this, the 
following points need to be considered.  First, the validation of the gene targets in terms of 
functional validity using over expression, knock out models, and animal models; secondly 
the drug-ability of a given target, and finally the ability to predict toxicity from mouse 
models.   
 
Understanding the extent and relevance of SLCO1B3 in RDEB SCC is crucial to developing a 
therapy targeted to this protein, as the tissue distribution and organ specific entry of drugs 
is often facilitated by drug transporters.  Essential to understanding the function in RDEB 
SCC is the need for efficacy and bioavailability testing of any compound used to selectively 
kill the tumour cells.  However, before this can be done it is of utmost precedence to 
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establish whether SLCO1B3 is an appropriate target for therapeutic intervention in RDEB 
SCC and capable of transporting compounds into cells. 
 
Thus far we have shown only an increase in mRNA expression of SLCO1B3 but have not 
demonstrated that this up-regulation of SLCO1B3 transcription is translated to expression 
at the protein level.  Therefore, the first aim of this chapter was to demonstrate OAT1PB3 
protein expression in RDEB SCC keratinocytes and tissue. 
 
Next, in order to assess the functional characteristics of OATP1B3 in RDEB SCC, two 
transporter assays were performed to establish whether OATP1B3 is an active transporter 
in RDEB SCC keratinocytes and is capable of transporting known substrates into cells.  Two 
independent measures of transport were used by employing a fluorescently labelled and a 
radioactively labelled substrate to measure uptake in various SCC keratinocyte cell lines.  
Furthermore, having assessed the transporter function of OATP1B3 this chapter covers the 
selective killing of cells expressing OATP1B3 using a toxin produced by cyanobacteria 
known as Microcystin-LR which causes liver toxicity by entering cells via the OATP1B1 and 
OATP1B3 transporters.  
 
5.2 Methods and Results 
5.2.1 OATP1B3 is localised to the cell membranes in RDEB SCC tissue 
When starting this investigation there were 3 commercially available antibodies raised 
against the OATP1B3 protein; D-16 and C-14, both goat-polyclonal antibodies (Santa Cruz, 
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California) and OATP8 mouse antibody (Novus Biologics).  Immunoblotting was performed 
using all 3 antibodies to examine the protein expression in RDEB SCC keratinocytes.  
However, the initial results from immunoblotting RDEB SCC and non-RDEB SCC whole-cell 
lysates showed no specific bands of the expected size. Figure 5.1A demonstrates that the 
antibody was non-specific and produced a high background of multiple bands. There was 
no correlation of between the banding patterns produced and therefore were unable to 
confirm OATP1B3 protein expression using western blotting with this antibody.  The same 
results were seen using the other 2 commercially available antibodies (Appendix 1.3).   
 
 It has been established that in culture the expression of the protein is gradually reduced 
even in hepatocytes (Jigorel et al. 2005; Richert et al. 2006), therefore the next logical step 
was to try and demonstrate expression of the protein in RDEB SCC tissue samples, where 
the expression is likely to be higher.  Whilst we were unable to detect OATP1B3 in RDEB 
SCC keratinocytes, immunofluorescent staining of RDEB SCC tissue sections revealed some 
positive immuno-reactivity using the D-16 antibody (Figure 5.1B).  Although the staining 
pattern is weak, it does imply that OATP1B3 is localised to the cell membranes as 
demonstrated in RDEB SCC tissue sections (Figure 5.1B).  Further staining of other tissue 
sections showed a lower immuno-reactivity in RDEB SCC (Appendix 1.4). 
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Figure 5.1 Immunofluorescent staining showing some positive membrane bound 
expression of OATP1B3 in RDEB SCC tissue.  A) Immunoblotting cultured NHK, non-RDEB 
SCC (SCC), RDEB SCC, and RDEB SCC empty vector (PB) and cells over-expressing COL7A1 
(C7) does not demonstrate expression of OATP1B3. B) Immunofluorescent staining of RDEB 
SCC tissue using the Santa Cruz anti goat D-16 antibody (green) and Dapi nuclear staining 
(blue) identifies OATP1B3 membrane bound expression. Scale bar ~20μm 
A 
B 
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5.2.2 Transport assays do not show OATP1B3 specific transport in RDEB SCC 
keratinocytes 
Having identified that OATP1B3 is localised to the cell membranes in tissue, it leads to 
question whether this protein can transport substrates into cells.  The fluorescent calcium 
indicator; Fluo-3 was demonstrated by Cui and colleagues to be a substrate of OATP1B3 in 
MDCK cells (Cui et al. 2001).  An uptake assay utilising Fluo-3 was later developed to 
measure the transport into cells via OATP1B1 and OATP1B3 (Baldes et al. 2006), this 
protocol was used to investigate OATP1B3 transport in RDEB SCC keratinocytes. 
 
Initial results showed that a dose dependent uptake of Fluo-3 in RDEB SCC keratinocytes, 
when using a range of 0.125 to 20μM Fluo-3 (Figure 5.2A).  As a preliminary run, two 
concentrations of Fluo-3 were used to look at uptake in non-RDEB SCC keratinocytes, 
results showed no significant difference in uptake values of 0.125μM and 5μM of Fluo-3, as 
the level of fluorescence was almost equal to the background fluorescence seen in cells 
contains no Fluo-3 (Figure 5.2A).  This experiment was conducting using a HT synergy 
fluorimeter to measure fluorescence.  
 
After the promising preliminary results using Fluo-3 uptake as a measure of transport 
activity in RDEB SCC keratinocytes, both RDEB SCC and non-RDEB SCC samples were used to 
look at the differences in uptake between cells expressing SLCO1B3 and those which do not 
express this gene.  Results showed the same dose dependent uptake of Fluo-3 in RDEB SCC 
3, however using the full concentration range on non-RDEB SCC cells (SCC 3), showed that  
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Figure 5.2 Dose dependent uptake of Fluo-3 in SCC keratinocytes 
A) Initial results showed a dose dependent uptake of Fluo-3 in RDEB SCC 1 (n=1), whilst the two 
concentrations of Fluo-3 added to SCC 3 (n=1) showed no change in the uptake in terms of 
fluorescence after the cells were lysed. B) A repeat run of the uptake assay using the full range of 
Fluo-3 concentrations on non-RDEB SCC (SCC 3), shows a dose dependent increase in fluorescence 
which is proportional to the uptake in each cell line.  Samples represent biological replicates (n=3).  
The difference in scale between the two graphs is due to using two different fluorimeters to measure 
fluorescence.  
B 
A 
199 
 
these cells also had an apparent dose dependent uptake of Fluo-3 based on the level of 
fluorescence after incubation with the substrate (Figure 5.2B).  The difference in the scale 
used for the graphs seen in figure 5.2 A and B was due to using two different fluorimeters, 
the experiment performed in Figure 5.2A was performed on a LabTek Fluorimeter whilst 
experiments performed from Figure 5.2B onwards were performed on a Fluorimeter by 
Molecular Devices. 
 
Rifampicin a known substrate of OATP which reduces the uptake of Fluo-3 through 
competition (Baldes et al. 2006), was used to further assess whether the transport of Fluo-3 
into cells could be inhibited.  Results showed that uptake of 5μM of Fluo-3 in RDEB SCC 3 
cells was reduced by prior incubation with 0.5-25μM of Rifampicin, whilst the effect on 
uptake of 10μM Fluo-3 was variable (Figure 5.3A).  RDEB SCC 3 cells pre-incubated with 0.5 
to 10μM of Rifampicin, then exposed to 10μM Fluo-3, showed an increased uptake of Fluo-
3, whilst, 25-50μM of Rifampicin caused no change in the uptake of 10μM Fluo-3 (Figure 
5.3A). 
 
The previous chapter showed that SLCO1B3 mRNA expression is reduced in RDEB SCC 
keratinocytes that have been retrovirally transduced to re-express Type VII Collagen.  
Therefore, using these cells in this uptake assay would help assess whether the uptake that 
we see is OATP1B3 mediated transport.  In RDEB SCC 3 cells that have been retrovirally 
transduced to express Type VII collagen the uptake of Fluo-3 was variable over the entire 
concentration range, where 2.5μM has a high standard deviation due to triplicate values 
being widely distributed in terms of fluorescence (Figure 5.3B).  In RDEB SCC 3 C7, 10μM of 
Fluo-3 showed no uptake and 20μM shows uptake of an equal amount to 2.5μM Fluo-3 
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(Figure 5.3B).  Whilst no significant change in uptake is seen in RDEB SCC Pb empty vector 
control cells.  Comparing the control cells to the COL7A1 cells, shows that 3 of the 4 
concentrations of Fluo-3 (2.5, 5, and 20μM) caused slightly more uptake of Fluo-3 in 
COL7A1 over-expressing cells compared to the RDEB SCC Pb cells, which is the opposite to 
the hypothesised result that COL7A1 cells would have a reduced uptake of Fluo-3 as the 
expression of SLCO1B3 is lower when Type VII Collagen is expressed. 
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Figure 5.3 Uptake of Fluo-3 is not significantly inhibited by Rifampicin or reduced by Type 
VII Collagen expression. A) When RDEB SCC cells (n=1) are treated with Rifampicin prior to 
adding Fluo-3, there is an inhibition of Fluo-3 uptake in a Rifampicin dose dependent 
manner when 5μM of Fluo-3 is added. B) In RDEB SCC 3 cells that have been retrovirally 
transduced to express Type VII collagen the uptake is increased in RDEB SCC C7 (n=1) cells 
expressing Type VII Collagen, in comparison to the PB empty vector cells (n=1) in using 3 
different concentrations of Fluo-3.  
B 
A 
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The Fluo-3 uptake assay although at first provided promising results to suggest SLCO1B3 is 
translated into an active transporter of substrates into RDEB SCC keratinocytes, variability 
in assay results indicate that this assay is not a reliable predictor of transporter function in 
these cells.  Further experiments using the same cell line demonstrated varying results, 
with no two experimental runs showing consistent uptake of the similar amounts of Fluo-3.  
Furthermore, when investigating uptake in the RDEB SCC cell lines expressing COL7A1 in 
order to confirm that this assay is able to show OATP1B3 specific uptake, the results 
confounded the situation even more.  The reason behind these baffling and unexpected 
results could be firstly that as we have been unable to show protein expression of OATP1B3 
in these cells, that the expression of the protein is too low to show specific uptake 
mediated by this transporter alone, or secondly that the protein is expressed but does not 
act as a transporter in these cells.  In addition, the experimental procedure using a 
fluorescently labelled substrate requires cells to be washed and then lysed before 
measuring the fluorescence.  Variation in fluorescence levels could be attributed to the 
substrate being “sticky” and residual Fluo-3 remains on the plastic edges of the wells, or 
that insufficient lysis of cell monolayers creates inconsistent results which may be 
responsible for the sometimes high variability in replicate samples potentially skewing the 
results.   
 
In an attempt to establish a definitive answer to the question; is OATP1B3 an active 
transporter in RDEB SCC keratinocytes; another OATP transport assay was used.  This assay 
was developed by Gui and colleagues and demonstrated that tritiated estradiol-17β-
glucuronide can be used to measure uptake of cells, they also demonstrated that several 
other substrates can enhance or attenuate the uptake of tritiated estradiol in Chinese 
Hamster Ovary cells over-expressing OATP1B1 and OATP1B3 (Gui et al. 2008).   
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Briefly, RDEB SCC 1 cells were plated out on 24-well plates at a density of 80,000 cells per 
well and incubated for 24 hours prior to the start of the uptake experiment.  Experiment 
procedure for this uptake assay can be found in Chapter 2 Section 2.2.5.3.  Incubating the 
cells with a concentration range of 1.25 to 50nM of [3H]-estradiol-17β-glucuronide for 1 
hour prior to cell lysis and scintillation counting demonstrated a clear dose dependent 
uptake of tritiated estradiol in RDEB SCC 1 cells (Figure 5.4A), further more when cells were 
pre-incubated with uptake solution containing Clotrimazole, an antibiotic known to 
specifically enhance uptake through the OATP1B3 pathway (Gui et al. 2008), whilst inhibit 
uptake through the OATP1B1 pathway (Gui et al. 2008), the RDEB SCC 1 cells show 
increased uptake of estradiol in correlation with increasing concentrations of Clotrimazole 
ranging from 2.5 to 10μM (Figure 5.4B).  
 
The assay was then repeated using NHK, three non-RDEB SCC samples and 3 RDEB SCC 
keratinocyte samples, to look at uptake across the whole sample range.  The results 
showed that in all 3 RDEB SCC samples, there was uptake of [3H]-estradiol-17β-glucuronide 
and significantly enhanced uptake of tritiated estradiol after incubation with 10μM 
Clotrimazole (Figure 5.5).  The enhanced uptake of the tritiated substrate in all 3 cells lines 
suggested that uptake was specifically OATP1B3 mediated up in the RDEB SCC cell lines 
expressing SLCO1B3.  However, further investigations using NHK and 3 non-RDEB SCC cell 
lines, demonstrated uptake of [3H]-estradiol-17β-glucuronide, which is unsurprising as this 
common substrate can be transported by several transporters, but perplexingly, the pre-
incubation of cells with Clotrimazole also caused an increased uptake of [3H]-estradiol-17β-
glucuronide in NHK and 2 non-RDEB SCC samples (SCC 4 and 5), whilst SCC 3 showed no 
difference in the uptake after exposure to Clotrimazole (Figure 5.5). 
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Figure 5.4 Uptake of [3H]-estradiol-17β-glucoronide is seen in a dose dependent manner in RDEB 
SCC 1 cells and is enhanced by Clotrimazole. 
 A) Tritiated estradiol was taken up in a dose dependent manner in RDEB SCC 1 cells (n=1). B) 
Clotrimazole enhances the uptake of 5nM of [3H]-estradiol-17β-glucoronide, in a dose dependent 
manner (n=1). 
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Figure 5.5 [3H]-estradiol-17β-glucuronide uptake is seen in all cell lines and enhanced in the 
majority of SCC cell lines. Uptake of tritiated estradiol was demonstrated in all cell lines, with all 3 
non-RDEB SCC keratinocytes showing the least uptake.  Pre-incubating the cells with and without 
(w/o) 10 μM of Clotrimazole caused the uptake of 20nM [3H]-estradiol-17β-glucurondie to be 
increased in all cell lines except one non-RDEB SCC cell line; SCC 3 which showed no difference in 
uptake of the substrate after exposure to Clotrimazole.  Significance was granted >0.05 and those 
cell lines showing a significant difference in uptake are denoted by *(p=<0.05) R=+/- SD Student’s T-
Test. Samples are biological replicates (n=3). 
 
Confounding results, still leaves the question as to whether OATP1B3 mediates uptake in 
RDEB SCC keratinocytes open for debate.  As we have previously demonstrated that NHK 
and non-RDEB SCC keratinocytes do not express SLCO1B3 at the mRNA level, but still show 
enhanced uptake of β-estradiol.  It does suggest that, uptake in these cell lines is not 
dependent on expression of OATP1B3 and that other transporter mechanisms may be 
occurring in these cells.  Therefore these results cannot be relied up on to confirm 
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transporter function in RDEB SCC keratinocytes as the mechanisms causing uptake in NHK 
and non-RDEB SCC may also be contributing to uptake in RDEB SCC keratinocytes.   
 
This led to a change in the direction of the study, and required that a stable clone was 
produced that over-expressed SLCO1B3.  This provided a much needed positive control for 
experiments concerning the protein expression and the functional characteristics of this 
transporter in RDEB SCC cells; this also creates a useful system for the validation of these 
experiments.  In reference to the uptake assays, it’s important to point out that even the 
OATP1B3 expression in liver tissue is low (Konig et al. 2006) and both transport assays used 
so far have previously only been carried out in over-expression systems where the 
expression of OATP1B3 is exogenous, whereas in these experiments I have been trying to 
demonstrate uptake of substrates by the endogenous expression of OATP1B3 which is quite 
probably has a low magnitude of protein expression. 
 
5.2.3 Creating an stably over-expressing SLCO1B3 cell line 
An SLCO1B3 image clone was purchased from Open Biosystems, and was used to amplify 
the SLCO1B3 ORF using the following primers; forward primer included the KOZAK 
sequence: AAG CAG AGG GGC CGT CAA GG and the reverse sequence CAT GAG GCC TTA 
GTT GGC AGC which included an additional 3 nucleotides on the 5’ end to include a STOP 
codon that was missing from the image clone sequence.  
 
Prior to using PCR to amplify the ORF, the image clone was expanded by adding a 
pipette scraping of the glycerol stock to a universal tube containing 5ml LB Broth 
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and 5μl spectinomycin (100mg/ml) (Sigma Aldrich, Poole, Dorset, UK).  The 
universal was briefly vortexed and the broth culture grown over night in a shaking 
incubator at 37°C.  This starter culture was then used as a template for the PCR 
reaction, by first incubating 2μl of culture diluted in 23μl of dH2O for 5 minutes at 
95°C. 2μl of the boiled culture was then used as a template for the FastStart High 
Fidelity PCR reaction, and 2uL dH2O as the NTC, and ran with an annealing 
temperature of 58°C. Reaction component volumes and cycling parameters are 
detailed in Chapter 2 Section 2.2.2.8.  During the final extension, the reaction was 
stopped and 0.5μl SuperTaq and 0.5μl dNTPs (10mM) was added to each reaction 
and incubated for 5 minutes at 72°C to create AA overhangs required for 
subsequent cloning.  Then 5.5μl of the amplified product was visualised on a 1% 
agarose gel (Figure 5.6). 
 
 
 
Figure 5.6 SLCO1B3 ORF was PCR amplified and digested with BsmI.  The RE digested the ORF in 
two places creating 2 fragments of correct size.  
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Next having successfully, amplified the ORF of SLCO1B3 using the image clone as a 
template.  The ORF was inserted into the PCR II vector included in the Invitrogen 
TOPO II Clone kit. Using the following technique, 0.5μl PCR, 1.5μl dH2O and 0.5uL 
TOPO PCRII vector, this reaction was then incubated at room temperature for 5 
minutes and then placed on ice. The 0.5μl of the Topo clone reaction was added to 
a 2mm electroporation cuvette (PeqLab) and along with 20μl of Top10 electro-
competent bugs at 1.2 volts using the GenePulse electroporator (BioRad).  Each 
electroporation reaction should create a time constant of ~4.6.  750μl SOC medium 
(Invitrogen) was added to the electroporated bugs and then aliquoted into a bijou 
tube and recovered in a shaking incubator at 37°C for 45 minutes.  100μl of the 
Topo clone culture was then plated using aseptic technique onto an agar plate 
containing Ampicillin (0.1mg/ml) and grown overnight at 37°C.  Four colonies were 
prepped and inoculated in 5ml LB broth and grown over night. The next day, 
glycerol stocks were created and the remaining culture was prepped using the 
Wizard plus DNA purification system, detailed methods of this kit are outline in 
Chapter 2 section 2.2.3.2.   
 
500ng of the SLCO1B3 ORF Topo clone was then digested using BstXI, by incubating 
at 37°C for 1 hour and visualised on a 1% agarose gel.   The digested DNA showed 
two brighter bands one at approximately 2kb and one at 4kb, both of the correct 
size, a third fainter band can be seen at the top of the gel and is likely to be uncut 
plasmid (Figure 5.7).  1μg of the plasmid prep (SLCO1B3 ORF Topo) and 1μg of 
pBabe puro retroviral vector were then digested separately with the BstXI RE over 
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night at 37°C.  To the retroviral vector; 0.5μl of alkaline phosphatase (AP), 4.5μl 
dH2O and 5μl AP Buffer was added and incubated for a further 30 minutes at 37°C, 
this prevents the sticky ends produced by the vector re-annealing.  The ORF which is 
approximately 2kb was successfully excised from the Topo clone and the open 
linear pBabe puro vector was then purified by gel extraction.  The two purified 
products were next ligated together using the Sigma Ligation Kit; using a ratio of 
1:10 in terms of DNA concentration of vector:insert.  The ligated products were 
then transformed into Top10 electrocompetent cells via electroporation and grown 
overnight at 37°C on Ampicillin agar plates.  Eight colonies from the ligation cultures 
were prepped, starter cultures made and DNA was purified using the Wizard Plus 
DNA Purification kit.  200ng of DNA from each colony was digested with XbalI and 
HindIII by incubating DNA for 1 hour at 37°C.  Figure 5.8 displays the visualised DNA 
digestions using the two RE.  This allowed the identification of ligations that 
contained the ORF in the correction orientation, reading from 5’ to 3’ which is 
 
Figure 5.7 TOPO clone digestion with BstXI.  Demonstrates that the ORF was efficiently inserted into 
the PCR II Topo vector.  The BstXI RE cut the vector in two places (right hand lane), creating 2 linear 
pieces of DNA approximately 2kb (the inserted ORF) and 4 kb (Topo vector).  A third fainter band is 
uncut supercoiled DNA. 
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required for transcription of the gene once inside the viral packaging cells.  
Correctly orientated ORF from 3 of the ligation colonies was confirmed by 
sequencing.   One of the clones was then transfected into phoenix cells (packaging 
cell line) following the protocol in Chapter 2 Section 2.2.3.7.    
 
 
Figure 5.8 DNA from 8 ligation colonies was digested with Xbal and HindIII.  The correctly 
orientated ORF produced a banding pattern of 1004, 1438, 2273 and 2665bp (Lanes 2,5,6 and 8) 
whilst the incorrect orientation produced bands of 590, 1004, 2605, 3121bp.  The digestion identifies 
that 50% (4 of the 8) of the colonies that were prepped contained the SLCO1B3 ORF in the correct 
orientation.   
 
After retroviral transduction of RDEB SCC 1 cells with the SLCO1B3 construct, were 
expanded and grown until confluency.  Figure 5.9A, demonstrates that the pBabe puro (Pb) 
empty vector cells and the SLCO1B3 over-expressing cells (SLC) do not show any 
morphological changes in the cell shape and structure.  qRT-PCR using RNA isolated from 
the transduced cells demonstrated that the SLCO1B3 clones; RDEB SCC 1 SLC do indeed 
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express higher levels of SLCO1B3 compared to both the parental cell line RDEB SCC 1 and 
the empty vector control (RDEB SCC 1 PB).  There was no significant difference in the mRNA 
expression of SLCO1B3 between the parental cell line RDEB SCC 1 and the empty vector 
control, RDEB SCC 1 PB (Figure 5.9).   To confirm this transcript is translated into a protein, 
western blotting was first performed using the 3 commercially available antibodies which 
were documented at the beginning of this results chapter.  The results showed that like 
cells with only endogenous SLCO1B3 expression, there was no common band that 
convincingly showed the OATP1B3 protein was expressed in these samples.  At this time, 
Professor Bruno Steiger, of University Hospital, Zurich kindly donated a custom made 
OATP1B3 antibody with an epitope targeted against the c-terminus of the protein.  
Immunoblotting confirmed that the RDEB SCC 1 SLC cells do in fact express the protein, at 
the expected size, using the new antibody (Figure 5.9C).  The antibody was however unable 
to detect the endogenous expression of OATP1B3 in the empty vector control. Further 
confirmation of expression was seen via immunoflourescence staining of the cells using the 
antibody, and it clearly shows expression of OATP1B3 at cell-cell junctions and membrane 
of the cells (Figure 5.10).  
 
Having created a cell line with stable expression of OATP1B3 which has been verified to 
express both mRNA and protein expression, this cell line was used to repeat the tritiated 
uptake assay.  Using the parental cell line (RDEB SCC 1) and the over-expressing cells (RDEB 
SCC 1 SLC), I was able to show that there was no difference in the uptake of [3H]-estradiol- 
17β-glucuronide in the over-expressing cells (Figure 5.10).  This immediately indicates that 
this assay does not demonstrate OATP1B3 specific uptake, as the protein level was 
detectable in the RDEB SCC 1 SLC cells, but not in the RDEB SCC 1 parental line.  Using 
Clotrimazole to enhance the uptake of the tritiated substrate showed no effect on the 
212 
 
parental line, whilst a small increase in uptake was seen in RDEB SCC keratinocytes.  
Rifampicin was also used to show inhibition of uptake; which was seen slightly in both the 
parental cell line and SLCO1B3 over-expressing cells. 
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Figure 5.9 Confirmation of RDEB SCC 1 retrovirally transduced to express SLCO1B3 show high levels 
of SLCO1B3 and OATP1B3 expression.  A) Confluent monolayers of both RDEB SCC 1 Pb (empty 
vector control cells) and RDEB SCC 1 SLC cells show no morphological differences after transduction. 
B) mRNA expression of SLCO1B3 is significantly higher in RDEB SCC 1 SLC than both the parental cell 
line and empty vector control. Immunoblotting using a custom made OATP1B3 antibody shows 
expression of OATP1B3 but no detectable endogenous expression in RDEB SCC 1 PB control cells. 
Samples are technical replicates (n=3). C) Immunohistrochemistry confirms expression of OATP1B3 
in the RDEB SCC 1 SLC cells. 
A 
B 
C 
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Figure 5.10 Uptake of [3H]-estradiol-17β-glucuronide in OATP1B3 over-expressing RDEB SCC 1 cells 
is no different to the parental cell line. RDEB SCC 1 cells over-expressing OATP1B3 showed uptake of 
tritiated estradiol and an enhanced uptake after incubation with Clotrimazole.  Rifampicin 
attenuated the uptake in both the parental and over-expressing cells.  The parental cell-line RDEB 
SCC 1 was also used, and showed that there was no significant increase in the uptake of [3H]-
estradiol-17β-glucuronide between RDEB SCC 1 and RDEB SCC 1 SLC. Samples represent biological 
replicates (n=3). 
 
5.2.3 Confirmation of OATP1B3 expression in RDEB SCC keratinocytes and tissue 
The custom made OATP1B3 antibody was able to detect protein in the RDEB SCC 1 SLC 
cells.  Further immunofluorescence staining, confirms the expression of OATP1B3 in the 
retrovirally transduced RDEB SCC 1 cells (Figure 5.11). 
 
0
10
20
30
40
50
60
70
80
90
RDEB SCC 1 RDEB SCC 1 SLC
C
P
M
 
Samples 
3H-β-estradiol Uptake in SLCO1B3 Over-Expressing RDEB SCC 
Keratinocytes 
5μM 3H-β-estradiol  
5μM 3H-β-estradiol + 
10μM Clotrimazole 
5μM 3H-β-estradiol + 
100μM Rifampicin 
215 
 
 
 
Figure 5.11 Retrovirally transduced RDEB SCC 1 cells demonstrate membrane bound expression of 
OATP1B3. Immunohistochemistry confirms expression of OATP1B3 at the protein level using a 
custom made OATP1B3 antibody, donated by Professor Bruno Stieger, University Hospital, Zurich. All 
panels on the left in Red show OATP1B3 expression. In all cases, it is clear that the protein is 
localised to the cell membranes.  The right hand panel shows Nuclei staining in blue.  Scale bar 
~40μm, images taken under 65x objective. 
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Immunofluorescent staining performed on RDEB SCC tissue samples; include 2 RDEB SCC 
tissues, 1 RDEB SCC xenografts section from mouse, and a healthy skin section (Figure 5.12).  
Results indicated positive staining in all RDEB SCC tissues, whilst only background 
fluorescence was seen in normal skin.  RDEB SCC7 showed hyperkeratotic whirls, which are 
condensed sections of keratin within the tumour sample; this made it difficult to assess the 
localisation of the protein in this case due to IMF background.  In the RDEB43 sample and 
the RDEB SCC xenografts; OATP1B3 seems to localise to the cytoplasm (Figure 5.12).   
 
Further Immunofluorescent staining was carried out on RDEB SCC and non-RDEB SCC cell 
lines.  Results indicated that in fact the endogenous expression of OATP1B3 is detectable in 
RDEB SCC keratinocytes, in all 3 independent samples (Figure 5.13) whilst, the non-RDEB 
SCC (SCC 3) sample did not show any positive staining.   
 
 
 
  
  
217 
 
 
 
 
 
 
218 
 
 
 
 
 
Figure 5.12 Immunofluorescence staining confirms OATP1B3 expression in RDEB SCC tissue.  Tissue 
sections from 2 RDEB SCC tissue samples, and 1 sample taken from a mouse xenografts of RDEB 
SCCK 1 cells, confirms expression of OATP1B3 in vivo, in comparison to NH Skin which shows no 
specific positive staining. Scale bar ~20μm, images taken under 16x objective. 
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Figure 5.13 Immunofluorescence staining of 3 RDEB SCC cell lines, and 1 non-RDEB SCC cell line 
shows positive staining of OATP1B3 in RDEB SCC. Panels on the left show OATP1B3 positive staining 
in Red, with RDEB SCC 2 showing the strongest expression.  Panels on the right show blue nuclei 
staining as a positive control. Negative control panels are used as a control, with cells exposed to the 
secondary antibody only.  Scale bar ~20μm, images taken under 40x objective. 
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Having confirmed the expression of the protein in RDEB SCC, it still leaves the question; is it 
an active transporter in these cells, open to further investigation.  The two different uptake 
assays used were unable to draw any OATP1B3 specific conclusions regarding the function 
of this transporter in RDEB SCC cells, and therefore directs our need towards a completely 
different and yet sensitive method for assessing OATP1B3 activity.  
 
OATP1B1 and OATP1B3 transport the liver toxin Microcystin-LR, a toxin produced by blue 
green algal blooms; ingestion of which causes liver failure. Studies have shown that this 
toxin and other microcystin analogues are specifically transported into hepatocytes by the 
two liver specific OATPs (Monks et al. 2007).  To further investigate to transporter function 
of OATP1B3 in RDEB SCC and to establish whether it is possible to selectively kill SCC cells 
based on their OATP1B3 expression, the MTS assay was used to measure the cell viability 
after exposure to Microcystin-LR (detailed methods can be found in Chapter 2 Section 
2.2.5.0).   
 
Results using the RDEB SCC 1 SLC cells over-expressing OATP1B3 and the empty vector 
control cells, indicates MC-LR does in fact cause cell death in RDEB SCC SLC cells, whilst the 
empty vector cells only show a small reduction in cell viability after exposure to 1μM MC-LR 
for 48 hours (Figure 5.14). These results indicate that OATP1B3 expression mediates 
transport of this toxin into RDEB SCC.  To validate this experiment further a positive control 
is needed, one of two approaches could be used; firstly knock-down of SLCO1B3 expression 
in the over-expressing cells to see if the toxicity of MC-LR is attenuated by lack of OATP1B3 
expression or secondly use  a hepatocyte cell line which is known to express OATP1B3 and 
transport MC-LR. 
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Figure 5.14 Preliminary results using the MTS assay, show that OATP1B3 over expressing cells have 
decreased cell viability after 48 hours exposure to 1nM and 1μM of Microcystin-LR (MC-LR). RDEB 
SCC 1 Pb shows a slight decrease in cell viability after 48 hrs exposure to 1μM MC-LR, whilst both 
1nM and 1μM decrease cell viability in RDEB SCC 1 SLC cells.  Samples represent biological replicates 
(n=4).  Significant difference p=<0.05 denoted at * 
 
5.2.4 Optimisation of siRNA knockdown of SLCO1B3 
Small interfering RNA (siRNA) are short RNA sequences which can be used to 
transcriptionally repress genes, can provide another strategy for investigating the 
functional significance of OATP1B3 expression in cells.  Furthermore future transport assays 
used to demonstrate OATP1B3 expression can be confirmed by knocking-down expression 
of the gene to demonstrate attenuation of the transport of a particular substrate in cells 
expression SLCO1B3. Transfecting RDEB SCC 1 cells with a pool of 3 siRNAs targeting 
SLCO1B3 and culturing cells for a further 48 hours shows that SLCO1B3 expression is 
* 
* 
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reduced by 40% at the mRNA level in comparison the untransfected control cells (Figure 
5.15), the level of knockdown was measured using qRT-PCR.  This reduction is also seen in 
comparison to the mock transfected cells and the cells transfected with a non-targeting 
scrambled siRNA.  This assay has been optimised and could potentially be used to confirm 
future assay results by preventing expression of OATP1B3 and thus reducing transport in 
uptake assays or used in cell viability assays to prevent a reduction in cell viability after 
exposure to MC-LR in OATP1B3 expressing cells thus confirm that OATP1B3 mediated 
uptake was responsible for the intake of toxins into the cells causing apoptosis.  However, 
time constraints have prevented these experiments being carried out.  Had time not been 
an issue, it would also be possible to repeat the knockdown of OATP1B3 in RDEB SCC cells 
to establish if this alone would have an effect on the viability of the cell.  
   
Figure 5.15 Knockdown can be achieved using a pool of 3 SLCO1B3 specific siRNA oligonucleotides. 
siRNA knockdown is achieved up to 48hours after transfection of RDEB SCC 1 cells with siRNA 
specific to SLCO1B3.  Knockdown is 40% lower than that of the control and mock cells.  Samples 
represent technical replicates (n=3)    
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5.3 Discussion   
The expression of SLCO1B3 in RDEB SCC is an appealing therapeutic target as it is an organic 
anion transporter normally only expressed in the liver.  In theory this would provide a 
physical mechanism for drug delivery, whilst minimising the off target effects and systemic 
toxification to other organs often seen when using common chemotherapy regimens, as 
the protein is only expressed in the liver.   
 
5.3.1 SLCO1B3 expression does translate to an OATP1B3 expression 
We have been able to confirm that the OATP1B3 protein encoded by SLCO1B3 is expressed 
in RDEB SCC by immunofluorescent staining of keratinocytes (Figure 5.12); furthermore 
OATP1B3 is expressed in RDEB SCC tissue (Figure 5.11).  In RDEB SCC cultures, the 
cytoplasmic expression was mainly seen, whilst in the RDEB SCC keratinocytes exogenously 
over-expressing OATP1B3 demonstrated a membrane bound localisation.  Although the 
cultured RDEB SCC cells lack the obvious membrane bound staining seen in liver 
hepatocytes and SLCO1B3 over-expressing cells, this could be a result of the low level of 
expression in culture which means that the protein is undetectable in the cell membranes.   
Cytoplasmic expression is also seen in colon tumours which have shown a correlation 
between expression and prognosis based on improved 5-year survival, and with poorly 
differentiated tumours (Lockhart et al. 2008).  This is concordant with a report that 
OATP1B3 expression is associated with better prognosis based on differentiation of 
tumours in breast cancer (Muto et al. 2007).  No studies have yet determined whether the 
expression of OATP1B3 in the cytoplasm of tumour cells confers an altered cellular 
behaviour. 
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5.3.2 Uptake assays were an ineffective measure of transport activity 
Confirming the expression of this gene at the protein level has opened up a number of 
questions regarding OATP1B3 tumoural expression.  The normal function of OATP1B3 in 
hepatocytes is to transport molecules from the blood into liver cells, where it facilitates the 
accumulation of compounds prior to metabolising and biliary secretion (Smith et al. 2005), 
it is pertinent to establish if this transporter function is retained in RDEB SCC cells.  Two 
transport assays were conducted to investigate the transport function of OATP1B3 in RDEB 
SCC cells.  Results from both assays showed a dose dependent uptake of the substrate into 
RDEB SCC keratinocytes (Figures 5.2 and 5.4); however neither were able to demonstrate 
that the uptake of substrates was dependent and specific on OATP1B3 expression.  The 
inability of these assays could be due to low expression of the protein, which despite its 
induction in RDEB SCC, it may be too low to demonstrate uptake above the background 
seen by natural diffusion of substrates, or movement of substrates via other transporter 
proteins.  Also, it has been reported that SNPs that occur in SLCO1B3 can cause changes to 
the transport function of OATP1B3 by direct conformational changes of the protein or be 
changes in affinity to certain substrates.  The first SNP identified in SLCO1B3 were within 
the non coding region and included a non-synonymous two now common SNPs; 334T>G 
and 699G>A and one rare (1546G>T) SNP (Iida et al. 2001).  Functional analysis of these SNP 
have demonstrated that they cause alterations of the transport function and the cellular 
localisation of the protein (Letschert et al. 2004).  Other transport assays have been 
developed and used in OATP studies which may be more amenable to the use with 
SLCO1B3 expression in RDEB SCC, including using Xenopus Laevis oocytes injected with 
cRNA of the OATP1B3. One study, using this method was able to show the anticancer drugs 
Docetaxel and Paclitaxel were taken up into cells more so by OATP1B3 than OATP1B1, by a 
2.2 and 3.3 fold higher, respectively (Smith et al. 2005).  
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In retrospect, looking at the transporter activity experiments used, it would be important to 
use a positive control for these experiments.  This could be doing using a liver cells grown in 
culture, particularly a well known hepatoma cell known; HepG2.  Also, when performing 
tritiated assays, other controls could be performed to establish the number of counts 
generated by the scintillation counter by directly measuring various concentrations of 
tritiated β-estradiol diluted in emulsifier.  This would help determine if lower count 
numbers seen in some of the repeated assays are resulting from the experiment failing or 
that there is just a low count number for those particular cells in question.  Further still, this 
would help ascertain whether the other substrates used; such as Rifampicin or Clotrimazole 
are having an effect on the counts in each experiment, as appropriate controls are carried 
out to help clarify this in each run of the assay.   
 
Other limitations of the uptake assays are that the lysing of the cells doesn’t produce a 
clear lysate that may affect the luminometer results for the Fluo-3 experiment. Whilst 
inadequate cell lysis may skew results as the substrates are not entirely released in to the 
lysate and therefore an inaccurate reading is taken.  This is a limitation of both the Fluo-3 
assay and the β-estradiol assay.  Other methods of lysis could be used, and some were tried 
in these experiments to over-come these problems, including using different methods to 
homogenise the lysate, such as passing the lysate through a syringe however this did not 
over-come this problem.   
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5.3.3 Future work should involve the investigation of COL7A1 on SLCO1B3 promoter 
activity 
Due to time restrictions, promoter studies to investigate the regulation of SLCO1B3 
expression via COL7A1 were not carried out.  This remains an important question in relation 
to the expression of SLCO1B3 and the primary disease, RDEB.  If future studies confirm that 
COL7A1 does regulate the expression of SLCO1B3 it would be interesting to see if this is 
then linked to cancer initiation in these patients.  A simple basis to further expand this 
theory may to look at cell growth and proliferation using the MTS assay and cell migration 
using scratch wound assays to establish if SLCO1B3 expressing cells have a growth 
advantage over those without expression of this transporter.      
 
Further promoter studies that could be conducted include; DNAse I footprint analyses using 
RDEB SCC keratinocytes with and without COL7A1 expression and control lysates.  This 
would determine cell type specific binding of proteins to the promoter region (Jung et al. 
2001).  Site directed mutagenesis can be used to alter the minimal promoter region, and to 
determine the critical regions required for expression in RDEB SCC keratinocytes.  It is 
however, possible that COL7A1 regulates the expression of SLCO1B3 at the post 
transcriptional level in which case mRNA transcription can be investigated using nuclear run 
on assays. Also, in relevance to RDEB, it would be important to establish if the expression of 
specific Type VII collagen domains are sufficient to drive the suppression of SLCO1B3 
transcriptional activity in RDEB SCC.  
 
One could speculate that perhaps it is not SLCO1B3 promoter that is directly affected by 
Type VII Collagen.  It may be that the Type VII Collagen acts as a ligand to a regulator of 
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SLCO1B3 expression such as PXR, FXR or HNF4A. It could also be possible that SLCO1B3 is 
expression is related to a feedback loop that is triggered by a reduction in Type VII Collagen 
in RDEB skin, which leads to the expression of OATP1B3 to specifically increase uptake of 
steroids into the skin such as estrogen which is a regulator of collagen synthesis.  This 
mechanism could be tested by measuring estrogen levels inside keratinocytes expressing 
COL7A1 at normal levels and those with a reduced expression, along with testing the 
differences caused by reduced and enhanced expression of SLCO1B3.  Further work is 
required to elucidate the mechanism and link between COL7A1 expression and SLCO1B3 
expression in RDEB SCC. 
 
5.3.4 OATP1B3 is a potential target for selective killing of RDEB SCC cells 
To conclude, OATP1B3 is expressed at both the mRNA and protein level in RDEB SCC and 
RDEB SCC tissue.  Functional assay were unable to determine specific OATP1B3 mediated 
transport, however cell viability can be used to establish if cells can be selectively killed 
based on the expression of OATP1B3.  These results further confirm that SLCO1B3 
represents a potential therapeutic target in RDEB SCC, and a physical pathway for delivering 
anti-neoplastic drugs specifically to tumour cells thus preventing systemic damage to 
healthy cells.  It remains a pertinent question, however, to the functional consequence of 
OATP1B3 expression in tumours, in terms of whether this protein is creating a growth and 
survival advantage to the tumour cells, or is its over-expression just the result of genetic 
instability as a consequence of tumour development. 
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Chapter 6 
Final Conclusion and Future Work 
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The main treatment regime used to tackle SCC that develop in RDEB patients is surgical 
excision, other conventional cancer treatments such as chemotherapy only impede the 
primary disease management in RDEB patients.  These patients are susceptible to life 
threatening infections due to chronic open wounds and system toxicity induced by 
chemotherapy only puts pressure on their already over burdened immune system thus 
reducing tumour cell immune-surveillance.  Therefore, adjuvant therapies are rarely used in 
this patient group, unlike in those who develop UV-induced SCC, who may be administered 
adjuvant chemotherapy in cases where patients present with an invasive and or metastatic 
tumour.   
 
RDEB patients already suffer from considerable morbidity caused by their primary disease; 
the development of SCC is undoubtedly a “ticking time bomb” in these patients whilst 
clinicians and researchers are still uncertain as to the exact pathophysiology and what 
genetic aberrations causes the development of SCC in these patients, it is highly likely that 
they will develop SCC at some point in their lives, with a 75% cumulative risk by the age of 
45 (Fine et al. 2009).  This is hampered further by the aggressive nature and metastatic 
potential of these tumours which are habitually treated by surgical excision and remain the 
leading cause of mortality in RDEB suffers.  This clearly outlines a clinical need for the 
research into RDEB specific therapeutic targets of SCC, in the hope to find and develop a 
therapeutic treatment strategy that provides a better prognosis if not a cure for SCC in 
these patients.  
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6.1 Summary of TP53 status in RDEB SCC keratinocytes 
mRNA expression analysis and direct sequencing revealed that p53 isoforms are not 
differentially expressed between RDEB associated SCC and non-RDEB SCC.  Furthermore, 
the mutation spectrum is not unique in either sample set, and no common mutations were 
found.  However, it is yet to be elucidated as to the effects of these mutations on the 
function of p53 and its downstream targets in these SCC samples, although with its 
interplay with other signalling pathways.    
 
Given that 100% of SCC samples studied harboured p53 mutations this is an interesting 
gene to consider in SCC development.  Especially the GOF effects of specific mutanats 
which could be confirmed by further experiments using siRNA knockdown of wt-p53 and 
mutant p53 and establishing if there are any differences in selected target genes.  Further 
experiments could be performed to investigate the functional consequences of all the 
mutations identified.  Another prospective avenue of investigation is to establish the p53 
isoform expression in RDEB skin to determine whether p53 is an early event in the multi-
step process of tumourigenesis in these patients.  Also, one RDEB SCC keratinocyte sample 
was found to harbour a UV-signature mutation, this is somewhat unusual and unexpected.  
Due to the severity of the chronic wounds and generalised skin involvement in RDEB 
patients, they tend to have wounds bandaged and as this is where the tumours develop it 
seems unlikely to have been caused by UV-damage.  It is most likely that the CC to TT 
mutation in the RDEB SCC samples was caused by other means than UV radiation. 
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6.2 Genome wide expression profiling and qRT-PCR suggests RDEB SCC and non-
RDEB SCC are genetically similar 
Analysis of the genome wide expression array identified only 36 genes with significantly 
different expression levels between RDEB SCC and non-RDEB SCC keratinocytes, suggesting 
the two SCC groups are not significantly different.  However, the dysregulation of these 36 
genes may hold the reason to the aggressive behaviour of these tumours and give them 
metastatic potential to spread.  Microarray analysis and qRT-PCR has identified 14 genes 
that demonstrate the same trend of expression in terms of up and down regulation in RDEB 
SCC compared to non-RDEB SCC keratinocytes, however only 5 of which were significantly 
different in both experiments.  This study did confirm that RDEB SCC and non-RDEB are not 
significantly genetically different with 22 of the genes showing opposing trends of 
expression in the microarray and qRT-PCR.  Whilst the main aim of this thesis has been to 
identify candidate therapeutic targets of RDEB SCC, increasing the sample size may 
elaborate on whether the 11 genes that were not significantly differentially expressed in 
both experiments but showed the same pattern of expression are still important targets of 
RDEB SCC and also whether they may contribute to the highly malignant potential of the 
SCC keratinocytes in RDEB patients, by increasing the migration, invasion and overall 
metastatic potential of these cells.  Functional assays could be utilised to investigate this 
are; siRNA screens, scratch wound assays and cell proliferation assays.    
 
As the expression array suggests the two tumour types are more similar than different, it 
does question the role of the tumour microenvironment; which is the milieu of cells 
surrounding the tumour and may create a favourable environment which potentiates 
inflammation, tumour growth and progression.  This has been implied by research that 
shows tumour-stromal fibroblasts are capable of remodelling the extracellular matrix to 
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favour tumour invasion (Gaggioli et al. 2007) and more recently, Erez and colleagues have 
shown cancer associated fibroblasts are able to support tumour growth by stimulating 
angiogenesis, proliferation and tumour enhancing inflammation (Erez et al. 2010).  
 
In respect to identifying a RDEB specific therapeutics target, it is worth while considering 
that the RDEB keratinocytes have genes which are dysregulated in comparison to NHK.  The 
original global expression array contained both sample groups and can be used to correlate 
genes which are then further dysregulated in the SCC samples and perhaps provide 
tumourigenic stimuli that initiate the carcinogenic conversion of keratinocytes in RDEB 
patients, Appendix 1.5 displays a table of genes derived from the microarray showing genes 
differentially regulated between NHK and EBK.  A versatile study to validate these genes is 
to perform a siRNA screen of the tumour related genes and those which are consistently 
dysregulated in RDEB keratinocytes and further still in RDEB SCC keratinocytes.  This 
method of investigation has been used to successfully identify therapeutics targets of SCC 
(Watt et al. 2011).   
 
This study confirmed that in fact RDEB SCC and non-RDEB SCC are genetically similar.  This 
has prompted research into other avenues of RDEB that could provide patients with a high 
risk of developing SCC.  These avenues include work performed by Dr Andrew South’s 
Laboratory; investigating the effects of COL7A1 on RDEB SCC keratinocytes and the effect of 
re-expression.  Also, of particular importance is whilst the genetic characterisations of RDEB 
SCC keratinocytes show mainly similarities that perhaps the tumour microenvironment is 
responsible for the high propensity of cutaneous SCC development and aggressive nature in 
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RDEB patient, therefore the characterisation RDEB SCC fibroblasts have become the 
objective of these studies.   
 
6.2 SLCO1B3, an up-regulated organic anion transporter capable of transporting 
chemotherapeutic agents, is a potential therapeutic target of SCC specifically in 
RDEB patients 
The most interesting finding of this investigation has been the identification of the over-
expression of the organic anion transporter; SLCO1B3 in RDEB associated SCC.  
Furthermore, in relation to the primary disease; RDEB, the re-expression of COL7A1; the 
gene whose genetic mutations give rise to the RDEB phenotype, reduce the expression of 
SLCO1B3.  This is the first time an extracellular matrix protein has been known to possibly 
interact and transcriptionally suppress the expression of a membrane transporter protein.  
In culture the expression of SLCO1B3 is low in comparison to tissue, and therefore using 
cultures cells may not have provided the ideal system to assay transport function.  Even in 
the liver where this gene is normally expressed, serial passaging of cultured hepatocytes 
have been known to shown reduced and low expression of SLCO1B3 (Konig et al. 2006).   
 
Although the uptake studies did not successfully confirm the transport activity of OATP1B3 
in RDEB SCC, this is in line with other uptake study reports that in fact use over-expression 
systems by creating cell lines to transiently or stably express OATP1B3 exogenously rather 
than performing these functional assays using the endogenous OATP1B3 expression (Cui et 
al. 2001; Baldes et al. 2006; Gui et al. 2008).  Other uptake assays are available; such as 
utilizing Xenopus laevis oocytes as described by Ballestro and colleagues, and involves 
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injecting oocytes with the SLCO1B3 cRNA so that the oocytes express the gene of interest, 
then perform the uptake assay (Ballestero et al. 2006).    
 
This thesis documents the creation of an over-expression construct and stable expression of 
SLCO1B3 in RDEB SCC 1 cells.  This provides a cellular model that is more efficient for 
investigating transport of molecules via the OATP1B3 protein, and this is shown by cell 
viability assays using the MC-LR toxin which selectively kills cells based on the expression of 
SLCO1B3.  This could also be used to investigate the transport and selective killing by 
chemotherapeutic agents known to be transported by SLCO1B3, to characterise the 
transport function in keratinocytes.  
 
The over expression of SLCO1B3 is reported in several cancers, including breast and brain 
tumours and has been suggested to play a role in the regulation of cellular processes such 
as proliferation and apoptosis (Bronger et al. 2005; Nozawa et al. 2005; Al Sarakbi et al. 
2006).  The underlying expression of OATP1B3 in cancer cells remains unclear, it is 
intriguing that a transporter protein which is more likely to be found liver and is linked to 
expression in tumours that have poor prognosis and lack response to available 
chemotherapy treatments (Ballestero et al. 2006) is expressed in cutaneous SCC in RDEB 
patients.  The effect of the over-expression in RDEB SCC could be further investigated to 
establish what, if any, advantage the over-expression gives to the tumour cells.  One study, 
has suggested that OATP1B3 over-expression in colorectal cancer cells confers anti-
apoptotic mechanisms by altering the p53-dependent pathway, specifically reducing the 
transcriptional activity of p53 in over-expressing cells (Lee et al. 2008).  This is not the case 
in RDEB SCC cells, as results in Chapter 1 demonstrate all 3 RDEB SCC keratinocyte cell lines 
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used over-express mutant p53, suggesting that other mechanisms may be occurring in 
these cells.     
 
6.3 OATP1B3 as a cancer therapeutic target 
As already mentioned, this transporter is known to be capable of transporting several 
anticancer drugs, such as Methotrexate, Paclitaxel, Docetaxel, and SN-38, an active 
metabolite of Irinotecan.   The over-expression of OATP1B3 has been suggested to  
facilitate the accumulation of anti-cancer drugs in cells (Ichihara et al. 2010), given that 
over-expression is seen in RDEB SCC cells the accumulation of drugs delivered to cells via 
the OATP1B3 transporter would thereby enhance their cytotoxic effect.  It has been 
documented in this thesis that the exogenous over-expression in RDEB SCCK mediates the 
uptake of MC-LR toxin into cells and effectively causes cell death.   
 
The next step in this investigation would be to utilize the expression of OATP1B3 and the 
MTS assay to establish if a selection of anticancer drugs, such as Methotrexate and 
Paclitaxel are capable of causing cell death at low doses in RDEB SCCK in culture, and using 
cell lines not expressing SLCO1B3 as a control for necrotic cell death.  In RDEB patients, 
treatment with the chemotherapeutic agent Methotrexate has been reported with limited 
success, and does not provide an effective treatment.  Further still, the systemic side effects 
caused by these cancer therapeutics would be detrimental to RDEB patients.  However, to 
establish transporter function in vitro, this could provide a good tool for this investigation.  
If this transporter proves to be a useful therapeutic target, the coupling of a 
pharmacological active agent to a ligand that is a substrate of OATP1B3 will create shuttle 
molecules that can be recognised by these transporter proteins (Tsuji 1999).  When 
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considering using a transporter to facilitate the delivery of drugs to tumours cells, it is 
imperative to examine the expression of other transporters in these cells and essential to 
ensure drugs used are not substrates of other transporters such as MDR, MRP3, ATP 
binding cassette transporters and other OATP transporters.  As the effect of other 
transporters may contribute to the failure of chemotherapy by efflux of the anticancer 
agents out of the cells (Leonard et al. 2003).   As this study has confirmed that the SCC that 
develop in RDEB patients and the general population are genetically similar, further work is 
required to understand the mechanisms that underlie the aggressive nature of these 
tumours in RDEB patients. 
 
Although the confirmation of OATP1B3 over-expression in RDEB SCC cells has identified a 
pathway that could be exploited to selectively target cancer cells with therapeutic agents, it 
could result in being more susceptible to chemotherapy resistance.  This is a similar 
scenario to the over-expression of p-glycoprotein/MCR1 and breast cancer resistance 
protein/abcg2 which are known to confer chemotherapeutic resistance in malignant 
tumours (Perez-Tomas 2006).  
 
To conclude, the over-expression of OATP1B3 provides a direct pathway for the delivery of 
drugs to cancer cells in RDEB patients.  The validation of the transporter function of this 
protein in RDEB SCC keratinocytes will hopefully elucidate if indeed this pathway can be 
exploited for the therapeutic targeting of cancer cells specifically in RDEB patients whose 
tumours express SLCO1B3.  
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Appendix 1.0 p53 mRNA expression by PCR amplification 
 
 
 
 
 
 
 
 
  
A 
B 
C 
D 
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A) Amplification of p53, p53β, p53γ and in  two independent RDEB SCC samples and 
two non-RDEB SCC samples.  B) p53β was amplified in SCC (n=2) and NHK  C) p53γ is 
amplified in RDEB SCC and non-RDEB SCC D) repeat of p53 amplification in SCC4 and SCC5 
confirms no expression is seen in SCC4. E) Δp53 is amplified in 2 of 3 RDEB SCC samples and 
all 5 non-RDEB SCC samples. F) Δp53β was expressed in 2 of 3 RDEB SCC samples 
and 4 of 5 non-RDEB SCC samples G) Δp53γ is amplifiedin all non-RDEB SCC samples 
and only 2 of 3 RDEB SCC samples.  
G 
F 
E 
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Appendix 1.1 p53 protein isoform expression 
 
 
p53 protein isoform expression demonstrated by western blotting and performed by Dr 
Carol Hogan. 
Appendix 1.2 Type VII Collagen Expression in RDEB SCC transduced cells 
 
 
 
Type VII Collagen expression in RDEB SCC keratinocyte cell lines after being retrovirally 
transduced to re-express COL7A performed by Dr Celine Pourreyron. 
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Appendix 1.3 Commercially available antibodies used in Immunoblotting 
 
Commercially available antibodies against OATP1B3; A) Mouse OATP8 (Novus Biologicals) B) 
Goat C-14 (Santa Cruz), show no specific OATP1B3 bands in RDEB SCC keratinocytes. 
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Appendix 1.4 Immunofluorescent staining of OATP1B3 in RDEB SCC tissue  
 
Immunoflourescent staining using OATP1B3 D-16 antibody at a dilution of 1 in 500.  A) 
Normal Dermis, B and C) two independent RDEB SCC tissues.  
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Appendix 1.5 NHK vs EBK gene list generated from the microarray analysis 
 
GI Number Gene Name Chromosome Fold Change p value 
GI_6138970-S ACP5 19p13.3-p13.2 2.204873 0.000919 
GI_4557342-S ALDH7A1 5q31 2.678544 0.002105 
GI_4826642-S ANXA3 4q13-q22 0.367718 0.000287 
GI_21361257-S RND3 2q23.3 0.175303 0.000229 
GI_20357534-S ATP6V1G1 9q32 0.415318 0.000254 
GI_40353770-S BOP1 8q24.3 0.488506 0.000318 
GI_8922518-S C14orf104 14q22.1 1.868757 0.000485 
GI_42476067-S C20orf30 20p12.3 0.165571 0.000052 
GI_9951924-S CA12 15q22 0.547859 0.004343 
GI_7706340-S YPEL5 2p23.1 3.990615 0.000749 
GI_11641403-S CKMT1 15q15 0.517688 0.002523 
GI_18765747-A COL18A1 21q22.3 4.393860 0.004956 
GI_38569504-A DDX52 17q21.2 4.256464 0.000329 
GI_19923594-S DDX54 12q24.13 0.484485 0.000405 
GI_41393585-A DGKA 12q13.3 0.150960 0.004932 
GI_30153783-S DNAH17 17q25.3 2.515196 0.000471 
GI_7657036-I DOC1 3q12.1 0.020676 0.000020 
GI_32967308-S EPHA1 7q34 0.202338 0.002333 
GI_10518499-S F3 1p22-p21 4.169823 0.000254 
GI_34304362-S FADS3 11q12-q13.1 0.298760 0.000997 
GI_17149847-S FKBP5 6p21.3-p21.2 0.181001 0.000931 
GI_39725951-S AGGF1 5q13.3 4.264469 0.000130 
GI_8922347-S TMEM39B 1p35.1 2.987290 0.000995 
GI_8922706-S TMEM34 4q31.23 0.512801 0.000961 
GI_40254892-S FLJ11273 6q13 0.355386 0.000183 
GI_31377643-S ATAD1 10q23.2 0.455931 0.000103 
GI_31377616-S HERPUD2 7p14.2 0.322850 0.004043 
GI_31542744-S GPR177 1p31.3 3.431327 0.000320 
GI_20127628-S ZNF768 16p11.2 1.851232 0.000852 
GI_44680151-S FOSL2 2p23.3 2.153615 0.000065 
GI_20070269-S G0S2 1q32.2-q41 0.073010 0.004104 
GI_45359844-S G3BP2 4q21.1 0.255402 0.002283 
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GI_24308156-S GBP3 1p22.2 0.247191 0.002699 
GI_20336263-A GGA2 16p12 2.585786 0.002299 
GI_18104958-S TXNDC9 2q11.2 2.909977 0.001516 
GI_13518031-S GLI3 7p13 2.962542 0.000909 
GI_4759061-A GPSN2 19p13.12 0.193629 0.002040 
GI_31542938-S HPGD 4q34-q35 0.247527 0.002128 
GI_15451900-S KCNK1 1q42-q43 0.383427 0.000746 
GI_45267831-S FASTKD2 2q33.3 0.475805 0.000079 
GI_42660245-S KIAA1305 14q12 2.523499 0.003401 
GI_39930390-S DIP2B 12q13.12 6.234034 0.000259 
GI_27894338-I KRT23 17q21.2 0.141580 0.004818 
GI_17318577-S KRT5 12q12-q13 1.727019 0.000430 
GI_42734380-S TYW3 1p31.1 0.292116 0.000795 
GI_37059758-S CD300LG 17q21.31 0.203229 0.000203 
GI_42659549-S LOC220906 10p12.1 0.166582 0.000631 
GI_37538380-S MGC87042 7p15.3 0.318666 0.000320 
GI_37542995-S LOC341315 12q14.2 3.148946 0.000778 
GI_37546020-S LOC374571 14q32.33 0.078759 0.003857 
GI_29735784-S PPP1R3E 14q11.2 0.411220 0.000490 
GI_29789400-S UBE2Q2 15q24.2 0.154882 0.000044 
GI_24475622-S MDK 11p11.2 0.394566 0.003858 
GI_42476197-S CCDC104 2p16.1 0.296648 0.000220 
GI_29729561-S MGC21874 4p16.1 0.292934 0.002252 
GI_39930530-S c3orf64 3p14.1 0.332586 0.001208 
GI_19923760-S MINPP1 10q23 0.275762 0.002794 
GI_6912507-S MMD 17q 0.233155 0.003532 
GI_29826286-I MRPL47 3q26.33 3.544673 0.000947 
GI_31543213-S MT1X 16q13 0.365543 0.000839 
GI_37537693-S MTMR6 13q12 0.177049 0.000047 
GI_16506290-S OSR2 8q22.2 0.233719 0.002691 
GI_38045914-S PAPPA 9q33.2 0.303215 0.004735 
GI_33386694-A PBEF1 7q22.2 0.365580 0.001889 
GI_5031976-I PBEF1 7q22.2 0.230978 0.003355 
GI_25777743-S PGBD3 10q11  2.743783 0.000163 
GI_34147645-S PLOD3 7q22 3.445257 0.001989 
GI_30795205-S PPP2R5A 1q32.2-q32.3 3.046272 0.004080 
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GI_42476154-S PTMS 12p13 3.035154 0.000549 
GI_24416001-S UBR4 1p36.13 0.331009 0.002991 
GI_34147329-S RRS1 8q13.1 4.372495 0.004953 
GI_8400731-S SFRP1 8p12-p11.1 6.242949 0.000024 
GI_20336278-A SLC26A6 3p21.3 0.365709 0.001452 
GI_18765730-A SNAP23 15q15.1 0.192280 0.004430 
GI_29893560-S SNN 16p13 0.338538 0.001565 
GI_33386698-S TMSL1 1p34.2 0.084730 0.002729 
GI_32189375-S TRIP4 15q22.31 0.300121 0.000105 
GI_23308730-S TRIP6 7q22 1.752771 0.000041 
GI_23510347-S TTRAP 6p22.3-p22.1 0.170801 0.000364 
GI_19718775-S WEE1 11p15.3-p15.1 2.889024 0.004871 
GI_23199973-A WTAP 6q25-q27 0.273361 0.003192 
GI_39841070-S ZNF322B 9q22.33 0.239149 0.000154 
 
 
Table of genes differentially expressed between EBK and NHK, identified by microarray 
analysis. 
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